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Summary 
Acute pancreatitis is a human disease in which cytosolic Ca2+ overload and mitochondrial 
dysfunction have been implicated as the initial triggers. Sustained elevations in cytosolic Ca2+ 
result in intracellular activation of digestive enzymes, mitochondrial dysfunction and cellular 
necrosis. This leads to autodigestion of the pancreas and subsequent inflammation, which can 
prove fatal. Intracellular Ca2+ release from stores is coupled to the activation of store-
operated Ca2+ entry (SOCE) channels such as the Ca2+ release activated Ca2+ (CRAC) 
channel or the canonical transient receptor potential (TRPC) 3 channels in the plasma 
membrane. These channels drive cytosolic Ca2+ overload. Targeting these channels is an 
appealing therapeutic strategy. One of aim of this study was to determine if there are any 
inhibitors, in addition to GSK-7975A, that can specifically block these channels and prevent 
cytosolic Ca2+ overload.  
Analogues of 2-APB, a well know but problematic inhibitor of SOCE channels, DPB163-AE 
and DPB162-AE were found to inhibit SOCE channels efficiently at a low micromolar 
concentration. This was similar to the effect seen with the inhibitor GSK-7975A. However, 
increasing concentrations of DPB163 resulted in impaired clearance of Ca2+ from the cytosol, 
whereas DPB162 inhibited SOCE further. RO2959, another reported CRAC channel 
inhibitor, was found to be less effective at inhibiting SOCE in pancreatic acinar cells than in 
other cell types. This phenomenon was true for the DPB compounds. RO2959 was effective 
at inhibiting SOCE in dose dependent manner when applied acutely or when pre-incubated 
with cells. In addition, there were observed effects of RO2959 on Ca2+ clearance from the 
cytosol. This likely contributed to the observed finding that RO2959 also increased levels of 
necrosis, due to impaired Ca2+ clearance.  
Targeting TRPC3 channels, the non-specific cation channels, has been difficult as it is 
lacking a specific inhibitor. Treatment with Pyr3, initially thought to be a specific TRPC3 
inhibitor was particularly effective at inhibiting SOCE. However, during the time course of 
this work it came to light that TRPC3 at low micromolar concentration does not discriminate 
between TRPC3 and CRAC channels. Treatment with a reportedly specific inhibitor, Pyr10, 
resulted in a reduction in Ca2+ influx. However, in a similar manner to DPB163 and RO2959 
there appeared to be an effect of Pyr10 on the Ca2+ clearance from the cell.   
A second aim of this thesis was to investigate the role of calmodulin in SOCE in pancreatic 
acinar cells. Calmodulin is thought to regulate CRAC channels by mediating Ca2+-dependent 
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inactivation of the channel. Inhibitors of calmodulin: calmidazolium and W-7 were used. 
Both inhibitors resulted in an inhibition of SOCE. However, this inhibition was not as 
remarkable as CRAC channel inhibition. This could have been because the calmodulin 
inhibitors were not directly inhibiting the Orai1 protein of the CRAC channel rather were 
targeting one of the channels regulating proteins - calmodulin. A cell permeable activator of 
calmodulin was also utilised in this study – CALP3. CALP3 had previously been shown to 
protect acinar cells from cytosolic Ca2+ overload and also to block non-specific cation 
channels in T cells. At the concentration found to protect against Ca2+ overload, no effect on 
SOCE was observed. Increasing the concentration resulted in significant inhibition, but it was 
likely due to a non-specific effect of a supramaximal concentration. 
CRAC channel inhibition was the more effective as a target for reducing SOCE and 
subsequent Ca2+ overload than targeting calmodulin-regulation of CRAC channels or 
targeting TRPC3 channels. However, several of the “specific” inhibitors available to target 
this channel, including DPB163 and RO2959 had a multitude of off-target effects including a 
significant effect on the Ca2+ extrusion mechanism of pancreatic acinar cells. GSK-7975A 
had the fewest undesired effects and also inhibited SOCE more than any other inhibitor. It is 
an ideal candidate for future drug development.  
When the work in this study is viewed in the context of the wider published work, the idea of 
focusing on CRAC channel inhibition as a potential therapeutic for acute pancreatitis is a 
promising future avenue. 
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1 Introduction.  
1.1  Calcium signalling in mammalian cells 
The role of calcium (Ca2+) as a signalling molecule dates back to 1882, when Sydney Ringer 
sought to determine the effect of different components of blood on the contraction of the 
ventricle (1). He found that saline solution, when used to perfuse the ventricle, induced 
contraction of the muscle. Ringer clarified his finding in a second paper, where he noted that 
the saline solution he had used was not made from distilled water, as he originally thought, 
but rather was made from “pipe water” or tap water; which in London at the time consisted of 
38.3 parts per million of Ca2+ (2). When Ringer proceeded to add Ca2+ to his saline solution, 
made with distilled water, he was able to reproduce his findings from his original paper, 
indicating that Ca2+ was the key for contraction of the ventricles (2,3). This was the 
beginning of the discovery of the diverse role Ca2+ plays as an intracellular signalling 
molecule (3).  
Ca2+ is a ubiquitous intracellular messenger molecule that is responsible for controlling a 
variety of cellular processes from fertilisation, gene transcription, neurotransmitter release, 
memory formation, muscular contraction to exocytosis. However, Ca2+ is also implicated in 
various pathologies such as cardiac arrhythmia (4), Alzheimer’s disease (5), cancer (6) and 
the focus of this thesis: acute pancreatitis (7). Under resting conditions intracellular cytosolic 
Ca2+ levels are tightly regulated and remain at approximately 50 - 100 nM dependent on the 
cell type (8). Elevations in cytosolic Ca2+ levels, as a response to an external stimulus, can 
reach micromolar range. If these elevated levels of Ca2+ are sustained and not cleared from 
the cytosol, in a timely fashion, typically the outcome is cell death. This intracellular 
messenger is vital for physiology but an excess of Ca2+ is toxic for cells, therefore tightly 
regulated Ca2+ homeostasis is imperative for cell survival (9). Cytosolic Ca2+ levels are in 
constant flux and are an equilibrium between mechanisms that increase cytosolic Ca2+ 
concentrations and mechanisms that decrease cytosolic Ca
2+ concentrations (10).  
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Figure 1.1 Intracellular Ca2+ signalling is broken down into "on" and "off" reactions 
The left side of the schematic describes mechanisms by which mammalian cells increase 
cytosolic Ca2+ concentration from the stimulus of a receptor (R) at the plasma membrane, 
to the generation of a second messenger molecule that elicits Ca2+ release from 
intracellular stores and subsequent activation of store-operated Ca2+ entry. The right side 
of the schematic depicts the mechanisms by which mammalian cells clear Ca2+ from the 
cytoplasm, sequestration into ER stores, uptake into mitochondria and extrusion across the 
plasma membrane. The effector panel at the bottom of the schematic describes the 
physiological functions of increased cytosolic Ca2+ and the time scale over which these 
cytosolic Ca2+ signals persist. Schematic taken from a review (10).  
 
The Ca2+ required for these intracellular signals is derived from two major sources: an 
intracellular store or the extracellular medium. The major intracellular store is the 
endoplasmic reticulum (ER) or in muscle it is known as the sarcoplasmic reticulum (SR); on 
the membranes of both stores 
there are release channels that 
allow cells to liberate Ca2+ 
for signalling.  
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There are a huge number of ways in which cells permit Ca2+ to cross the plasma membrane, 
which vary dependent on the nature of the cell in question, there are voltage-gated Ca2+ 
channels, store-operated Ca2+ channels, receptor-operated Ca
2+ channels to mention but a few 
(10). Increases in cytosolic Ca2+ are therefore elicited by different mechanisms dependent on 
the cell type and function, there are several conserved receptors, channels and pumps across 
the spectrum of mammalian cells. These are detailed in the following sections, which are 
subdivided into: Plasma membrane receptors, plasma membrane channels, intracellular Ca2+ 
release channels and Ca2+ clearance mechanisms.  
Generally, intracellular Ca2+ signals can be broken down into “on” reactions and “off” 
reactions as described in (10).  Mechanisms that serve to increase cytosolic Ca2+ 
concentration are considered “on” reactions and mechanisms that serve to decrease cytosolic 
Ca2+ concentration are considered “off” reactions.  The schematic, figure 1.1, depicts a 
summary of all the mechanisms by which it is possible to elevate cytosolic Ca2+ and remove 
cytosolic Ca2+ from the cell.
1.1.1 Plasma membrane receptors 
The combination of plasma membrane receptors expressed by a cell varies depending on the 
cell type, for example pancreatic acinar cells are largely dependent on the activation of 
muscarinic acetylcholine receptors (mAChR) and cholecystokinin (CCK) receptors in order 
to mobilise Ca2+(11), whereas cardiac myocytes express angiotensin II, endothelin and 
several subtypes of adrenoceptors (12). These are all examples of G-protein coupled 
receptors (GPCR) and they transduce their signals through different alpha subunits. Most 
GPCRs activate phospholipase C (PLC) and stimulate the hydrolysis of phosphatidylinositol-
4,5-bisphosphate (PIP2) to second messengers: diacylglycerol (DAG) and inositol-3,4,5-
trisphosphate (IP3). IP3 is the ligand for the intracellular ER Ca
2+ release channel the IP3 
receptor (IP3R) (13). Other alpha subtypes of GPCRs are known to activate adenylyl cyclase, 
an enzyme that catalyses the conversion of adenosine trisphosphate (ATP) to the second 
messenger - cyclic adenosine monophosphate (cAMP). 
1.1.2 Plasma membrane channels  
In the extracellular medium Ca2+ is at a significantly higher concentration compared to in the 
cytosol and this maintains the potential difference across the cell membrane. Extracellular 
Ca2+ concentration is in the millimolar range (14). Generally, mammalian cells can be 
subdivided into electrically excitable and electrically non-excitable cells. These cells possess 
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different mechanisms that allow Ca2+ to cross the plasma membrane. In the plasma 
membrane of excitable cells, such as neurones and myocytes, are voltage-gated Ca2+ channels 
that upon depolarisation of the membrane by an action potential, open to allow Ca2+ to enter 
the cell, down its concentration gradient. This results in an elevation in the concentration of 
cytosolic Ca2+ which is often the stimulus for subsequent Ca2+ release that is described in 
section 1.1.3. In non-excitable cells, such as pancreatic acinar cells or more generally 
epithelial cells, the plasma membrane is not electrically excitable meaning that voltage-gated 
Ca2+ channels would be redundant, as there is not a change in the membrane potential to 
activate and open the channel. Such non-excitable cells possess store-operated Ca2+ channels 
that are activated upon the depletion of the intracellular Ca2+ store, the ER. There is a Ca2+ 
sensor that spans the ER membrane and detects the intra-luminal Ca2+ concentration, any 
depletion in luminal Ca2+ results in the activation of the closely apposed store-operated Ca2+ 
channel which opens and allows Ca2+ to enter the cytosol. The store-operated channels are 
thought to exist in both a Ca2+ selective form and a non-selective cation form. 
1.1.3 Intracellular Ca2+ release channels 
As previously mentioned the ER is the major intracellular Ca2+ store in cells, the ER luminal 
free Ca2+ concentration is in the region of 100 – 300 µM (15). This again maintains the 
potential difference across the ER membrane and provides a concentration gradient for Ca2+ 
release from the ER when the channels are open. The IP3R in the ER membrane is one such 
Ca2+ release channel, for activation of the IP3R both its ligand IP3 (16) and Ca
2+ are required. 
Activation of the IP3R occurs when a PLC-coupled cell surface receptor is stimulated, such as 
the mAChR activation by ACh, due to the production of IP3. Once the IP3R is activated 
Ca2+ is able to move from the ER lumen into the cytosol down the concentration gradient 
(17). In addition to the IP3R the other major ER Ca
2+ release channel is the ryanodine receptor 
(RyR). RyR, like IP3R, is activated by Ca
2+ and also by second messengers such as cyclic 
ADP ribose (cADPR), which is a cyclic adenine nucleotide like cAMP, and nicotinic acid 
adenine dinucleotide phosphate (NAADP) (18). Ca2+ is sufficient to activate RyR alone, as 
opposed to IP3R that requires dual activation by both IP3 and Ca
2+.  The two-pore channels 
exists on the membrane of acidic Ca2+ stores, NAADP is the major ligand for activation of 
these channels and subsequent liberation of Ca2+, which is thought to serve to activate RyR-
mediated Ca2+ release through a process known as Ca2+ induced Ca2+ release (CICR) (19). 
Both IP3R and RyR have three isoforms, different cell types have differential expression of 
each isoform; furthermore, in some cells the major Ca2+ release channel is the RyR and in 
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others it is the IP3R. In cardiac muscle the pre-dominant Ca
2+ release channel is the RyR, 
specifically RyR2, which mediates CICR that provides the majority of the Ca2+ required for 
cardiac myocyte contraction, as opposed to the initial Ca2+ influx through the voltage-gated 
Ca2+ channels (20). Cardiac myocytes also express IP3R, but Ca
2+ released through IP3R does 
not contribute the bulk Ca2+ required for a successful cardiac Ca2+ transient. Conversely, in 
pancreatic acinar cells IP3Rs are the major release channel with IP3R2 and IP3R3 being the 
dominant isoforms (21). Pancreatic acinar cells also express RyR (18,22) but at a lower level 
than the expression of IP3R. It is thought that the Ca
2+ release mediated through the different 
release channels plays a role in the spatiotemporal dynamics of a cells Ca2+ signal, IP3R 
release Ca2+ apically in pancreatic acinar cells (23), whereas RyR propagate the signal 
towards the basolateral pole of the cell, contributing to a global signal (24,25).  
1.1.4 Ca2+ clearance mechanisms 
Elevations in cytosolic Ca2+, due to Ca2+ influx and Ca2+ release from intracellular stores, 
provides the necessary Ca2+ for physiological signalling; but as mentioned previously 
sustained elevations in cytosolic Ca2+ have severe consequences for cells (9). Therefore, 
mammalian cells have several mechanisms which they can employ to clear Ca2+ from the 
cytosol. The SR/ER Ca2+-ATPase (SERCA) is found in the SR/ER membrane and actively 
pumps Ca2+ from the cytosol into the ER. The plasma membrane Ca2+-ATPase (PMCA) is 
ubiquitously expressed in the plasma membrane of most eukaryotic cells and actively pumps 
Ca2+ from the cytosol across the cell membrane into the extracellular medium (26). These 
two Ca2+ clearance mechanisms are common to both excitable and non-excitable cells. 
Excitable cells also have a Na+-Ca2+ exchanger (NCX), an ionic antiporter that in its forward-
mode pumps Ca2+ out of the cell in exchange for Na
+ ions pumped into the cell. In cells where 
NCX is not expressed or is not functional then PMCA is the major pump that is responsible 
for clearing Ca2+ from the cytosol, across the plasma membrane.  Further to these 
mechanisms it has long been known that mitochondria are capable of taking up Ca2+ from the 
cytosol (27), it is now known that this is via the mitochondrial Ca2+ uniporter (MCU) (28), 
which is localised on the inner mitochondrial membrane (29). Mitochondrial Ca2+ uptake is a 
rapid process, with the peak increase in mitochondrial Ca2+ concentration closely following 
the peak increase in cytosolic Ca2+ concentration (30), this increase in mitochondrial Ca2+ is 
dependent on ER Ca2+ release and subsequent Ca2+ influx into the cell to maintain high Ca2+ 
concentration within the ER/mitochondrial Ca2+ microdomain (30). Mitochondrial Ca2+ 
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uptake is a necessary physiological phenomenon (31) but can have pathological 
consequences when mitochondrial homeostasis is disrupted (32). 
1.1.5 Cytosolic Ca2+ buffers 
Cytosolic Ca2+ buffers are defined as molecules that chelate Ca2+ ions, they contain 
negatively charged groups that can trap the Ca2+ ion (33). Cytosolic Ca2+ buffers serve to 
reduce the concentration of free intracellular Ca2+. Not all proteins that bind Ca2+ are 
considered to be cytosolic Ca2+ buffers. The EF hand family of proteins, proteins that possess 
an EF-hand which is a Ca2+ binding motif, are considered to be Ca2+ sensors. When EF-hand 
containing proteins bind Ca2+ there is a conformational change that is conducive to signal 
transduction; Ca2+ buffers do not undergo conformational changes when Ca2+ binds (34). Not 
all Ca2+ sensors are Ca2+ buffers, a Ca2+ sensor can serve as a Ca2+ buffer when it is at a 
sufficiently high concentration, calmodulin is an EF hand containing protein that is 
considered to be a Ca2+ sensor, as it binds Ca2+ and results in signal transduction, in turn it 
also buffers Ca2+ (33,35). Ca2+ buffers serve to modulate the spatiotemporal profile of Ca2+ 
signals by altering the amplitude and rate of increase or decrease of Ca2+ signals (10). 
Calbindin D-28 and calretinin are cytosolic Ca2+ buffers that served to chelate cytosolic Ca2+ 
ions, reducing cytosolic Ca2+ concentration (10,33). Calbindin and calretinin have fast 
buffering properties whereas parvalbumin, another cytosolic Ca2+ buffer, has much slower 
buffering kinetics (33). Parvalbumin is present in mouse fast twitch muscle fibres at 
approximately 1 mM (36), there is considerable heterogeneity in the concentration of this 
buffer present in other cell types, for example in dendritic cells it is present at approximately 
80 µM (37). The importance of Ca2+ is highlighted by the altered Ca2+ signal dynamics 
observed in knock out animals (37,38). 
1.2 Ca2+ signalling in non-excitable cells 
There are clear distinctions between Ca2+ signalling in electrically excitable cells and non-
electrically excitable cells. Typically in excitable cells there is a need for the Ca2+ signal to be 
rapid and short-lasting, consider the cardiac myocyte as an example: in order to activate the 
contractile machinery for a successful heart beat there must be a whole-cell Ca2+ transient, 
that is a global elevation in cytosolic Ca2+. To achieve a heart rate of 60 beats per minute, the 
cardiac myocytes need to achieve one global Ca2+ transients per second, this includes both 
the increase and decrease in cytosolic Ca2+ back to pre-stimulation levels. This is achieved 
via membrane depolarisation of the cardiac myocytes plasma membrane (including the t-
tubular network). The change in membrane potential opens voltage-gated Ca2+ channels and 
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allows for Ca2+ influx, down its concentration gradient, into the cell. RyRs are closely 
apposed to the plasma membrane in cardiac myocytes, as such in the ER/PM microdomain 
Ca2+ concentrations are high and this facilitates CICR. The primary Ca2+ influx is amplified 
by the Ca2+ release from the ER via the RyR. There is saltatory propagation of the Ca2+signal 
from clusters of RyR to the next etc. This provides the Ca2+ to bind to troponin C and elicit 
contraction. This is known as excitation-contraction coupling (20).  
In non-electrically excitable cells, it is not possible to depolarise the membrane and 
furthermore the cells do not possess voltage-gated Ca2+ channels (39). Rather the primary 
source of Ca2+ for intracellular Ca2+ signals is Ca2+ release from intracellular stores, primarily 
the ER. As there is no initiating Ca2+ signal via voltage-gated channels, there is a necessity 
for an alternative signal to liberate Ca2+ from the ER store. This comes in the form of a 
second messenger, which for the vast majority of non-excitable cells is likely to be IP3 
(13,40,41), it couples activation of cell surface receptors with an increase in cytosolic Ca2+ 
concentration. IP3, as mentioned previously, is formed from the hydrolysis of PIP2 catalysed 
by PLC, which is activated upstream by an alpha subunit of a GPCR (10,42). 
1.2.1 IP3 Receptor  
The IP3R is the major Ca
2+ releasing channel in the ER of non-excitable cells expressing 
PLC-coupled cell surface receptors (43). Binding of IP3 and Ca
2+ are both required to activate 
the IP3R (44). The IP3R receptors form homotetramers (45), there are three isoforms of the 
IP3R encoded by three genes, all three isoforms have different sensitivities to IP3 (46,47). 
There is evidence suggesting that IP3 must bind to more than one IP3 binding site on the 
receptor before it can open (48,49), but not all IP3 binding sites need to be occupied (50). 
IP3R activation is biphasically dependent on cytosolic Ca
2+, 0.5 to 1 µM cytosolic Ca2+ will 
serve to co-activate the receptor, whereas cytosolic Ca2+ concentrations over 1 µM will 
inhibit IP3R (17,44). Once activated, the channel allows for the permeation of Ca
2+ and thus 
efflux of Ca2+ from the ER into the cytoplasm. In this way IP3R mediates CICR, providing 
there is sufficient IP3 available to bind to and co-activate receptors, this is the mechanism by 
which non-excitable cells can amplify the primary Ca2+ signal to give rise to global Ca2+ 
signals. IP3R are susceptible to inhibition of Ca
2+ release by the action of heparin (51,52) and 
caffeine (53).  Dependent on the nature of the non-excitable cell in question will affect what 
the requirement is for the increase in cytosolic Ca2+ concentration for example stimulus-
secretion coupling, similar in nature to excitation-coupling, is a phenomenon in secretory 
epithelia cells such as salivary glands and the exocrine pancreas, this initial phase of this 
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process is dependent on Ca2+ release from the ER via IP3R whereas for continued secretion, 
Ca2+ influx from the extracellular medium is required (39).  
1.2.2 Ryanodine Receptor 
RyRs are another group of intracellular Ca2+ release channels closely related to IP3R, there is 
approximately 17 % sequence homology between the two types of channels (54,55). RyRs 
have been most extensively studied in cardiac and skeletal muscle (56–58). There are three 
isoforms, with differential expression in different cell types, for example RyR2 is the pre-
dominant isoform in cardiac tissue and RyR1 pre-dominant in skeletal muscle (59)  In 
addition to the expression of RyRs in excitable cells, expression of RyRs has also been 
demonstrated in non-excitable cells such as hepatocytes (60,61). Caffeine treatment, in 
cardiac myocytes, has a potentiating effect on Ca2+ released from RyRs, but in hepatocytes 
caffeine treatment inhibited Ca2+ signals, as caffeine was found to inhibit IP3 synthesis (62), 
thereby inhibiting IP3-induced Ca
2+ release (53). Kidney tissue was demonstrated to express 
RyR2, to exclude contamination from smooth muscle present due to blood vessels the results 
were confirmed in a kidney epithelial cell line (63). Further expression of different isoforms 
of RyR were identified in parotid acinar cells (64,65). RyRs are sensitive to inhibition by 
ryanodine, a plant alkaloid that inhibits its namesake receptor by binding to it in its open state 
and inhibiting the channel in a dose-dependent manner (59). Furthermore, RyRs are also 
sensitive to inhibition by ruthenium red (66).  Generally, RyRs are much less abundant in 
non-excitable cells than in excitable cells, but they have a much larger conductance, as such 
they still contribute to CICR but are not the predominant channel through which Ca2+ 
permeates.  
1.2.3 Store-operated Ca2+ entry 
As seen in figure 1.1, the time scale over which certain Ca2+ signals are required to last can 
be quite prolonged, the signals required for fertilisation and proliferation last for hours, which 
is clearly very different to the time scale of the Ca2+ signal that initiates cardiac myocyte 
contraction. Even though in some cells like pancreatic acinar cells the ER Ca2+ store is quite 
large it is still finite, therefore an alternative source of Ca2+ is required to drive the prolonged 
signal and to refill the ER stores upon termination of the stimulus. The initial Ca2+ release 
from the ER results in a fall in ER luminal Ca2+ concentration, which is now known to be 
detected by Stromal interaction molecule 1 (STIM1), the recently discovered ER Ca2+ sensor 
(discussed in further detail in the section below). Studies have shown that upon store 
depletion this protein aggregates and translocates to parts of the ER membrane that are in 
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close apposition to the plasma membrane, more specifically closely apposed to the Ca2+ 
release activated Ca2+ (CRAC) channels, a type of store-operated Ca
2+ entry channel. 
Aggregated and activated STIM1 activates CRAC channels, opening them and allowing the 
influx of Ca2+ into the cytosol from the extracellular medium. There is a large driving force 
for Ca2+ across the plasma membrane into the cell, as long as the channels remain open Ca2+ 
will enter the cell. Ca2+ influx via store-operated Ca2+ channels provides the Ca2+ required to 
drive the physiological process which is stimulated by a prolonged elevation in cytosolic 
Ca2+.  
1.2.4 Ca2+ extrusion 
Once the stimulus at the cell surface receptor has terminated there will be no further 
hydrolysis of PIP2 at the membrane by PLC and no subsequent production of IP3. IP3 is 
degraded by several enzymes, such as IP3 3-kinase and inositol polyphosphatase 5-
phosphatase (67), thereby can no longer bind to its receptor to elicit Ca2+ release from the ER. 
Whenever there is an elevation in cytosolic Ca2+ the extrusion mechanisms are activated in 
order to clear this elevated Ca2+; during sustained stimulation the magnitude of the “on” 
reactions is greater than the magnitude of the “off” reactions and therefore cytosolic Ca2+ 
concentrations increase. Once the cell surface receptor stimulation ceases, the “on” 
mechanisms cease and therefore the magnitude of the “off” reactions is greater than the “on” 
mechanisms and cytosolic Ca2+ concentrations decrease (10,42).  
During sustained cell surface receptor stimulation, SERCA pumps have very little effect on 
removing Ca2+ from the cytosol as the Ca2+ release channels are open, as such PMCA is 
primarily responsible for Ca2+ extrusion (68) and is the only mechanism in non-excitable 
cells to remove Ca2+ across the plasma membrane (69). In excitable cells the NCX is 
expressed and extrudes Ca2+ across the plasma membrane, in exchange for Na+, it is a low-
affinity extrusion mechanism compared to PMCA but has a higher conductance (69). There is 
some evidence for NCX in expression in some non-excitable cells (70), but it is likely to play 
only a minor role in maintenance of Ca2+ homeostasis. Conversely, PMCA is a high affinity 
pump and is activated at Ca2+ concentrations in the region of 100-300 nM, it therefore 
enables maintenance of cytosolic Ca2+ homeostasis when Ca2+ is not significantly elevated 
above resting concentrations (71,72). There is also evidence that PMCA alone is sufficient to 
maintain Ca2+ homeostasis in cardiac specific NCX knock-out mice (73). Once receptor 
stimulation has ceased, SERCA has more of an impact in Ca2+ uptake from the cytosol as the 
Ca2+ release channels of the ER will no longer be open. The activity of SERCA is largely 
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dependent on the concentration of Ca2+ within the ER as opposed to the concentration of Ca2+ 
in the cytosol (11). As PMCA extrudes all the Ca2+ across the membrane during sustained 
receptor stimulation, in order to refill the ER stores Ca2+ must re-enter the cell, this occurs 
through store-operated Ca2+ channels such as the CRAC channel and does not significantly 
change in cytosolic Ca2+ concentration (74). 
1.3 Ca2+ signalling in exocrine cells 
In exocrine cells Ca2+ signalling is primarily responsible for the regulation of exocytosis, 
fluid secretion and gene expression (75). Exocrine cells typically have highly polarised 
structures, which translates to a functional polarisation and thereby polarisation in the 
regulatory signal, in this case Ca2+ signalling. Both salivary glands and the exocrine pancreas 
have been extensively studied as models of non-excitable, exocrine cells (11,75,76). Due to 
the structural polarity of cells, organelles have distinct subcellular locations. The bulk of the 
ER is located in the basal region of exocrine cells, but IP3R are localised in the apical region 
of both pancreatic acinar cells and salivary acinar cells (77–80), present on thin extensions of 
ER membrane that extend from the base of the cell towards the apical region (81). This 
structural data supported the previously determined spatial profile of Ca2+ signals seen in 
exocrine cells: in hepatocytes, pancreatic acinar cells, lacrimal acinar cells, submandibular 
gland acinar cell and submandibular gland duct cells; in which the Ca2+ signal is initiated in 
the apical pole of the cells and propagates around to the basolateral pole of the cell (75). 
Functionally, the purpose of Ca2+ release from the ER through IP3R in the apical pole is to 
provide the stimulus required for secretion. In pancreatic acinar cells the secretory granules 
that contain the digestive proenzymes are located at the apical pole of the cell, fluid secretion 
in salivary gland cells and all ductal cells occurs across the apical membrane too. There is 
expression of IP3R found at the basal pole of some exocrine cells, which likely aids in the 
propagation of the Ca2+ signal. Furthermore there is also expression of RyR at basolateral 
pole of cells this too allows for propagation of a whole cell Ca2+ wave via CICR (82).  
PMCA is largely localised to the apical region of cells, in order to extrude Ca2+ from the 
region in which it is primarily liberated, to prevent the unnecessary propagation of Ca2+ 
signals. There is also expression on the basolateral membrane, but much less (79). As this is a 
high-affinity pump it is activated with each oscillation in cytosolic Ca2+ thus ensuring the 
tight regulation of cytosolic Ca2+ (68).  Furthermore, it maintains the apical luminal Ca2+ 
concentration which maintaining the driving force of Ca2+ into the cell and provides Ca2+ 
required for endocytosis (83). SERCA is primarily located at the basal pole of exocrine cells 
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to allow for store refilling directly into the ER, of which the bulk is situated in the basal 
region of the cell (79,81).  
1.4 Ca2+ signalling in pancreatic acinar cells 
As previously discussed pancreatic acinar cells are one of the most extensively studied 
exocrine cells and as such largely match the description of exocrine cells given in section 1.3. 
A schematic diagram of a polarised pancreatic acinar cell is shown in figure 1.2. This 
schematic demonstrates that the bulk of ER is localised in the basal region of the cell, with 
projections into the apical region, where the bulk of the IP3R are localised. IP3R localisation 
in the apical region promotes local Ca2+ signals, these signals are largely restricted to the 
apical pole due to the perigranular mitochondria. Local Ca2+ signals promote the exocytosis 
of zymogen granules which are also localised in the apical pole of the cell. The store-operated 
Ca2+ channels are localised in the basal pole, as are SERCA pumps which serve to actively 
refill the ER Ca2+ store  
These cells are responsible for the synthesis and the secretion of digestive proenzymes, 
predominantly trypsinogen, chymotrypsinogen and to a lesser extent pancreatic amylase and 
lipase (84,85). The sight, smell and taste of food are sufficient to stimulate pancreatic enzyme 
secretion, this is known as the cephalic phase of digestion and is mediated via the vagal 
cholinergic system (86,87). The gastric phase of digestion also stimulates secretion of 
pancreatic enzymes, mediated via the cholinergic system (88). The secretion of the digestive 
enzymes is stimulated by the ingestion of food, the duodenum is the most responsive part of 
the gastrointestinal tract in its response to nutrients and elicits high levels of enzyme secretion 
upon nutrient exposure (89), this comprises the intestinal phase of digestion. The entry of 
chyme into the duodenum initiates the release of neurotransmitters and hormones that 
activate the release of digestive enzymes from pancreatic acinar cells (87,89).  
Digestive proenzymes are stored in zymogen granules, in pancreatic acinar cells (90) after 
their synthesis in the rough ER and packaging into vesicles in the Golgi. The pro-enzymes are 
inactive forms of the digestive enzymes, which are activated in the lumen after secretion (91). 
As the apical region of the cell is the closest to the duct of the exocrine pancreas, the apical 
pole is region in which the zymogen granules are stored (90,92), poised to begin the process 
of exocytosis upon receiving the Ca2+ signal. 
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Figure 1.2 Schematic figure of a polarised pancreatic acinar cell 
Pancreatic acinar cells are the prototypical exocrine cells and are highly polarised. The 
digestive proenzymes synthesised in these cells are stored in zymogen granules located in the 
apical pole. The bulk of the endoplasmic reticulum (ER) is localised in the basal region of the 
cell with thin projections that reach into the apical pole. The bulk of the Ca2+ release 
channels, predominantly IP3R are localised in the apical pole. There are three major sub-
cellular locations of mitochondria – sub-plasmalemmal, perigranular and perinuclear. The 
cell surface receptors are largely localised on the basal membrane of the cell with the SOCE 
channels. Ca2+ uptake pumps such as SERCA are found in the basal part of the cell ready to 
take up Ca2+ that enters the cell through SOCE channels.  
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The zymogen granules themselves are an intracellular store of Ca2+, forming part of the 
acidic Ca2+ store, which to can liberate Ca2+ in response to agonists such as IP3 (93) but this 
does not render ER Ca2+ release unnecessary (11). 
It was established more than forty years ago that an increase in cytosolic Ca2+ was required 
for enzyme secretion from pancreatic acinar cells, it was first demonstrated in submandibular 
salivary glands; it was also known that physiological agents that induced pancreatic enzyme 
secretion, such as ACh, also released Ca2+ into the cytosol (94,95) – although the mechanism 
of this release was yet to be deduced (40). The increase in cytosolic Ca2+ due to Ca2+ release, 
induced by ACh application, always preceded the release of amylase (95). A later paper 
demonstrated that initial amylase release, stimulated by ACh, was independent of 
extracellular Ca2+ but could not be sustained in the absence of extracellular Ca2+. Re-
introduction of Ca2+ to the extracellular solution, during maintained ACh stimulation, 
resulted in amylase release once again (96). This is because sustained amylase release 
requires sustained elevation in cytosolic Ca2+ which is driven by Ca2+ entry from the 
extracellular solution (97). Increase in cytosolic Ca2+ upon CCK stimulation was later 
visualised using quin2 as a fluorescent Ca2+ probe (98). It was observed that the amplitude of 
the Ca2+ signal was directly proportional to the concentration of agonist used to stimulate said 
signal - until a peak in intracellular Ca2+ was attained; however, the magnitude of amylase 
released had a biphasic relationship with the concentrations of agonist applied to cells 
(98,99). The Ca2+ signal that is responsible for triggering the exocytosis of enzymes in acinar 
cells was demonstrated to be an oscillatory signal (100,101) 
Pancreatic acinar cells express CCK receptors for which the ligand is the hormone CCK, the 
release of which is stimulated during the intestinal phase of digestion (102,103). In addition, 
acinar cells also express mAChR for which the ligand is the neurotransmitter acetylcholine 
(ACh), which is released during all stages of digestion (87,88,104). In addition, vasoactive 
intestinal peptide, substance P, gastrin-releasing peptide and secretin also regulate enzyme 
secretion by the acinar cells (105).  
mAChR are GPCRs that are coupled to PLC (106), which hydrolyses PIP2 resulting in the 
production of the second messenger IP3 and the downstream liberation of Ca
2+ from Ca2+ 
stores via the IP3R. The CCK receptor type 1 has two different affinity states in pancreatic 
acinar cells (107,108), when activated by physiological concentrations of CCK it is thought 
that the high affinity binding site on the CCK receptor is occupied and coupled to an ADP-
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ribosyl cyclase (109) – one of which is CD38(110). ADP-ribosyl cyclases, such as CD38 are 
responsible for the synthesis of two second messengers: cADPR and NAADP (111), at least 
in pancreatic acinar cells. NAADP was first demonstrated to release Ca2+ from intracellular 
stores in sea urchin eggs (112) and later  in pancreatic acinar cells (113). It was also 
demonstrated that cADPR liberates Ca2+ from intracellular stores localised in the apical pole 
of pancreatic acinar cells (114). cADPR-induced Ca2+ released was demonstrated to be both 
heparin and ryanodine sensitive, indicating it liberated Ca2+ from both IP3R and RyR (114). It 
is thought that NAADP releases Ca2+ from acidic organelles through two-pore channels (19) 
localised on lysosomes (115), the ER store directly via RyR (18) and indirectly through CICR 
from RyR (19,110,115). cADPR has also been demonstrated to liberate Ca2+ from other 
acidic stores such as zymogen granules (93). When supra-physiological concentrations of 
CCK are present, CCK is thought to bind to the low affinity binding site on the CCK 
receptor, PLC is activated and IP3 is formed, liberating Ca
2+ from the ER through the IP3R 
(107,108). The cell surface receptors and the second messengers produced upon binding of 
the appropriate ligand is summarised in figure 1.3, detailing the intracellular receptors that 
are targeted by the second messengers.  
Stimulation of cell surface receptors such as mAChR and CCK receptors, on the basolateral 
membrane, stimulates the formation of IP3, NAADP and cADPR, which bind to their 
respective receptors on the membrane of intracellular Ca2+ stores, resulting in the release of 
Ca2+ into the apical region of the acinar cell. Ca2+ signals, both local and global signals, are 
always initiated in the apical region of pancreatic acinar cells, even if they are elicited 
differently (23,116).  Stimulation of the cell surface receptors at physiological concentrations 
of an agonist results in a Ca2+ signal that is oscillatory and is restricted to the apical pole 
(23,117). Each oscillation in cytosolic Ca2+ has been shown to precede a wave of exocytosis 
of secretory granules, often measured by monitoring changes in membrane capacitance 
(118,119). The restriction of these oscillatory Ca2+ signals is due in large part to the Ca2+ 
buffering capacity of the cytosol (120). In pancreatic acinar cells there is a distinct feature 
that aids the restriction of Ca2+ signals to the apical pole, this is the perigranular belt of 
mitochondria around the granular region of the cell (121–123). This belt of mitochondria 
(figure 1.2) serves to increase the buffering capacity of this sub-cellular region, as 
mitochondria have the capacity to take up Ca2+ via the MCU; cytosolic Ca2+ signals in the 
apical pole are followed by mitochondrial Ca2+signals in the perigranular mitochondria (122).  
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Figure 1.3 Schematic diagram of the Ca2+ signalling pathway in a pancreatic acinar cell 
The two major cell surface receptors in pancreatic acinar cells are the muscarinic ACh 
receptors and the CCK1 receptor. ACh is coupled to PLC which hydrolyses PIP2 to give IP3 
and DAG. IP3 binds to the IP3R on the ER membrane and results in the release of Ca
2+ from 
the ER store. The CCK1 receptor has two affinity states, when CCK binds to the high affinity 
state CD38 is activated resulting in the production of NAADP and cADPR as second 
messengers. Which can liberate Ca2+ from RyR on the ER membrane (and other channels on 
lysosomes – not shown). If CCK binds to the low affinity binding site then PLC is activated 
and IP3 is produced. Both IP3R and RyR have calmodulin binding domains. Once Ca
2+ is 
liberated from the ER STIM1, in the ER membrane, detects ER store Ca2+ content and 
oligomerises and translocates to ER-PM junctions to activate CRAC channels, allowing Ca2+ 
to enter the cell from the extracellular space. CRAC channels also possess calmodulin 
binding domains. STIM1 also has a calmodulin binding domain. SERCA is a Ca2+-ATPase 
that actively pumps Ca2+ back into the ER and PMCA is another Ca2+-ATPase that actively 
pumps Ca2+ out of the cell across the plasma membrane both are activated by increased 
cytosolic Ca2+ levels.  
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Furthermore, the proximity of the mitochondria to the granular region provides the ATP 
required by the secretory machinery of the cell (11), ATP production by mitochondria is also 
driven by Ca2+ (31). 
The initial Ca2+ signal for exocytosis is primarily elicited by IP3-induced Ca
2+ release from 
the ER (23,124) and is independent of extracellular Ca2+ (125). However, for sustained 
release of enzymes, in order to digest a sizeable meal, continuous oscillations in intracellular 
Ca2+ for that duration of time would be required, thereby Ca2+ influx from the extracellular 
medium is also required (125). There is sufficient Ca2+ stored in the ER to respond to 
stimulation by a physiological concentration of ACh for 7-8 minutes in the absence of 
extracellular Ca2+, after that the frequency and the amplitude of Ca2+ oscillations decreased 
until they ceased (126). Ca2+ influx across the membrane provides the necessary Ca2+ to drive 
prolonged intracellular Ca2+ signals, Ca2+ entry is through store-operated Ca2+ entry channels 
located on the basal membrane of acinar cells (74). It is now known that the ER Ca2+ filled 
status is monitored by STIM1, which upon Ca2+ depletion, oligomerises and activates, 
leading to activation and opening of the CRAC channels found in the plasma membrane (for 
more extensive details on mechanism of store-operated Ca2+ entry, see section 1.5) (127). 
Both STIM1 and Orai1, the two key constituents of the CRAC channel are expressed in 
pancreatic acinar cells and functionally mediate store-operated Ca2+ entry (80,128–130). In 
instances where cell surface receptor stimulation is sufficiently high, due to high 
concentration of agonist, global Ca2+ signals are elicited (23,120). The signal is initiated 
apically and overwhelms the buffering capacity of the cytosol and the perigranular 
mitochondria (121), resulting in the propagation of the Ca2+ signal to the basolateral poles of 
the cell via CICR and the RyRs play a key role in this (25) (figure 1.3). 
In addition to the ER intracellular Ca2+ store pancreatic acinar cells also possess an acidic 
Ca2+ store, localised in the apical region. Lysosomes contain a lot of Ca2+ creating an 
electrochemical gradient for release to the cytosol. In the lysosome membrane are channels 
known as two pore channels which release Ca2+ when stimulated by their agonist NAADP. 
This process contributes to elevations in cytosolic Ca2+ in response to agonist stimulation 
(18,131).
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Figure 1.4 Schematic diagram demonstrating how NAADP-induced Ca2+ release can 
contribute to an elevation in cytosolic Ca2+ 
NAADP stimulates Ca2+ release from lysosomes or endosomes through the two pore 
channels, which results in CICR through RyR located on zymogen granules and the ER. 
Figure from (18). 
The PMCA is the major Ca2+ extrusion pathway in pancreatic acinar cells. Experiments 
indicated that Ca2+ extrusion in this cell type was not mediated by NCX (132). ACh 
stimulated an increase in cytosolic Ca2+ concentration, that resulted in an increase in 
extracellular Ca2+ concentration that was similar in amplitude (132,133), indicating that the 
majority of Ca2+ that was released by maximal stimulation by ACh was extruded across the 
plasma membrane (83), rather than taken back up into intracellular Ca2+ stores or into 
mitochondria. In addition to extruding Ca2+ released by maximal stimulation of the cell, the 
PMCA also pumps Ca2+ released by physiological stimulation of cells, in the form of 
oscillatory signals, across the membrane resulting in step-wise increase in extracellular Ca2+ 
concentration. This action of the PMCA enabled resting cytosolic Ca2+ concentrations to be 
restored (68). The PMCA is primarily localised at the apical membrane of the cell, where 
there is expression on the lateral membrane and much less expression on the basal membrane 
(83,134). It has a calmodulin-binding domain which facilitates its activation by intracellular 
Ca2+, by increasing the affinity of the pump for Ca2+ and increasing the maximum pumping 
capacity. The PMCA was found to be saturated at cytosolic Ca2+ concentrations of 
approximately 400 nM, indicating its role in maintaining resting cytosolic Ca2+ 
concentrations (135).  
The SERCA actively pumps Ca2+back into the ER and provides another Ca2+ extrusion 
pathway in pancreatic acinar cells (136). Pancreatic acinar cells express SERCA2a and 
SERCA2b, SERCA2a was shown to be exclusively expressed at the apical pole of the cell, 
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whereas high levels of SERCA2b expression was detected primarily at the basal pole of the 
cell, with further staining noted on the nuclear envelope (134). Basal expression of SERCA 
allows for uptake of Ca2+ into the ER in the basal part of the cell, where the bulk of the ER is 
located in the polarised pancreatic acinar cell (137), store-operated Ca2+ influx through a 
focal point on the basal membrane resulted in reloading of the ER stores with Ca2+, with no 
notable increase in cytosolic Ca2+ (74), due to local Ca2+ entry and local uptake. Of note, 
subsequent stimulation of the cells resulted in a Ca2+ signal initiated apically, indicating a 
tunnelling of the Ca2+ through the ER from the base of the cell to the apical region (74) 
demonstrating the lumen of the ER is continuous. There is further evidence suggesting that 
the movement of Ca2+ from the ER bulk in the basal region of the cell to the ER extensions in 
the apical region of the cell is rapid, once Ca2+ is released from the apical termini (137). The 
SERCA was found to be more than 20 times faster in resequestering Ca2+ into ER stores 
when cytosolic Ca2+ concentrations were elevated (350 nM) as opposed to closer to resting 
concentration (120 nM) suggesting the uptake of Ca2+ into ER stores is largely reserved for 
removing Ca2+ from the cytosol after global signalling events (135).  
1.5 Store-operated Ca2+ entry.  
Several cellular functions, not limited to exocytosis, are dependent on prolonged intracellular 
Ca2+ signals (138) and intracellular Ca2+ stores provide only a finite source of Ca2+. Ca2+ 
entry across the plasma membrane down the huge concentration gradient for Ca2+ provides an 
almost limitless supply of Ca2+ to drive intracellular Ca2+ signalling needs. In non-excitable 
cells this Ca2+ entry is via store-operated channels in the plasma membrane rather than 
voltage-gated channels; the CRAC channel is the most well studied store operated Ca2+ 
channel, although the molecular identity of the channel components remained elusive for 
many decades. Gene expression is another cellular process that has a requirement for Ca2+ 
entry through CRAC channels. Nuclear factor of activated T cells (NFAT) is a downstream 
effector of increased cytosolic Ca2+. The NFATs are a family of transcription factors that 
under resting conditions are localised in the cytosol of cells, in a highly phosphorylated state. 
Calcineurin is a Ca2+/calmodulin-dependent phosphatase that is responsible for 
dephosphorylating NFAT resulting in its translocation from the cytosol to the nucleus, where 
it can regulate transcription of its associated genes. NFAT molecules provide the link 
between intracellular Ca2+ signals and gene expression (139). Translocation of NFAT to the 
nucleus can therefore be utilised as a read out for CRAC channel activity, as following even a 
short pulse of Ca2+ entry through CRAC channels NFAT translocates to the nucleus (140) – it 
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can be monitored using fluorescently tagged NFAT or utilising a GFP gene under NFAT 
promoter which will be expressed after NFAT has translocated.   
The idea of capacitative Ca2+ entry was first introduced in 1981 (141) and then by Putney in 
1986 (142). The idea proposed was that Ca2+ entry occurs in response to intracellular Ca2+ 
store depletion in order to refill intracellular store and that the activating feature, Ca2+ store 
depletion, is as a result of Ca2+ release. Putney attributes the hypothesis to two papers from 
the 1970s using  lacrimal and parotid acinar cells respectively (143,144) where stores were 
shown to be refilled by Ca2+ entry and in one report this refilling was shown to be 
independent of cell surface receptor  activation (143). His idea in identifying store-operated 
Ca2+ as “Capacitative Ca2+ entry” was due to continuous loading and release of Ca2+ into and 
fro, stores, like a capacitor in a circuit (145). It remained unclear where the Ca2+ that entered 
across the plasma membrane went, it was originally hypothesised that it directly entered the 
intracellular stores which were thought to be connected to the plasma membrane (145). A 
later study provided evidence that Ca2+ enters the cytosol before uptake into the intracellular 
stores (146), it also demonstrated that thapsigargin, which is now a known SERCA pump 
inhibitor, inhibited Ca2+ uptake into the intracellular store (146) - thapsigargin became a very 
useful tool to study store-operated Ca2+ entry.  
Hoth and Penner undertook extensive electrophysiological recordings combined with Fura-2 
measurements and demonstrated the existence of a Ca2+ selective ion channel which is known 
as the CRAC channel, through which Ca2+ enters the cell across the plasma membrane. 
Removal of extracellular Ca2+ resulted in loss of CRAC channel current (ICRAC) (147). 
Chelation of divalent ions in the extracellular medium resulted in an increase in the 
permeability of monovalent ions, through CRAC channels, that did not exist in the presence 
of divalent ions (148); when conducted by monovalent ions ICRAC is larger than when 
conducted by Ca2+ (149). The channel conductance is so small it could not be measured 
directly, it was indirectly measured by Zweifach and Lewis to be 24 fS. When current was 
carried by Na+ (in the absence of divalent ions in the extracellular medium) it was 
approximated to be 2.6 pS (149). The channels also exhibited intracellular Ca2+ dependent 
inactivation (147) and extracellular Ca2+ dependent potentiation of the channel (148).  
For many years it was clear that these channels were activated by the depletion of Ca2+ from 
the ER stores, rather than an increase in cytosolic Ca2+ levels. The mechanism by which 
store-depletion activated ICRAC remained elusive until the identity of the components of the 
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CRAC channel were determined. Hypotheses ranged from a diffusible signal, which confers 
information on the depletion status of intracellular stores to activate Ca2+ entry, to a 
conformational change model similar to the one that occurs in skeletal muscle between 
ryanodine receptors and voltage gated Ca2+ channels. In the skeletal muscle conformational-
change model the voltage gated Ca2+ channel, in the plasma membrane, is physically coupled 
to intracellular RyR found in the ER membrane situated at an ER-PM junction, where the ER 
and plasma membrane a within a few nanometres of one another. The idea was suggested that 
CRAC channel was somehow physically coupled to IP3 receptors, which could convey ER 
Ca2+ store status to the plasma membrane channel, thus a fall in ER Ca2+ would result in a 
conformational change in the IP3 receptor and activation of the CRAC channel and 
subsequent Ca2+ influx. However, there is a lack of evidence to support this particular 
hypothesis of a direct physical coupling, although the close spatial association of the ER and 
PM is now known. The formation of ER-PM junctions is now key to the accepted mechanism 
of store-depletion and CRAC channel activation. 
The molecular identity of both the ER Ca2+ sensor (150,151) and the CRAC channel (152–
154) were determined in 2005 and 2006 respectively. STIM1 and STIM2 were identified in a 
small interrupting RNA (siRNA) screen in HeLa cells (151); at the same time another group 
identified STIM1 in Drosophila S2 cells (150). The siRNA screens in which STIM1 or 
STIM2 had been knocked down demonstrated normal Ca2+ release dynamics, but the 
subsequent plateau in intracellular Ca2+ was markedly reduced in STIM1 knockdown, STIM2 
knockdown and STIM1/2 knockdown experiments (151). Authors noted that in response to 
store depletion there was a rapid translocation of STIM1 from a disperse expression pattern 
across the ER at rest, to punctate structures located at sites of the ER that were juxtaposed to 
the plasma membrane. STIM1 was identified as being the ER Ca2+ sensor, it is a single 
transmembrane protein that spans the ER membrane with its amino terminus located inside 
the lumen of the ER. The luminal terminus of STIM1 contains a Ca2+ binding motif known as 
an EF-hand domain, this domain allows STIM1 to monitor the concentration of free Ca2+ 
within the lumen of the ER. Mutations of residues in the EF-hand that prevent Ca2+ from 
binding allow Ca2+ entry independent of ER store content (151,155). The second laboratory 
that identified STIM1 determined that it had a significant role in store-operated Ca2+ entry 
utilised a small scale RNA interference (RNAi) screen in Drosophila S2 cells and identified 
that Stim knockdown resulted in a reduction in store-operated Ca2+ influx in both Ca2+ 
imaging and electrophysiological experiments (150). Authors then moved to study the role of 
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STIM1 in Jurkat T cells, knockdown of STIM1 in these cells resulted in a dramatic reduction 
in Ca2+ entry, which was also seen in HEK293 cells where the pattern of STIM1 expression 
was confirmed to be the same as the other study(151) and was reduced upon STIM1 
knockdown (150).  
A year after the work identifying STIM1 several groups identified Orai1, a four 
transmembrane domain channel protein that is the pore forming subunit of the CRAC 
channel. The groups identified Orai1 using patients who had severe combined 
immunodeficiency (SCID) and their families, researchers identified mutations in a gene 
associated with SCID through genetic linkage analysis (152). A concurrent RNAi screen in 
Drosophila cells that sought to identify regulators of NFAT resulted in the identification of 
dStim and dOrai. Knockdown of either dStim or dOrai resulted in inhibition of thapsigargin-
activated store operated Ca2+ entry (152). Expression of wild-type Orai1 rescued the CRAC 
current in T cells derived from SCID patients. Further siRNA studies were undertaken to 
identify other components involved in SOCE. A second laboratory also utilised Drosophila 
S2 cells for a high-throughput genome wide RNAi screen, where 23 000 genes were tested 
for their involvement in SOCE (154). Using STIM1 as a positive control two genes were 
identified as having an involvement in store-operated Ca2+ entry - CRACM1 and CRACM2. 
siRNA against CRACM1 in HEK293 and Jurkat T cells resulted in a significant reduction 
CRAC currents as stimulated by IP3 mediated store depletion (154). The third laboratory to 
identify Orai1 also used Drosophila S2 cells in a genome wide RNAi screen, they identified 
Ca2+ entry inhibition when dOrai was knocked-down. The results of the screen were 
confirmed in individual patch-clamp experiments where CRAC currents were measured in 
cells pre-treated with dOrai dsRNA, current was almost completely inhibited compared to 
control (153).  
Three separate groups determined that Orai1/CRACM1 was a component of the CRAC 
channel but it remained unclear exactly what its role was (152–154). Further studies utilised 
mutagenesis of two conserved acidic residues of Orai1 and found altered ion selectivity of 
Orai1 when the mutant protein was overexpressed in HEK293 cells, this provided strong 
evidence for the role of Orai1 as the pore forming subunit of the CRAC channel, rather than a 
plasma membrane bound accessory protein of the channel (156). The exquisite selectivity of 
Orai1 for Ca2+, under physiological conditions, is because when Ca2+ is bound to the pore of 
the channel monovalent ions such as Na+ cannot permeate, this is similar to channel 
selectivity of voltage-gated Ca2+ channels for Ca2+ (156,157). Furthermore, it was determined 
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that CRAC channels have a very low conductance, which lead to difficulties in the 
measurement of the current, the conductance of the CRAC channel is 100 times smaller than 
that of other Ca2+ permeable channels (158). It is now known the Orai1 has an intracellular 
calmodulin-binding domain that facilitates Ca2+-dependent inactivation of the channel 
(159,160), which is similar to the mechanism by which voltage gated Ca2+ channels are 



















Adapted from  (162)
Figure 1.5 Schematic diagram demonstrating the dynamics of store operated Ca2+ entry 
and the key components involved: STIM1, STIM2 and Orai1 
A - At rest, the ER is replete with Ca2+ which is sensed by the ER Ca2+ sensors STIM1 and 
STIM2, which are found dispersed throughout the ER membrane when they are bound to 
Ca2+. Orai1 is localised in the plasma membrane and it thought to exist as a hexamer (shown 
here as a tetramer). STIM2 is responsible for maintaining resting levels of Ca2+ and so 
aggregates and activates Orai1 even at rest. B- In response to cell surface stimulation Ca2+ is 
released from the ER, this loss of Ca2+ from the ER is sense by STIM1, which aggregates and 
translocates to ER-PM junctions where it activates Orai1. Once activated Orai1 opens permit 
the influx of Ca2+ from the extracellular milieu.  
Pre-stimulation, at rest: After stimulation and Ca
2+ release: A B 
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The mechanism by which STIM1 activated Orai1 was not clear immediately after the 
discovery of the two proteins. A simplified schematic diagram of the changes that occur to 
STIM1 and Orai1 during SOCE is shown in figure 1.4. It demonstrates the dispersed 
expression of STIM1in the ER membrane at rest and the translocation to ER-PM junctions, 
closely apposed to Orai1 after ER store depletion. It was known that the two proteins 
colocalised and were localised at ER-PM junctions (163,164). Whether the two proteins 
directly interacted or not was highly controversial for a period of time. Studies using confocal 
Förster resonance energy transfer (FRET) microscopy measured the interaction between 
fluorescently tagged Orai1 and STIM1. Orai1-CFP (cyan fluorescent protein) and STIM1-
YFP (yellow fluorescent protein) were co-expressed in HEK293 cells and FRET 
measurements were made, FRET interactions dramatically increased upon depletion of ER 
stores by either thapsigargin or ionomycin (165). This supported the idea that STIM1 
physically interacts with Orai1 (165,166). Upon store depletion, Ca2+ dissociates from the EF 
hand on STIM1 catalysing the oligomerisation of STIM1 (167); this step precedes the 
activation of Orai1 at the plasma membrane. STIM1 dimers can form without the cytosolic 
domain of STIM1 (168), in response  to Ca2+ depletion. However aggregates of STIM1 are 
only stable when, in the very least, the CRAC activation domain (CAD) of STIM is present 
(169), meaning that the CAD domain of STIM1 mediates the oligomerisation of STIM1 but 
also binds to the N- and C-terminus of Orai1and activates it (170,171). STIM1 has a diffuse 
localisation in resting cells, with replete Ca2+ stores, which upon store depletion oligomerises 
before diffusing through the ER to the ER-PM junctions where they form puncta (172).  
STIM1 and Orai1 form the minimal required constituents for CRAC channel activation and 
Ca2+ entry (163,171,173) but many other proteins have been found to play a role in the 
modulation of CRAC channel activity such as: the CRAC regulator 2A (CRACR2A) (174), 
SARAF (175) and calmodulin (176) are a few STIM1 binding proteins. In addition 
calmodulin also binds Orai1 (159,177) as does CRACR2A. Several other modulating proteins 
of CRAC channels have also been identified and are well reviewed by Prakriya and Lewis 
(127).  
CRAC channels are highly conserved from yeast to humans (138,178) further emphasising 
the importance of store-operated Ca2+ entry to cells in physiology. Dysregulation in Ca2+ 
homeostasis is the precursor to many diseases as noted in section 1.1, more specifically 
dysregulation in store-operated Ca2+ entry has also been implicated in Alzheimer’s disease 
(179), Cancer (180–182) and many diseases of the immune system (183–186). As early as 
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2000 (187) store-operated Ca2+ entry, which is now known to be mediated by the 
STIM1/Orai1 pathway, was identified as a potential therapeutic target for acute pancreatitis. 
It was noted by authors that supramaximal stimulation of cells resulted in a global and 
sustained increase in cytosolic Ca2+ that persisted until extracellular Ca
2+ was removed, thus 
preventing further Ca2+ entry. By preventing Ca2+ re-entering cells, PMCA and SERCA can 
efficiently extrude elevated Ca2+ from the cytosol and reduce Ca2+ back to pre-stimulation 
levels. It was concluded that inhibiting Ca2+ entry would be an “attractive therapy for 
prevention of premature protease activation” (187). Orai1 and STIM1 expression in 
pancreatic acinar cells has since been reported (80). As seen in other cell types STIM1 has a 
dispersed localisation on the ER membrane of unstimulated pancreatic acinar cells, upon 
store depletion it translocates and forms puncta in sub-plasma membrane locations in the 
basolateral poles of the cells. The puncta formed by STIM1 colocalise with Orai1 (80). Ca2+ 
entry across the basolateral pole of the acinar cells serves to refill the ER stores after store 
depletion (74), the ER Ca2+ tunnel hypothesis indicates that Ca2+ uptake into the ER by 
SERCA in the basolateral region of the cell would then be tunnelled through the ER towards 
the apical region where it can be released through IP3R and provide the signal for continued 
exocytosis (74). Once cell surface receptor stimulation has ceased, Ca2+ continues to enter the 
basolateral region of the cell to be taken up into the ER, store depletion status is still 
monitored by STIM1 and upon completion of refilling STIM1 is deactivated and re-
translocates to a disperse expression across the ER membrane and Orai1 is no longer 
activated and open, as such Ca2+ influx also ceases.  
1.5.1 Pharmacology of CRAC channels 
As sustained activation of Orai1 and STIM1 mediated store-operated Ca2+ entry has been 
implicated in many different diseases, CRAC channels have been identified as a potential 
therapeutic target (183). The limiting factor has been and remains to be the lack of specific 
inhibitors of CRAC channels. Trivalent ions, such as lanthanum (La3+) and gadolinium 
(Gd3+), are very potent inhibitors of CRAC channel mediated Ca2+ entry, inhibiting at low 
nanomolar concentration. In addition to inhibiting Ca2+ entry mediated by CRAC channels 
the lanthanides also have non-specific effects on other Ca2+ entry channels like voltage-gated 
Ca2+ channels (188), non-specific cation channels (189) and potentially the PMCA (190), but 
at slightly higher concentrations. The mechanism by which Gd3+ ions block CRAC channels 
is by preventing Ca2+ from accessing the selectivity filter and pore of the channel, preventing 
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Ca2+ ion permeation (191). Due to the non-specific effects of the lanthanides their use in the 
development of further CRAC channel inhibitors is limited.  
2-aminoethyl diphenylborinate (2-APB), originally developed as an IP3R antagonist, was 
noted to inhibit CRAC channels (192). It was further noted that 2-APB had a biphasic action 
on CRAC channel currents (193); this is detailed further in chapter 3. Despite the ability of 2-
APB to inhibit CRAC channel mediated Ca2+ entry, it was found to have numerous off-
targets effects which rendered it unusable as a therapeutic agent, although it is a useful 
pharmacological tool in the laboratory, particularly due to its differential action on the 
different Orai isoforms. 2-APB it is capable of potentiating Ca2+ influx mediated by Orai1 
and Orai2 at low doses and inhibit Orai1 and Orai2 at higher concentrations, whereas it can 
activate Orai3-mediated Ca2+ influx in a store-independent manner (193,194).  
There are a plethora of pyrazole derived compounds that have been designed to target CRAC 
channels and these compounds have been used extensively in vitro (195,196). The pyrazole 
derivatives were originally developed as immunosuppressive agents, as those that were used 
clinically, such as cyclosporine A, were associated with nephrotoxicity and neurotoxicity 
(197). 3,5-bistrifluoromethyl  pyrazole (BTP) compounds blocked the translocation of NFAT 
from the cytoplasm to the nucleus. When this was investigated further it was found to be due 
to an inhibitory effect on Ca2+ influx through CRAC channels. BTP2 or YM-58483 inhibited 
Ca2+ influx induced in Jurkat T cells in a dose-dependent manner, although used at doses of 
10 nM only when it was used at doses of 1 µM was a remarkable inhibition of Ca2+ influx 
observed. When cells were pre-treated with BTP2 for one minute the observed IC50 was 100 
± 40 nM (198). In another experiment where peripheral blood lymphocytes were used, cells 
were pre-treated with 100 nM BTP2 for 24 hours before the experiment, however even this 
was not sufficient to entirely inhibit store operated Ca2+ entry (199). It was also shown to 
affect other channels that permit Ca2+ entry into the cell, BTP2 was shown to activate 
TRPM4 at low nanomolar concentration, a Ca2+ activated non-selective cation channel (200), 
this action rendered it unusable clinically, despite its preferential targeting of CRAC channels 
over inwardly rectifying K+ channels, PMCA and voltage-gated Ca2+ channels (198,199). 
Synta 66 is structurally very similar to BTP2 and was also demonstrated to be a CRAC 
channel inhibitor in RBL-1 cells (201) - a mast cell line, in Jurkat T cells and RBL-2H3 cells 
(202). The IC50 for Synta 66 in RBL-1 cells was 3 µM, and in RBL-2H3 cells it was 
measured to be 1.4 µM. Pre-treatment for 5 minutes with 10 µM Synta 66 was sufficient for 
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nearly complete inhibition of CRAC channel current (201). It was found that 10 µM Synta 66 
had no effect on PMCA or inwardly rectifying K+ currents, two major ion transport 
mechanisms in the plasma membrane of mast cells. However, in vascular smooth muscle 
cells Synta 66 was particularly potent at inhibiting CRAC channels between, the IC50 was 
between 26 – 43 nM, however it appears that this study utilised 200 µM Ca2+ in the 
extracellular solution (203), which is 10 fold smaller than other experiments, thus resulting in 
a reduced driving force for Ca2+ to cross the membrane (201). Overall Synta 66 has a 
relatively high IC50 compared to BTP-2, so similarly would be of limited clinical use, but 
together the two compounds present ideal candidates from which chemists could develop new 
inhibitors (183).  
Pyrazole derivatives have been particularly efficient as CRAC channel inhibitors but the 
specificity of the inhibitors for the CRAC channel only has always been limited. A novel 
compound GSK-7975A has been reported (130,204–207) to completely inhibit CRAC-
mediated Ca2+ influx with a high degree of specificity within its therapeutic dose range (low 
micromolar) for further details see chapter 3. 
1.5.2 AnCoA4 inhibition of Orai1 
Using a technique known as a small molecule microarray (SMM) assay several drugs were 
identified as inhibitors of SOCE. SMM assays are a general binding assay that, compared to 
other assays used in high-throughput screens for drug development, requires little prior 
knowledge of protein structure or function (208). In SMM arrays nanolitres of organic 
compounds are arrayed onto glass slides and then incubated with the protein of interest. The 
protein of interest is conjugated to a fluorescent probe, in order that an interaction of the 
protein with the small molecule can be visualised (208).  
In a SMM assay study the known minimal functional domains of STIM-1 and Orai1: the 
(CAD of STIM-1 and the N-terminal, the C-terminal and the 2-3 loop domains of Orai1 
individually, were used to screen 12,000 small molecule compounds. STIM-1 CAD and 
Orai1 N-terminal, C-terminal and 2-3 loop were all conjugated to glutathione S-transferase 
(GST) and visualised using anti-GST fluorescent antibodies (209). Of the 12,000 compounds 
screened, 120 were found to bind to the Orai1 peptides and 51 of these compounds were 
commercially available and as such utilised in further testing. HEK293T cells were used to 
test the effects of the compounds in intact cells and an NFAT reporter gene assay was used. 
When SOCE occurs NFAT is dephosphorylated and is activated, as such an NFAT assay can 
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be used as readout of SOCE activity. The 51 commercially available compounds were 
applied to HEK293T cells at a concentration of 50 µM for 6 hours in the presence of 1 µM 
thapsigargin to activate SOCE, after which the NFAT-luciferase expression levels were 
measured. From the 51 compounds tested in intact cells four compounds were identified as 
having an inhibitory effect on the activation of the NFAT-luciferase reporter gene suggesting 
an inhibitory effect on Orai1. Of these four compounds AnCoA4 was identified as the most 
efficient inhibitor of Orai1 with an EC50 of 880 nM. AnCoA4 was found to bind directly to 
the C-terminal of Orai1 and prevented STIM1 binding. A fluorescence aggregation assay was 
used, in which mCherry constructs of the minimal functional domains of Orai1 were 
employed. Protein aggregation quenches the mCherry fluorescence, therefore compounds that 
bind the protein prevent aggregation and subsequent quenching, thereby increasing mCherry 
fluorescence. AnCoA4 is more efficient when pre-incubated with cells, before the 
recruitment of STIM1 to ER-PM junctions during store depletion, suggesting it is a 
competitive inhibitor of Orai1(209). This hypothesis was confirmed by an experiment in 
which an Orai1 mutant, that is constitutively active in the absence of STIM1, was inhibited 
by AnCoA4, confirming that AnCoA4 binds to the site of Orai1 responsible for channel 
gating and the interaction with STIM1.  
1.5.3 Transient receptor potential channels 
Transient receptor potential (TRP) channels is a large family of ion channels that are 
ubiquitously expressed by mammalian cell types. As a family they share a common primary 
structure and are all permeable to monovalent ions and/or Ca2+ (189). All TRP channels have 
six transmembrane domains that likely form tetramers, evolutionary they are from the same 
type of channel as voltage gated K+ channels. The family is divided into sub-types based on 
sequence homology, the sub-types are: the canonical subtype - TPRC channels, the vanilloid 
subtype – TRPV channels, the melastatin subtype – TRPM channels and the mucolipin 
subtype – TRPML channels are some of the subtypes. TRP channels, specifically TRPC1, 
TRPC3 and TRPV6 channels were thought to be the plasma membrane component involved 
in store-operated Ca2+ entry (210–212), before the molecular identification of Orai1 was 
made. These three channels are all Ca2+ permeable. 
Store-operated Ca2+ entry mediated through the Ca2+ selective CRAC channels is the major 
pathway through which Ca2+ enters non-excitable cells, however Ca2+ entry through non-
selective cation channels still contributes towards an elevation in cytosolic Ca2+ and there is 
evidence of store-operated Ca2+ channels with biophysical properties distinct from that of 
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CRAC channels (138). TRPC channels typically generate non-selective cation currents. The 
TRPC channels are all activated in response to PIP2 hydrolysis, due to stimulation of other 
cell surface receptors. Activation of TRPC channels by store-depletion is surrounded by a 
substantial amount of controversy in the field, some TRPC channels are activated in a store-
independent manner, whereas evidence surrounding TRPC1 or TRPC3 channels is somewhat 
contradictory, with evidence indicating that TRPC1 and TRPC3 might serve as subunits in 
store-operated Ca2+ channels and are gated by STIM1 (213–215).  
There is a lot of evidence supporting a role for TRPC1 and TRPC3 as subunits of store-
operated Ca2+ channels, these papers utilise TRPC1 and TRPC3 channels in over-expression 
systems in many different cell types, from cell lines (216) to submandibular salivary gland 
cells (217). Knockdown of TRPC1 was performed utilising antisense oligonucleotides 
targeted against the protein, this knockdown resulted in a reduction in store-operated Ca2+ 
entry (217). It was found by knocking out TRPC1 in mice there was a reduction in store-
operated Ca2+ entry induced by thapsigargin-mediated store depletion in salivary glands 
(218). Expression of the TRPC3 channel has been reported in pancreatic acinar cells (219). 
Knockout of TRPC3 in these cells or pharmacological inhibition of TRPC3 leads to a 
reduction in store-operated Ca2+ entry induced by thapsigargin-mediated store depletion 
(220,221).  
The store-operated nature of TRPC channels is highly contested in the field (183), there is 
evidence that TRPC1 binds to and is activated by STIM1, in turn TRPC1 forms 
heteromultimers with TRPC3 and as such confers STIM1 dependence to TRPC3 (222), but 
this view is not held by all in the field.  
1.6 Acute pancreatitis 
Acute pancreatitis is a human disease characterised by inflammation, oedema and necrosis of 
pancreatic tissue (223). In England between 2013 and 2014 there were 25,000 hospital 
admissions for acute pancreatitis (224). In the United States acute pancreatitis was the most 
common gastrointestinal diagnosis with 275,000 admissions to hospital in 2009 (225). 
Patients admitted to hospital experience severe abdominal pain, nausea and vomiting and a 
fever (224). The major causes of acute pancreatitis are gallstones and excessive alcohol 
intake, there are some links to an increased incidence of acute pancreatitis including heavy 
smoking of cigarettes, hypertriglyceridemia and some drugs such as asparaginase. 
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Furthermore there are some genetic links to acute pancreatitis (226,227). In 10-20% of cases 
no known cause is found, despite recurrent attacks (228). 
Most cases of acute pancreatitis resolve by themselves which is fortunate as there is no 
current specific therapy for acute pancreatitis. Typically the inflammation associated with 
acute pancreatitis is local but in some cases there is a systemic inflammatory response which 
impacts on the functioning of other organs (228). There is a 15 to 20 % risk of mortality due 
to organ failure, either the pancreas or a distant organ (228). One incidence of acute 
pancreatitis is linked to recurrent episodes of the acute form of the disease, recurrent episodes 
are linked with chronic pancreatitis, which has long term effects on the health of both the 
exocrine and endocrine pancreas, with implications in the development of diabetes and also 
pancreatic cancer (229).  
As early as 1896 acute pancreatitis was attributed to the inappropriate, premature activation 
of pancreatic digestive proenzymes within pancreatic acinar cells (7), rather than after 
exocytosis from the cell and release from the pancreatic ducts into the duodenal lumen by 
enterokinase (84). The primary function of the exocrine pancreatic acinar cells is the 
synthesis of digestive proenzymes which are stored in the apical region of the cells in 
zymogen granules (230), however pathological stimuli can lead to intracellular activation of 
these enzymes, in the apical region of the cell, resulting in digestion of the acinar cell and 
surrounding tissue (231). The digestion results in cellular necrosis and release of the cell 
contents including digestive enzymes, resulting in further digestion of pancreatic acinar cells 
- this is known as autodigestion (223). Pancreatic injury results in inflammation, oedema, 
infiltration of leucocytes and necrosis (232). Pancreatic acinar cells themselves release 
inflammatory mediators in response to pancreatic injury such as tumour necrosis factor-α. 
(TNF-α) (233) and interleukin-6 (IL-6). The release of TNF-α results in the recruitment of 
more leucocytes to the site of injury, primarily these leucocytes are neutrophils and 
macrophages that, in turn, also release TNF-α which serves to amplify the inflammatory 
signal resulting in further recruitment of immune cells. Dendritic cells and T-cells are also 
recruited, but T-cells are recruited in much smaller numbers than the innate immune cells 
(232). 
As noted, physiological secretion of digestive enzymes is coupled to an increase in cytosolic 
Ca2+ in an oscillatory pattern (100). The premature, intracellular activation of digestive 
enzymes, which ultimately leads to necrotic cell death of acinar cells, is also coupled to 
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intracellular Ca2+ release (234). The distinction between the physiological and 
pathophysiological outcomes is the spatio-temporal profile of the intracellular Ca2+ signal. 
Exocytosis of digestive enzymes is preceded by short-lasting, repetitive, transient oscillations 
in cytosolic Ca2+ localised to the apical pole of the acinar cell (23,100); whereas pathological 
intracellular activation of enzymes is preceded by a sustained global elevation in cytosolic 
Ca2+ due to emptying of intracellular stores and the subsequent Ca2+ entry from the 
extracellular space (7,187,235).  
1.6.1 Alcoholic acute pancreatitis 
Excessive alcohol intake has also been extensively implicated as a major cause of acute 
pancreatitis (231,236–239). A recent increase in hospital admissions for acute pancreatitis 
(239) has been positively correlated with an increase in chronic alcohol consumption and also 
binge drinking (239). Alcohol intake in excess of 4 drinks per day results in more than a 
doubling in the risk of developing pancreatitis (both acute and chronic forms) (240). Acute 
alcohol ingestion alone was insufficient to cause acute pancreatitis in a rat (241), further 
agents such as CCK were required to cause acute pancreatitis (242); suggesting that alcohol 
consumption may sensitise the pancreas to other triggers of acute pancreatitis (243). 
However, chronic administration of alcohol resulted in alterations to pancreatic morphology 
in animal model, such as lipid droplet accumulation, protein plugs in pancreatic ducts and 
sclerosis (244). Not all heavy drinkers develop acute pancreatitis, which is likely in part 
because when ethanol is applied to intact isolated pancreatic acinar cells, even in very high 
concentrations (850 mM), only a modest increase in cytosolic Ca2+ was elicited (237); in line 
with effects observed in rats fed with alcohol alone (241,242). There are evidently other 
factors involved in alcoholic acute pancreatitis.  
There is evidence to suggest that excessive alcohol intake combined with a particularly fatty 
diet could be the most dangerous risk factor in developing acute pancreatitis (245). Pancreatic 
acinar cells express fatty acid ethyl ester (FAEE) synthases, which are enzymes that 
synthesise FAEE from ethanol and free fatty acids (246), which is the non-oxidative 
metabolism of alcohol in the pancreas. The oxidative metabolism of alcohol is mediated by 
alcohol dehydrogenase which produces acetaldehyde (247), there is evidence indicating that 
high concentrations of acetaldehyde can damage the pancreas of some species (248) but this 
does not appear to be the case in other experiments (248). Carboxylester lipase is a FAEE 
synthase that is synthesised in the acinar cell and stored in zymogen granules in the apical 
region of the cell (249). In autopsies of patients who have abused ethanol, FAEEs were found 
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in high concentrations in the pancreas and liver due to the high concentration of FAEE 
synthases in these organs (236).  
The non-oxidative alcohol metabolites FAEEs have been implicated in mediating alcoholic 
acute pancreatitis by initiating a global, sustained increase in cytosolic Ca2+  concentration, 
that is responsible for prematurely activating digestive proenzymes; whereas the oxidative 
metabolite of alcohol, acetaldehyde, did not result in elevations in cytosolic Ca2+ (237). 
FAEEs when applied to pancreatic acinar cells induced significant cellular necrosis, but 
equivalent concentrations of acetaldehyde did not (237,250).  
FAEEs have been shown to be toxic in vivo, in addition to the toxic effects that were 
observed during in vitro experiments. FAEE administration resulted in an increased 
trypsinogen activation, pancreatic oedema and vacuolisation of cytoplasm, indicating the 
presence of fats (251). It was demonstrated that it was the non-oxidative metabolite of 
ethanol and fats that was mediating the toxic effect of ethanol on pancreatic acinar cells as 
opposed to ethanol alone or its oxidative metabolite acetaldehyde (237). Palmitoleic acid 
(POA) ethyl ester (POAEE), one form of FAEE, when applied to pancreatic acinar cells gave 
rise to large and sustained increases in cytosolic Ca2+ concentration, that were concentration 
dependent in nature. This increase in cytosolic Ca2+ was due to IP3R activation and Ca
2+ 
release from the ER (252). Subsequent activation of store-operated Ca2+ entry mechanisms 
drove the sustained elevation in cytosolic Ca2+, the increase was reversed when Ca2+ was 
removed from the extracellular solution (237) and when cells were treated with the CRAC 
channel inhibitor GSK7975-A in vitro (130) or in vivo application of GSK7975-A (253). 
POAEE was found to deplete the cell’s ATP supply, resulting in the failure of the ATP-
dependent pumps and ultimately necrosis of the cell (252).  
The fatty acid, POA, itself elicited a substantial increase in cytosolic Ca2+ levels and induced 
cell death, the increase in cytosolic Ca2+ was slower than when elicited with POAEE (237). 
The cytosolic Ca2+ increase induced by POA was not reversed by the removal of extracellular 
Ca2+ unlike the Ca2+ rise elicited by POAEE (237) and furthermore was not inhibited by 
caffeine (252), suggesting that it is not driven by IP3R-mediated Ca
2+ release or store 
operated Ca2+ entry. The effects of POA and POAEE on cytosolic Ca2+ are likely due to their 
known uncoupling effect on oxidative phosphorylation (252,254), resulting in a decrease in 
mitochondrial ATP production and therefore impaired SERCA and PMCA activity. With an 
insufficient supply of ATP SERCA is unable to sequester Ca2+ back into the ER and balance 
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the passive leak; PMCA is unable to actively pump Ca2+ across the plasma membrane to 
counteract store-operated Ca2+ entry. In addition to impaired SERCA and PMCA activity, the 
vacuolar H+-ATPase in no longer able to maintain the high concentration of Ca2+ in the acidic 
stores and so that store of Ca2+ is also released (238). In addition to the effect of POA and 
POAEE on mitochondrial ATP production, it has also been demonstrated that ethanol itself 
depolarises the mitochondrial membrane (255). 
Application of low doses of ethanol and POA were demonstrated to elicit oscillatory 
increases in cytosolic Ca2+ that were converted to global sustained increases in cytosolic Ca2+ 
by using 4-MP to block oxidative metabolism of alcohol, preventing the formation of 
acetaldehyde. Further experiment in which the non-oxidative pathway was blocked using an 
inhibitor of carboxylester lipase, preventing the synthesis of FAEE, resulted in almost no 
increase in cytosolic Ca2+ (250). In the human disease it would appear the FAEE are 
responsible for mediating the toxic effects of alcohol in the development of acute pancreatitis 
(236,237,251–253) and as a model of acute pancreatitis administration of ethanol has 
minimal injurious effects on the pancreas (244) a model in which animals are administered 
free fatty acids and ethanol is a simple and elegant way to induce acute pancreatitis (250). 
Analysis of this model indicated that the treatment induced pancreatic damage, histological 
staining demonstrated pancreatic cell oedema, neutrophil invasion and pancreatic acinar cell 
necrosis, furthermore there was an increase in serum amylase and trypsin (250). In vivo 
inhibition of the oxidative metabolic pathway of alcohol worsened the damage to the 
pancreas, whereas inhibition of the non-oxidative metabolic pathway of alcohol ameliorated 
the damage to the pancreas.  
1.6.2 Biliary acute pancreatitis 
Gallstones form in the gallbladder and are a mixture of cholesterol and bile salts, they are 
often asymptomatic. Although they form in the gallbladder they may pass into the cystic duct 
which joins the common hepatic duct and drain into the common bile duct. Further down the 
common bile duct is the junction at which the pancreatic duct joins, this junction is known as 
the ampulla of Vater. This is one site of gallstone blockage and results in the reflux of bile 
into the pancreatic duct (256); because the opening from the common bile duct into the 
duodenum is blocked there is retrograde flow of bile up the common bile duct or along the 
pancreatic duct, this can be referred to as the “common channel theory” of acute pancreatitis 
(223). Another potential site for a gallstone to get lodged is in the pancreatic duct, this would 
not result in bile reflux into the pancreatic duct as it is blocked but it would result in 
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pancreatic ductal hypertension which could result in acinar cell injury (231). There is 
evidence that this can cause necrotising pancreatitis in some species but not in others, it is 
unclear whether it can cause necrotising pancreatitis in humans (223). There is significantly 
more evidence to support the common channel or bile reflux theory as a cause of acute 
pancreatitis (257).   
Bile salts are toxic to pancreatic acinar cells, they can be taken up by acinar cells by 
transporters localised on the basolateral membranes of cells (258). Bile acids such as 
taurolithocholic acid 3-sulfate (TLC-S) have been demonstrated to elicit increases in 
cytosolic Ca2+ that increased with increasing concentration of bile acid (259). Some cells 
responded to TLC-S application with oscillatory Ca2+ signals and others with sustained 
increases; the proportion of cells that responded with sustained increased in cytosolic Ca2+ 
increased with increasing concentration of bile acids (259). When used in vitro TLC-S as 
well as other bile acids such as: sodium taurocholate and taurochenodeoxycholate all elicited 
large sustained increases in cytosolic Ca2+(258,259), in a concentration dependent manner. 
The initial Ca2+ signal was derived from ER Ca2+ release, the sustained elevation of cytosolic 
Ca2+ was sourced from the extracellular milieu, removal of Ca2+ from the extracellular 
solution resulted in a rapid reduction of intracellular Ca2+ and return to baseline values, in the 
continued presence of bile acids. When TLC-S was applied to cells in Ca2+ free extracellular 
solution oscillatory Ca2+ signals were observed, indicating that the source of Ca2+ for the 
initial signal is derived from an intracellular source that is IP3 sensitive, highlighted by the 
lack of response to TLC-S in the presence of caffeine (259). Experiments demonstrating that 
the removal of extracellular Ca2+, in the maintained presence of TLC-S, caused a decrease in 
intracellular Ca2+ concentration (259) were supported by experiments in which bile acid 
increased the rate of Mn2+  influx which is indicative of unidirectional Ca2+ influx 
(258,260,261). Elevated cytosolic Ca2+ gets taken up by mitochondria and cause 
mitochondrial dysfunction, resulting in impaired ATP production and in the long-term 
provides the trigger for apoptosis and necrosis (223).  
As bile acids are known to have detergent properties (262), it is often thought that their toxic 
effects on acinar cells are mediated by permeabilisation of the plasma membrane and the lysis 
of the cell rather than an interference with the cell signalling pathway in intact cells (258). 
The retrograde flow of bile through the pancreatic duct was found to be at an insufficient 
pressure, which would result in bile acids being present at insufficiently high concentration to 
cause pancreatic damage through detergent properties (263). Extensive damage of the plasma 
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membrane of cells exposed to bile acids in vitro was not observed, no leakage of fluorescent 
indicators suggests that the membrane integrity of cells remained intact (264) except when 
used at concentrations more than 10 times higher than was found to activate store-operated 
Ca2+ influx (258).  
The role of Ca2+ influx, specifically CRAC channel mediated Ca2+ influx, in driving the 
sustained plateau in cytosolic Ca2+ concentration induced by bile acids was recapitulated in 
vivo in a mouse model of biliary acute pancreatitis. In this mouse model retrograde perfusion 
of the pancreatic duct with TLC-S was used to induce acute pancreatitis (253,265), it was 
adapted from a similar model used in rat pancreas that had previously never been successful 
in mouse (257). Retrograde perfusion of the pancreatic ducts with TLC-S induced an increase 
in serum amylase and trypsin concentration, IL-6 concentration and concurrently increased 
pancreatic oedema, inflammation, necrosis, as observed by histological staining. Orai1 
inhibitors GSK-7975A and CM128 were found to be successful in ameliorating several 
hallmarks of acute pancreatitis exhibited by this mouse model, including reducing the TLC-S 
induced increase in the aforementioned hallmarks of acute pancreatitis (253).  
In addition to liberating Ca2+ from IP3 sensitive intracellular stores, bile acids have also been 
demonstrated to reduce ER store content, due to bile acid inhibition of the SERCA pump 
(258). This was not due to an alteration in ATP concentration, as at this concentration bile 
acids did not affect the level of ATP production, at higher concentrations of bile acids 
however, ATP production was affected (258). The previous experiments, in this paragraph 
were undertaken using a mixture of bile acids, TLC-S alone, at even very low concentrations 
10 µM such as were unlikely to cause any notable increase in cytosolic Ca2+ concentration, 
was found to depolarise the mitochondrial membrane. High concentrations of TLC-S resulted 
in incredibly large membrane depolarisation, to a similar extent to the positive control CCCP 
(carbonyl cyanide m-chlorophenylhydrazone). Buffering of cytosolic Ca2+ with the fast 
acting chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) 
prevented the depolarisation of the mitochondrial membrane observed with low 
concentrations of TLC-S (266).  
1.6.3 Therapeutic targets for AP 
As there are no current specific therapies for the treatment of acute pancreatitis, and it is the 
single most diagnosed gastrointestinal disease for which patients are admitted to hospital 
(239,267) it is prudent to consider targets for drug development.  
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The CRAC channel has already been identified as an ideal target in the treatment of acute 
pancreatitis (187). It is the channel through which Ca2+ enters the cytosol from the 
extracellular milieu, the source of the Ca2+ that drives the cytosolic Ca2+ overload that 
activates digestive proenzymes intracellularly, resulting in the onset of acute pancreatitis. 
Some strides have been made in focusing on this target in the treatment of acute pancreatitis 
(130,253,268) but also there is a keen interest in the development of CRAC channel 
inhibitors, as CRAC channel activity has been implicated in other diseases such as asthma 
and cancer (183) (for more information see section 1.5.1 and chapter 3).  
Store operated Ca2+ entry is preceded by Ca2+ release from ER via IP3R and RyR, without the 
depletion of Ca2+ from the ER the CRAC channels would not be activated, as such one way 
of preventing cytosolic Ca2+ overload during acute pancreatitis is to prevent Ca2+ release from 
the ER stores in the first instance. Some success via this pathway has been seen, using the 
calmodulin activating peptide CALP3 (7), as calmodulin is involved in the regulating of 
several mechanisms by which Ca2+ can enter the cytosol through IP3R (17,269) (for more 
information see chapter 4). 
Mitochondrial dysfunction has been shown to be a key event in the pathology of acute 
pancreatitis induced by FAEE (252) and by bile acids such as TLC-S(270). Cytosolic 
Ca2+ overload leads to mitochondrial Ca2+ overload; mitochondrial Ca2+ overload results in 
the opening of the mitochondrial permeability transition pore (MPTP), which permits 
molecules up to 1.5 kDa to enter the mitochondria, resulting in the loss of mitochondrial 
membrane potential which drives ATP production (271). With insufficient ATP production 
the Ca2+ ATPases are inactive, SERCA and PMCA cannot actively pump Ca2+ into the ER 
and across the plasma membrane, respectively. Cyclophilin D is an important regulator of the 
MPTP, loss of cyclophilin D resulted in improved cell survival (272) due to protection from 
Ca2+ overload, cells were particularly protected from necrotic cell death (273). In the 
cyclophilin D knock out cells the MPTP was more resistant to opening, and therefore the 
mitochondrial membrane was not depolarised and the cell did not undergo necrosis due to 
ATP depletion (255). Pancreatic acinar cells from cyclophilin D knockout mice did not 
exhibit the dramatic mitochondrial membrane depolarisation after ethanol treatment that wild 
type acinar cells did. Wild type cells incubated with ethanol and CCK demonstrated high 
levels of necrosis; the necrosis levels were reduced to wild type control levels (in absence of 
ethanol and CCK) in the presence of ethanol and CCK in the cyclophilin D knockout acinar 
cells (255). These experiments highlight the importance of cyclophilin D as a target in 
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diseases in which a hallmark is cellular necrosis, such as acute pancreatitis. Ethanol and CCK 
were used to induce alcoholic acute pancreatitis in mice, and in cyclophilin D knockout mice, 
the levels of necrosis were reduced, ATP levels were higher, serum amylase and trypsin 
levels were reduced, indicating protection against the hallmarks of acute pancreatitis. Small 
molecule inhibitors of cyclophilin D have been developed and one molecule has been found 
to have promise, it protected the mitochondrial membrane potential that is depolarised upon 
the application of TLC-S, it also reduced necrosis in both murine and human pancreatic 
acinar cells (274).  
Caffeine has been demonstrated to prevent IP3R-mediated Ca
2+ release in vitro (53,275). This 
is thought to be due to an inhibition of phospholipase C-mediated production of IP3. Caffeine 
and some of its metabolites were tested for their efficacy in inhibiting signals induced by 
various agents, including TLC-s. Caffeine inhibited signals induced by 500 µM TLC-S in a 
dose dependent manner. In vivo treatment of mouse models of acute pancreatitis with caffeine 
ameliorated most hallmarks of acute pancreatitis. In these mouse models acute pancreatitis 
was induced by several different agents: Caerulin, TLC-S and ethanol and POA. Even when 
caffeine treatment was not started for 24 hours after acute pancreatitis is induced, it was still 
effective in preventing a lot of the biochemical hallmarks of acute pancreatitis (275). This 
makes it a promising agent as patients often do not receive treatment within 48 hours after the 
onset of the disease process.  
As the cause of pancreatic necrosis is the activation of digestive proenzymes, one strategy for 
treating acute pancreatitis is to administer protease inhibitors (276), this was utilised in 
randomised controlled trials to treat patients with severe acute pancreatitis. It was found to be 
a promising intervention in observational studies, small trials (277) and one randomised 
controlled trial (278) but a meta-analysis of many trials involving the intravenous infusion of 
protease inhibitors found that there was no significant difference in the mortality rate of 
patients suffering from acute pancreatitis  who were treated with protease inhibitors 
compared to those patients who were not treated (279). This could be due to the fact that 
inhibiting activated proteases is too far downstream of the initial cellular mechanism that 
triggered the chain of events, which would indicate trials involving pharmacological agents 
with actions at an early stage of the pathology are necessary, such as those that are targeted 
towards Ca2+ signalling (276). 
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As acute pancreatitis is an inflammatory disease, one strategy to treat it has been the use of 
anti-inflammatory and immune-modulating agents. The recruitment of leucocytes to the site 
of pancreatic injury has been positively correlated with the severity of acute pancreatitis 
(280–283). For example a TNF-ɑ antibody was used successfully to reduce acinar cell 
necrosis by preventing trypsinogen activation by neutrophils (284). A further benefit to this 
strategy of intervention is that the recruitment of leucocytes to the pancreas has been 
implicated in the activation of pancreatic stellate cells which are involved in fibrosis of the 
pancreas, a hallmark of chronic pancreatitis (190). Despite the testing of many different 
inhibitors of pro and anti-inflammatory agents, no one agent has been successful in clinical 
trials (232,282).   
1.7 Aims of thesis 
It is known that store-operated Ca2+ entry plays a role in the onset of acute pancreatitis due to 
its contribution to elevating cytosolic Ca2+, regardless of the initial stimulus that elicits ER 
Ca2+ release. By contributing to cytosolic Ca2+ elevation, store-operated Ca2+ entry sustains 
cytosolic Ca2+ overload which results in the activation of the digestive proenzymes inside the 
pancreatic acinar cells and resultant cellular necrosis. Inhibition of the channels that are 
activated by store depletion means that this mechanism of elevating cytosolic Ca2+ is also 
inhibited. One aim of this thesis was to determine if there are any inhibitors that can 
maximally inhibit store-operated Ca2+ at lower concentration than GSK-7975A which has 
already been demonstrated to inhibit CRAC channel mediated Ca2+ influx. Such an inhibitor 
should be effective at low concentrations, sub-micromolar ideally, with minimal off-target 
effects. A second aim of this thesis was to determine if modulating calmodulin would be an 
effective method in reducing store-operated Ca2+ entry. This will be achieved through the use 
of both pharmacological agents and overexpression on mutant calmodulin protein. 
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2 Materials and Methods 
2.1 Buffers and Solutions 
2.1.1 Preparation of NaHEPES solution. 
NaHEPES based extracellular solution containing: 140 mM NaCl, 4.7 mM KCl, 10 mM 
HEPES (4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid), 1 mM MgCl2, 10 mM glucose 
(pH adjusted to 7.2 with NaOH). NaHEPES was supplemented with 1 mM CaCl2 for 
pancreatic acinar cell isolation.  All above reagents were obtained from Sigma-Aldrich.  
2.1.2 Preparation of Collagenase solution. 
Collagenase (Worthington Biochemical Corp, NJ, USA) was prepared using fresh NaHEPES 
solution supplemented with 1 mM CaCl2. Collagenase (4000 U) is dissolved in 20ml of 
NaHEPES, stored in 1ml aliquots at -20°C.  
2.1.3 Preparation of Fluorescent Ca2+-indicators. 
Both Fura-2 acetoxymethyl ester (AM) (cat. F-1201) was obtained from Molecular Probes, 
Life Technologies, Paisley UK. It was prepared in DMSO at stock concentrations of 2 mM, 
aliquoted and stored at -20°C and was protected from light.  
2.1.4 Reagents. 
GSK-7975A was initially obtained from GlaxoSmithKline, Stevenage, UK. It was prepared, 
in DMSO, at a stock concentration of 10 mM, aliquoted and stored at -20 ˚C. 
RO2959 was obtained from Glixx Laboratories (cat. GLXC-01511), Southborough, MA, 
USA. It was prepared in DMSO at stock concentration of 10mM and was stored at -20 ˚C and 
was protected from light.  
Pyr3 was obtained from Sigma-Aldrich (cat. P0032), Dorset, UK, as were Calmidazolium 
Chloride (cat. C3930) and Chymostatin (cat. C7268). These reagents were prepared in 
DMSO at stock concentration of 10 mM, aliquoted and stored at -20 ˚C for no more than 
three months. Soybean trypsin inhibitor was also obtained from Sigma-Aldrich. It was stored 
at +4 °C. It was prepared fresh at 0.01% concentration in NaHEPES and was used 
immediately.  
Cyclopiazonic acid (CPA) was obtained from both Tocris (cat. 1235), Bristol, UK and 
Calbiochem (cat. 239805), Merck Millipore, Watford UK. It was prepared in DMSO at stock 
concentration of 20 mM and stored at -20 °C for no more than three months.  
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Thapsigargin (cat. 586005) was obtained from Calbiochem, Merck Millipore, Watford UK. 
In addition, Pyr6 and Pyr10 were also obtained from Calbiochem. These reagents were 
prepared, in DMSO, at stock concentration of 10 mM, it was aliquoted and stored at -20 °C 
for no more than three months. Calmodulin was also obtained from Calbiochem, it was 
prepared in NaHEPES buffer, at a stock concentration of 2mM. It was aliquoted and stored at 
-20 °C. 
CALP-3 was obtained from both Tocris, Bristol, UK (cat. 2321) and Genscript, NJ, USA. It 
was prepared, in NaHEPES, at a stock concentration of 2mM, it was aliquoted and stored at -
20 ˚C.  
Protease inhibitor cocktail tablets (EDTA free) were obtained from Roche, Sigma-Aldrich, 
UK (cat. 11873580001) and were stored at +4 ˚C, it was prepared fresh using 1 tablet per 
30ml NaHEPES and used immediately.  
2.2 Isolation of primary pancreatic acinar cells 
Wild-type C57BL/6 male mice (Charles River) aged 6 – 8 weeks old weighing 23 ± 3g were 
killed humanely by cervical dislocation, in accordance with the UK Schedule 1 of the 
Animals (Scientific Procedures) Act, 1986. The pancreas was immediately dissected, washed 
twice with NaHEPES (supplemented with 1 mM Ca2+) and injected with collagenase solution 
(200 units/ml); it was then incubated in this solution at 37⁰C for 15-17 minutes, depending on 
the activity of a particular batch of collagenase. After the incubation the pancreas was 
triturated, using a pipette, in NaHEPES solution (supplemented with 1 mM Ca2+). Cells were 
collected in a tube and centrifuged for one minute at 1200 rpm. The supernatant was 
discarded and the cells were re-suspended in 2ml of NaHEPES solution (supplemented with 1 
mM Ca2+). Large pieces of tissue were allowed to settle to the bottom of the tube and then 
were discarded. Cells were centrifuged a second time as above, the supernatant discarded and 
the cells are re-suspended in 2ml of NaHEPES solution (supplemented with 1 mM Ca2+). 
2.3 Ca2+ measurements of intact cells  
Intact, freshly isolated pancreatic cells were loaded with Fura-2, in AM form, at a final 
concentration of 3 µM for 45 minutes at room temperature. After incubation with dye, the 
cells were centrifuged as above, supernatant discarded and the cells were re-suspended in 2ml 
of NaHEPES (+1 mM Ca2+) solution.  
An inverted Nikon Diaphot 200 system, using a 40x oil objective was used for Fura-2 
measurements. An LED imaging system was used to excite Fura-2 at 355nm and 385nm and 
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green emission at 510nm. In all experiments except figure 4.11 A to figure 4.19 A solutions 
used in experiments were perfused over cells. In the aforementioned experiments with 
calmodulin, the perfusion of solutions was stopped at the point that calmodulin was 
introduced to the chamber by hand addition. Perfusion was then restarted after the Ca2+ influx 
phase of the experiment. 
Image Pro Plus software was used to collect data during real time Ca2+ imaging.  
2.4 Culture of AR42J cells 
AR42J cells are a rat pancreatic exocrine explanted tumour cell line that most closely mimic 
primary pancreatic acinar cells. They have a secretory phenotype and respond to the usual 
agonists of pancreatic acinar cells such as CCK and ACh.  
The cells were maintained in DMEM medium (with glutamine and pyruvate) supplemented 
with 10% FBS, 10 mM HEPES, 2.5 µg/ml Fungizone and 50 µg/ml Gentamycin and were 
incubated at 37˚C, 5% CO2.  
2.4.1 Passaging 
When cells had achieved confluency (usually 1 week after seeding 1:10). The old medium 
was removed from the flask and cells were washed with 10 ml PBS (warmed to 37 ˚C), PBS 
was removed and cells were incubated with 800 µl trypsin + EDTA for 1 minute and 30 
seconds. Flask was gently tapped to remove cells that remained adhered to the culture 
surface. Cells were re-suspended in 10 ml DMEM (supplemented with FBS + antibiotics) and 
were well mixed to ensure that the clusters, that this cell type tend to form, were broken down 
into single cells. Cells were then re-seeded at 1:10 ratio into a new flask. Medium was 
refreshed once per week, in between passages.  
Cells for experiments were seeded onto glass coverslips (washed in ethanol and dried under 
UV light), in 2 ml of supplemented DMEM medium, at the appropriate density for 
transfection after 48 hours, thus allowing sufficient time for cells to adhere. 
2.4.2 Transfection 
Cells were transfected using PromoFectin from PromoKine (cat. PK-CT-2000-50) 
Heidelberg, Germany. PromoFectin is a non-liposomal transfection re-agent and was used 
according to the manufacturer’s instructions. Per 6 well plate: 
Table 1 Reagents required for transfection 
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Medium (µl) PromoFectin (µl) Plasmid DNA (µg) 
200 6 3 
  
In one 1.5 ml tube, 100 µl of DMEM medium (without antibiotics or FBS) was thoroughly 
mixed with 6 µl PromoFectin. In another 1.5 ml tube 100 µl DMEM was thoroughly mixed 
with 3 µg of desired plasmid DNA. The two tubes were combined and vortexed and left at 
room temperature to incubate for 30 minutes. The transfection mixture was then added drop-
by-drop to AR42J cells, previously seeded onto glass coverslips in a 6-well plate. Cells were 
incubated in the mixture for 6-8 hours at 37 ˚C and 5% CO2, at which point the medium was 
exchanged for fresh supplemented DMEM and cells were left to express the plasmid for a 
further 72 hours, at 37 ˚C and 5% CO2.  
2.4.3 Ca2+ imaging experiments – AR42J cells. 
Intracellular Ca2+ levels were measured using the ratiometric dye – Fura-2.  Cells were plated 
on glass coverslips in 6-well plates 24-48 hours before experiments and were maintained as 
in section 2.4. Cells were incubated with Fura-2 in AM form (3 µM) for 30 minutes at 37˚C, 
5% CO2. Cells were then rinsed once with NaHEPES buffer and incubated in NaHEPES + 1 
mM Ca2+ for 20 minutes at room temperature to allow for de-esterification of the dye. 
Coverslips were mounted onto an imaging chamber with high silicone grease, to allow for 
perfusion of cells.  
Ca2+ imaging was undertaken using an imaging system (Scientifica) and images were 
recorded using WinFluor software (The University of Strathclyde, Glasgow, UK). Fura-2 was 
excited at 355nm and 380nm, every 2 seconds and emission was collected at 510nm.  
Data represents normalised ratio values calculated as follows:  (F355/F380 )/ F0 which can be 
simplified to:  R/R0 . Data presented as mean ± standard error of the mean (SEM) number of 
cells (n) given.  
2.4.4 Ca2+ imaging experiments – mCherry-CaM-AR42J cells 
Cells were transfected according to the protocol in section 2.4.2, some cells were transfected 
with m-Cherry-CaMWT and others were transfected with mCherry-CaMmut1,2,3,4. On the day of 
experiments cells were incubated with Fura-2 according to the protocol in section 2.4.3. Ca2+ 
imaging experiments were undertaken on an inverted Leica SPE confocal microscope, Leica 
Microsystems, Heidelberg, GmBH. A 40x oil objective was used. mCherry was excited with 
532 nm laser and emission collected at 580-610 nm. A single image of the mCherry-CaM 
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expression was taken prior to the experiment, to ensure Ca2+ imaging data was collected from 
cells expressing the plasmid. Fura-2 was excited using a single wavelength with the 405nm 
laser and emission collected at 510 nm, images were collected every 2 seconds.  
As a single wavelength of Fura-2 was measured, when there was an increase in cytosolic Ca2+ 
the fluorescence of Fura-2 decreased (corresponding to the 380nm wavelength).  Data 
represents normalised ratio values calculated as follows: 1/ (F/ F0 ). The reason the data was 
inverted was to avoid confusion upon data analysis, as an increase in cytosolic Ca2+ is by 
convention reflected by an upward deflection on a graph.  Data presented as mean ± standard 
error of the mean (SEM) number of cells (n) given.  
2.5 Store depletion protocols 
2.5.1 Standard Store depletion protocol.  
Cells were perfused in a nominally Ca2+ free solution for approximately five minutes before 
commencement of recording to allow them to establish an equilibrium. Store-operated Ca2+ 
entry channels the ER stores were depleted using SERCA inhibitors thapsigargin (1 µM) or 
CPA (10 µM) in nominally Ca2+ free solution. Ca2+ was released from the ER and cytosolic 
Ca2+ levels increased. In the continued presence of the SERCA inhibitors Ca2+ could not be 
actively transported into the ER via SERCA.  Ca2+ was instead extruded from the cell across 
the plasma membrane by the PMCA. SOCE channels were activated by ER store depletion, 
there was no subsequent Ca2+ entry due to the nominally Ca2+ free extracellular solution. 
When resting levels of cytosolic Ca2+ were attained Ca2+ was re-admitted to the extracellular 
solution (10, 5 or 2 mM) and there was a subsequent increase in cytosolic Ca2+. When 
maximal Ca2+ entry and the resultant plateau in cytosolic Ca2+ was attained extracellular Ca2+ 
was removed and cytosolic Ca2+ concentration returned to baseline levels.  
2.5.2 Store depletion with pre-incubation of channel inhibitors. 
Cells were treated as above, with stores depleted by either thapsigargin or CPA in nominally 
Ca2+ free solution. During this store depletion inhibitors of SOCE were applied to cells in the 
continued presence of either thapsigargin or CPA. Channel inhibitors such as GSK-7975A, 
Pyr3, RO2959, Pyr6, Pyr10, DPB162-AE and DPB163-AE were applied at the 600 second 
time point, during an elevation of cytosolic Ca2+ but during the extrusion phase of store 
depletion. Cells were incubated for 10 minutes with inhibitors before the subsequent re-
admission of Ca2+ to the extracellular solution, in the continued presence of the inhibitor. As 
before, when maximal Ca2+entry and the resultant plateau in cytosolic Ca2+ were attained 
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extracellular Ca2+ was removed from the extracellular solution whilst the inhibitor was 
maintained until the cytosolic Ca2+ levels returned to baseline.  
2.5.3 Store depletion with acute application of channel inhibitors 
Cells were treated as in 2.5.1, store were depleted by either thapsigargin or CPA in nominally 
Ca2+ free solution and Ca2+ was re-introduced at the appropriate time point. When a plateau in 
Ca2+ influx was attained inhibitors such GSK-7975A, Pyr compounds, etc were applied to the 
extracellular solution in the maintained presence of extracellular Ca2+. Generally, the PMCA 
clears the elevated cytosolic Ca2+ levels and when a new plateau in cytosolic Ca2+ levels was 
attained then extracellular Ca2+was removed with inhibitors and cells were left until resting 
levels of cytosolic levels were re-attained.  
2.5.4 Store depletion with pre-incubation of calmodulin modulators.  
Ca2+itself is an activator of calmodulin. Therefore, it was necessary to deplete stores of Ca2+ 
as slowly as possible in order to not activate calmodulin due to the efflux of Ca2+ from the 
ER. A two-step store-depletion protocol was employed. An initial 10-fold lower 
concentration of thapsigargin (200 nM) or CPA (1 µM) was applied to cells in a nominally 
Ca2+ free extracellular solution and was maintained until cytosolic Ca2+levels had returned to 
baseline levels. A subsequent higher concentration of thapsigargin (2 µM) or CPA (10 µM) 
was applied to cells in order to ensure that stores has been fully depleted of Ca2+. The 
modulators of calmodulin were then admitted to the extracellular solution and cells were pre-
incubated in the continued presence of SERCA inhibitors before the re-admission of Ca2+ to 
the extracellular solution. Experiments then proceeded as in section 2.1.2 after maximal Ca2+ 
entry and the resultant plateau in cytosolic Ca2+ was attained.  
2.5.5 Store depletion with inhibitors of proteases for calmodulin pre-incubation. 
Experiments undertaken with calmodulin pre-incubation were undertaken in a similar manner 
as in section 2.5.4, with the admission of varying protease inhibitors in tandem with the 
second high concentration of CPA. 0.01% trypsin inhibitors, protease inhibitor cocktail, 10 
µM chymostatin and 100 µM EDTA were used to inhibit the various different proteases 
present in pancreatic acinar cell preparations, such as trypsin, chymotrypsin, metalloproteases 
and a multitude of other proteases.  
2.6 Cellular necrosis measurements 
Cells were isolated according to the protocol in section 2.2. The final cell suspension in 2 ml 
NaHEPES (1mM Ca2+) was split into 0.5 ml aliquots into four separate 15 ml tubes. Up to 
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four conditions were measured during each experiment: 1) control 2) necrosis-inducing agent 
3) necrosis-inducing agent + protective agent alone. 1) Control cells were incubated in the 
absence of any necrosis inducing agent or protective agent, with suitable vehicle control. 2) 
Cells were incubated with a necrosis-inducing agent such as POAEE or TLC-S, with suitable 
vehicle control. 3) Cells were incubated with either POAEE or TLC-s plus a protective agent 
such as a CRAC channel inhibitor. All cells were incubated for one hour at room 
temperature, in order to allow sufficient time to capture images of cells, the intervals at which 
the incubations were started was staggered, with each incubation time starting fifteen minutes 
after the previous. At the end of the hour incubation cells were stained with propidium iodide 
(final concentration 1 µg/ml). Images of the cells stained with propidium iodide were then 
captured using an inverted Zeiss (Zeiss UK, Cambridge, UK) spinning disc confocal 
microscope (20 x air objective), propidium iodide was excited using the 535 nm laser and 
collecting emission between 585 – 705 nm. 20 to 30 images were captured per condition and 
the number of viable cells and necrotic cells (propidium iodide positive staining) were 
counted. Data presented as the number of necrotic cells as a percentage of the total number of 
cells ± SEM.  
2.7 Plasmid DNA amplification 
2.7.1  Polymerase Chain Reaction (PCR) 
PCRs were performed using Phusion High Fidelity master-mix (Fisher-Scientific) according 
to the conditions outlined in tables 1.1, 1.2 and 1.3 below.  
Table 2 PCR components 
Phusion Master-Mix 25µl 
Forward Primer 0.5µM 
Reverse Primer 0.5µM 
Template 10ng 
Sterile Deionised Water to 50µl 
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Table 4 PCR programme 
  
Reaction Conditions 
 Temp(°C) Time Cycles 
Initial Denaturation 98 30 sec 1 
Denaturation 98 5 sec  
33 
Primer annealing 72 8-12 sec 
Extension 72 7 min 1 
Machine cool down 4 - - 
 
2.7.2  Agarose gel electrophoresis 
The gel tray was set-up in accordance with the BioRad manufacturer’s instructions. The 
appropriate amount of agarose was added to 1 X TAE (TAE, 50 X stock - 2M Tris, 2M acetic 
acid, 50mM EDTA) buffer to make the % agarose gel required. The mixture was heated in a 
microwave oven with occasional gentle shaking until the agarose had dissolved and the 
solution was clear. Ethidium bromide was added to achieve a final concentration of 0.2µg/ml. 
The solution was then poured into the gel tray and a comb inserted in order to form the wells. 
Once set, the gel tray was submerged in a gel tank containing fresh 1X TAE buffer. The 
comb was removed and the DNA samples in 1X DNA loading buffer were loaded on the gel 
with a DNA molecular weight (MW) marker. The voltage used for the electrophoresis was 
typically 80V and was stopped when the dye front had travelled three-quarters of the way 
through the gel. Visualisation of the gel was carried out on a UV transluminator and the 
image developed using a BioRad documentation system and BioRad Quantity One software.  
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2.7.3  Cloning of mCherry-CaMWT and mCherry-CaMmut1,2,3,4 into the pCR3 vector 
mCherry was amplified by PCR from the appropriate plasmid using the conditions described 
in section 2.7.1 and the primers listed in table 1.2 in order to incorporate a 5’-BamHI site and 
a 3’-EcoRV site for digestion of plasmid DNA. The appropriate buffers were used according 
to the manufacturer’s instructions and generally 1.5 µg of DNA (plasmid and insert) was used 
in a 100µl reaction for 3 hours at 37°C. The DNA digests were then purified using the 
QIquick PCR purification kit. Separation of double digested linear plasmid and insert DNA 
was achieved via agarose gel electrophoresis as described in section 2.7.2. Ligation of the 
DNA fragment into the pCR3 vector was carried out in a molar ratio of 5:1 of DNA insert to 
vector. 2U T4 DNA ligase was used for performing the ligation and was carried out in the 1X 
reaction buffer supplied followed by incubation at 16 °C overnight. This ligation mixture was 
then stored at 4°C prior to transformation into competent E.coli TOP10 bacterial cells. After 
confirmation of successful cloning of pCR3-mCherry, CaMWT and CaMmut1,2,3,4 were 
amplified by PCR from the appropriate plasmids and cloned in a similar fashion using 
EcoRV and NotI restriction enzymes into the pCR3-mCherry plasmid. 
2.7.4 Quantification of DNA 
The concentration of DNA was deduced by spectrophotometric quantification of duplicate 
1:100 dilution samples. The absorbance of the duplicates was measured at 260nm (A260) in a 
1.5ml quartz cuvette using a Perkin-Elmer MBA2000 spectrophotometer. The concentration 
was calculated automatically by using the equation 1unit A260 = 50µg/ml of double stranded 
DNA.  
2.7.5 Transformation into competent E.coli bacteria cells 
Frozen 100µl aliquots of chemically competent TOP10 E.coli cells were allowed to thaw on 
ice. Ligation mixture was added to these cells and mixed before incubation on ice for 30 
minutes. The mixture was then heat shocked at 42°C for 45 seconds before returning to ice 
for a further 5 minutes. 900µl of sterile antibiotic-free L.B. Lennox broth was added to the 
mixture followed by incubation with shaking for 1 hour at 37°C and 225rpm. Typically 200µl 
of the mixture was plated out on L.B. Lennox agar plates containing a 1:1000 dilution of the 
appropriate antibiotic. Agar plates were inverted and incubated overnight at 37°C.  
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Results 
2.7.6 Cloning of mCherry-CaMWT and mCherry-CaMmut1,2,3,4 into pCR3 vector. 
A two-step cloning strategy was used to create the mCherry-CaMWT and mCherry-
CaMmut1,2,3,4 constructs. mCherry was amplified by PCR from its plasmid using the 
appropriate primers to incorporate a 5’-BamHI site and a 3’-EcoRV site, for cloning into the 
pCR3 vector. After confirmation of successful cloning of this construct (Figure 2.1), CaMWT 
and CaMmut1,2,3,4 were amplified by PCR from their plasmids using the appropriate primers to 
incorporate 5’-EcoRV and 3’-NotI sites; and to provide an in-frame ligation point between 
mCherry and CaM constructs. Restriction digests with BamHI and NotI ensured successful 
ligations, confirming the presence of the inserts (Figure 2.2).  
 
Figure 2.1 Agarose gel showing positive clone of pCR3-mCherry 
1% agarose gel showing the products of enzymatic digestion of a DNA mini-prep 
corresponding to a positive clone of pCR3-mCherry, using BamHI and EcoRV restriction 
enzymes. The 5.1 kb band represents the pCR3 vector and the band between 500 and 1000 bp 
represents the mCherry insert. 
  63 
 
Figure 2.2 Agarose gel showing positive clones of pCR3-mCherry-CaMWT, pCR3-
mCherry-CaMmut1,2,3,4 and pCR3-mCherry 
0.9% agarose gel showing the products of enzymatic digestion of DNA maxi-preps 
corresponding to positive clones of pCR3-mCherry-CaMWT and pCR3-mCherry-CaMmut1,2,3,4 
(lane 3 is the control pCR3-mCherry plasmid), using BamHI and NotI restriction enzymes. 
The 5.1 kb band represents the pCR3 vector, the bands at 1.15 Kb represent the mCherry-
CaMWT and the mCherry-CaMmut1,2,3,4 inserts (lanes 2 and 3) and the band between 500 and 
1000 bp (lane 4) represents the mCherry insert. 
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Figure 2.3 Vector map of pCRTM 3 (courtesy of Invitrogen) 
 
2.8 Data handling and statistics 
Ratio fluorescence values from Fura-2 loaded cells were normalised to 1 by dividing all 
values by an average value of resting fluorescence (R/R0). All the Fura-2 traces are averages 
represented with the standard error of the mean as error bars.  
The changes in Ca2+ entry were measured by calculating the change in amplitude from the 
baseline (after store depletion) to the peak of Ca2+ influx. Data represented as the average 
change in R/Ro ± SEM. Where possible the rate of influx was measured as the time taken to 
reach half-maximal point of Ca2+ entry, data represented as mean t1/2 ± SEM . 
Data was tested for normal distribution using the D’Agostino and Pearson test for normality 
using GraphPad Prism. For data sets with two conditions in which the data points are 
normally distributed then a parametric test was used to test for statistical significance: 
unpaired T-test. For data that was not normally distributed a non-parametric test was used: a 
Mann-Whitney test was used, using GraphPad Prism. For data from more than two 
conditions, a one-way ANOVA was used for to test for significance from data that was 
normally distributed data. For data points, from more than two conditions, that are not 
normally distributed a Kruskal-Wallis test was used to test for significance. 
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Figure 2.4 Schematic diagram of proposed site of action of the pharmacological agents  
Blue arrows indicate the site of action that each pharmacological agent is reported to act upon. The red lines 
indicate the site of action it is hypothesised that the pharmacological agent also act upon. 
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3 Results - Pharmacological inhibition of Store-operated 
Calcium entry mechanisms in pancreatic acinar cells 
 Introduction 
 Orai1 inhibition  
As previously described the hallmark of acute pancreatitis, the inappropriate intracellular 
activation of digestive proenzymes such as trypsinogen, is the result of a sustained elevation 
in cytosolic Ca2+ levels. Ca2+ release from intracellular stores, such as the ER, gives rise to 
the initial increase in cytosolic Ca2+ concentration. ER Ca2+ stores are a finite source of Ca2+, 
once depleted cells are reliant on Ca2+ entry into the cell to drive sustained Ca2+ signalling. 
Elevated cytosolic Ca2+ is cleared via PMCA and mitochondrial Ca
2+ uptake (234). Within 
the ER membrane and extending both into the cytosol and into the ER lumen is the ER Ca2+ 
sensor STIM-1. STIM-1 detects Ca2+ depletion from the ER, it oligomerises and activates 
store-operated Ca2+ entry channels in the plasma membrane. CRAC channels are the main 
type of store-operated channels found in pancreatic acinar cells, Orai1 is the pore forming 
subunit of these channels. Upon store depletion, STIM-1 activates Orai1 and Ca2+ enters the 
cell down its electrochemical gradient, thus sustaining cytosolic Ca2+ signalling in physiology 
(127) and Ca2+ overload in pathology (183).  
The hypothesis that inhibiting store-operated calcium entry channels would be effective in 
reducing Ca2+ overload and as such trypsinogen activation (187) was suggested sixteen years 
ago. A non-physiological concentration of CCK (10 nM) was applied to cells and resulted in 
an initial release of Ca2+ from intracellular stores, after reaching a sharp peak Ca2+ was 
largely cleared from the cytosol. Ca2+ levels did not return to baseline levels and remained 
significantly elevated. This elevation persisted until extracellular Ca2+ was removed and then 
cytosolic Ca2+ levels returned to baseline. This treatment with CCK also resulted in 
intracellular trypsinogen activation. CCK application in Ca2+ free extracellular solution 
resulted in the preservation of the initial peak in cytosolic Ca2+ due to Ca2+ release from 
internal stores, but the sustained elevation in cytosolic Ca2+ was lost; further there was also 
no intracellular activation of trypsinogen. However, sixteen years ago there were no specific 
antagonists of store-operate Ca2+ channels, as such there was very little progress in testing 
this hypothesis.  
Pancreatic acinar cells express Orai1 both apically and basolaterally (80) and it has been 
demonstrated to functionally mediate SOCE in these cells. Relatively recently 
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GlaxoSmithKline generated a compound that has been demonstrated, at low micromolar 
concentration, to yield near complete inhibition of CRAC channel mediated Ca2+ entry in 
human lung mast cells (204), RBL-2H3 cells (205) and mast and T-cells derived from human, 
mice rat and guinea pig (206). In collaboration with GlaxoSmithKline, utilising their novel 
Orai1 specific inhibitor –GSK-7975A(205), we sought to determine the effect of inhibiting 
Orai1 in pancreatic acinar cells. The ER store depletion protocol is described in section 2.5.1 
and was utilised in the following study; store depletion was mediated by SERCA pump 
inhibitors in nominally Ca2+ free extracellular solution and resulted in the activation of 
CRAC channels. Upon re-addition of Ca2+ to the extracellular solution there was subsequent 
SOCE into the cell.  
Figure 3.1 A is an example of the classic store-operated Ca2+ entry protocol utilised to study 
CRAC channel mediated Ca2+ entry. It can be manipulated to introduce pharmacological 
agents. In figure 3.1B cells were pre-treated with GSK-7975A for 5 minutes, according to 
section 2.5.2. Five minutes pre-incubation with this inhibitory compound was sufficient to 
significantly reduce the amplitude of Ca2+ entry by approximately 83%. A double-pulse re-
introduction of Ca2+ was utilised in this figure and demonstrated that a subsequent re-
introduction of Ca2+ resulted in a peak of Ca2+ entry of the same amplitude as the first peak of 
Ca2+ entry. When the time of pre-incubation was increased from five to ten minutes, there 
was a further significant reduction in the amplitude of Ca2+ entry (figure 3.1C), with entry 
inhibited by 93.4 ± 5 %. Upon re-introduction of 5 mM Ca2+ to extracellular solution, after 
ten minutes of washing with physiological buffer, there was no recovery of Ca2+ entry (figure 
3.1D). This demonstrated that if GSK-7975A is reversible, 10 minutes was not sufficient time 
to see reversal of the inhibitory effects of the compound. The changes in Ca2+ entry due to the 
above interventions with GSK-7975A are summarised in Figure 3.1E as the change in F/F0 
due to Ca2+ influx. Figure 3.1 was taken from (130), an in vitro study on the effect of CRAC 
channel inhibition as a potential treatment for acute pancreatitis. 






Figure 3.1 GSK-7975A inhibited Orai1 mediated store-operated Ca2+ influx in 
pancreatic acinar cells 
Representative fluorescence traces of Fluo-4 loaded pancreatic acinar cells  
A – Stores depleted according to protocol in section 2.5.1, 5 mM extracellular Ca2+ was 
reintroduced (n=5). B – Cells are pre-incubated with10 µM GSK-7975A for five minutes 
according to protocol in section 2.5.2.  5 mM extracellular Ca2+ was re-introduced (n=5) in 
two separate phases to induce Ca2+ influx . C- 10 µM GSK-7975A was pre-incubated with 
cells for 10 minutes before 5 mM extracellular Ca2+ was  re-introduced (n = 14). D- After 
pre-incubation with 10 µM GSK-7975A ten minutes of washing in physiological buffer was 
not sufficient to prevent inhibition induced by 5 mM extracellular Ca2+.  E- Summary of the 
mean changes of Ca2+ influx (∆F/F0) in control cells (blue bar) and in cells pre-incubated 
with GSK-7975A for 5 minutes (fuscia bar) and ten minutes (Purple bar) cells washed after 
pre-incubation (red bar). Data presented as mean ± SEM. Adapted from (130) 
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Furthermore, GSK-7975A was found to inhibit sustained elevations in cytosolic Ca2+ induced 
by POAEE, a non-oxidative alcohol metabolite and prevented intracellular protease 
activation (130). In a paper published shortly after it was shown that 10 µM GSK-7975A was 
sufficient to inhibit sustained elevations in cytosolic Ca2+ induced by a high concentration of 
CCK and by acute pancreatitis inducing bile salt - TLC-S. Lastly, it was found to inhibit 
vacuolisation – another major hallmark of acute pancreatitis (268).  
Another paper extended on the work of the two aforementioned papers, the authors sought to 
determine if inhibition of SOCE entry had translational potential. As such the researchers 
utilised GSK-7975A and another CRAC channel inhibitor CM_128 on isolated human 
pancreatic acinar cells; 50 µM GSK-7975A was sufficient to near maximally inhibit Ca2+ 
entry in human pancreatic acinar cells. CM_128 was more potent at inhibiting Ca2+ entry in 
human acinar cells than GSK-7975A, significantly inhibiting SOCE at 1 µM (253). In mouse 
pancreatic acinar cells, at 1 µM, CM_128 was significantly more effective than 1 µM GSK-
7975A and had a striking inhibitory effect on Ca2+ entry (253). As with any potential 
therapeutic agent it was necessary for GSK-7975A to be tested in vivo, in an appropriate 
animal model for the human disease, before it could be considered for further trials. GSK-
7975A was tested in 3 different mouse models of acute pancreatitis. The authors used a high 
dose (49.3 µM) and a low dose (8.9 µM) of GSK-7975A to protect against acute pancreatitis. 
The biochemical markers of acute pancreatitis that were measured were: serum amylase, IL-
6, trypsin activity, pancreas and lung myeloperoxidase (MPO), all of which were reduced by 
GSK-7975A. Furthermore, oedema, necrosis and inflammation were all significantly reduced 
by both low and high doses of GSK-7975A (253). Together, these three papers provide strong 
evidence that CRAC channel inhibition is both sufficient and effective to ameliorate the 
hallmarks of this acute disease. In addition to GSK-7975A, CM_128 another novel inhibitor 
of Orai1, was also used and shown to be inhibitory at a lower concentration both in vitro and 
in vivo. 
 2-APB as a CRAC channel blocker.  
Over recent years there have been a variety of CRAC channel inhibitors that have been 
utilised, with varying success and specificity. 2-aminoethyl diphenylborinate (2-APB), 
initially thought to be an IP3R antagonist (286), is capable of potentiating CRAC channel 
mediated Ca2+ entry at low micromolar concentration (1-10 µM) and inhibiting the same 
channels at high micromolar concentration (30-100 µM) (287). 2-APB application inhibited 
SOCE induced by thapsigargin in a variety of cells including HeLa (288), rat basophilic 
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leukaemia (RBL) (289), primary hepatocytes (290) and Chinese hamster ovary (CHO) (291). 
2-APB also has multiple off-target effects, it has been reported to target SERCA (292), 
PMCA (192) and non-specific cation channels in the plasma membrane (289). Further, it 
affects the structure of mitochondria and their ability to release the Ca2+ they have taken up 
during periods of elevated cytosolic Ca2+ (288).  
In 2008, it was shown the 2-APB had differential effects on each of the Orai isoforms; it had 
a bimodal effect on Orai1 and 2, activating the two channels at lower concentrations and 
inhibiting them at higher concentrations, whereas Orai3 was only activated (194,293). At a 
high concentration of 50 µM 2-APB was shown to inhibit and reverse STIM-1 puncta 
formation (293). Another CRAC channel blocker Gd3+, although effective in reducing Ca2+ 
influx via CRAC channels, did not alter STIM-1 puncta formation (293). STIM-1 puncta 
formation reversal by 2-APB is only a partial explanation for the inhibitory effect on CRAC 
channels, as it is not observed with other channel inhibitors, the potentiation of the channel 
seems to be independent of STIM1 puncta formation (293).  
The laboratory of Dr Mikoshiba generated a database of 2-APB analogues in search of more 
potent inhibitors of CRAC channels, that had only a minimal effect on the IP3R (294,295). 
DPB163-AE and DPB162-AE were identified in the screening process as being 100 times 
more potent than 2-APB at inhibiting CRAC channel mediated Ca2+ entry, with maximal 
inhibitory activity on store-operated Ca2+ entry at high nanomolar to low micromolar 
concentration in CHO cells, HeLa cells and DT40 cells (294,295).. DPB162-AE is a bona 
fide CRAC channel inhibitor, which unlike 2-APB it has no potentiating effects. On the other 
hand, DPB163-AE has similar bimodal effects to 2-APB, although not in CHO-K1 cells. The 
bimodal activity of DPB163-AE was surprising as the two analogues are structural isomers of 
each other (296). The efficacy of the two 2-APB analogues varied between the cells tested, 
the compounds were the most effective in DT40 cells, then CHO cells and least inhibitory in 
HeLa cells which the authors interpret to mean that the cells have different composition of 
channel constituents.  Orai3 is activated by DPB163-AE at low concentrations. It can be 
hypothesised that if endogenous SOCE is potentiated by DPB163-AE at low concentrations it 
may functionally express the Orai3 isoform as part of its pore forming subunit. DPB162-AE 
was observed to reverse STIM1 puncta formation after store depletion. When DPB162-AE 
was pre-incubated with cells, before store depletion, it was able to inhibit STIM1 puncta 
formation, suggesting that DPB162-AE is more of a STIM inhibitor as opposed to a 
modulator of the CRAC channel pore (295).  
  71 
 TRPC3 mediated Ca2+ entry 
Expression of the canonical transient receptor potential (TRPC) channel, TRPC3, has also 
been reported in pancreatic acinar cells (219–221). TRPC channels are non-selective cation 
channels (297) activated by stimulation of PLC-coupled receptors and the subsequent 
hydrolysis of PIP2, in a manner similar to the whole TRPC sub-family (298). Before the 
identity of the CRAC channel was determined TRPC channels were considered as likely 
candidates as the main component of the CRAC channel. The store-operated nature of TRPC 
channels is still highly contested in the field (183). It is accepted that TRPC1, 4, and 5 all 
bind to STIM1 but TRPC3, 6 and 7 do not (299). However, it has been demonstrated that 
STIM1 regulates TRPC3, indirectly, via heteromultimerisation with TRPC1 (214). TRPC1 
directly binds STIM1 via electrostatic interaction (215) via two STIM1 lysines and two 
conserved aspartates and glutamates in the C-terminus of TRPC1 (222). Heteromultimers of 
TRPC1 and TRPC3 are known to form in several cell types such as: hippocampal neuronal 
cells, human parotid gland ductal cells, HEK-293 and myoblast cells (214,300–303). Ca2+ 
signalling through TRPC1 and TRPC3 is known to play a pathophysiological role in 
Duchenne muscular dystrophy (300).  
TRPC3 channels are expressed in the apical and lateral regions of pancreatic acinar cells 
(219–221) and therefore contribute to Ca2+ influx, likely of a store-operated nature. Studies 
utilising a TRPC3 knockout mouse found a significant reduction, of more than 50 %, in 
SOCE in pancreatic acinar cells and submandibular gland cells when using CPA to deplete 
ER stores (220). In addition to the effects on SOCE, the frequency of Ca2+ oscillations was 
reduced in TRPC3 knockout mice when compared with wild type, regardless of the nature of 
stimulation (CCK or carbachol). The study utilised a caerulin-induced model of acute 
pancreatitis in the TRPC3 knockout mice in which, when compared with wild type mice, 
there was an observed reduction in SOCE; this was correlated with a reduction in the severity 
of acute pancreatitis, as seen by a reduction in pancreatic oedema and reduced serum amylase 
(220). 
The TRPC subclass of the TRP family has very few specific inhibitors (304). In a 2011 study 
Pyr3, a compound reported to be a specific antagonist of TRPC3 channels, was utilised 
alongside the TRPC3 knock out mouse to determine the effect on intracellular Ca2+ 
signalling. The study sought to determine the outcomes of TRPC3 pharmacological and 
genetic targeting in pancreatic acinar cells and submandibular gland acini, and the subsequent 
implications for severity of acute pancreatitis and indirectly for Sjögren’s syndrome. The 
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frequency of Ca2+ oscillations, stimulated by CCK, was reduced in WT cells treated with 3 
µM Pyr3, which was found to be in line with genetic deletion of TRPC3. Treatment of acini 
from TRPC3 knockout mice with Pyr3 did not result in a significant reduction in the 
frequency of Ca2+ oscillations compared with TRPC3 knockout acini in the absence of Pyr3. 
This was similar to the effects on SOCE, WT pancreatic acini treated with 3 µM Pyr3 
exhibited a 50% reduction in SOCE, which was similar to the reduction in SOCE due to 
deletion of TRPC3. Treatment of TRPC3 knockout pancreatic acini with Pyr3 did not result 
in a further reduction of SOCE compared to TRPC3 knockout pancreatic acini in the absence 
of Pyr3. The caerulin-model of acute pancreatitis was utilised again in this study, 0.1 µg/g 
body weight of Pyr3 was administered to mice, these mice presented with a reduced serum 
amylase compared to caerulin treated mice in the absence of Pyr3, they also demonstrated a 
reduced oedema compared to the control (221). 
  Results - Inhibition of Orai1-mediated Ca2+ entry 
 2-APB analogues 
In the concentration that 2-APB maximally inhibits store-operated calcium entry it also 
released Ca2+ from ER stores. 100 µM 2-APB when applied in the presence of 1 mM 
extracellular Ca2+ to pancreatic acinar cells elicited a dramatic increase in cytosolic Ca2+ 
levels that was sustained in the maintained presence of 2-APB (130). DPB163-AE when 
applied to cells at the maximal inhibitory concentration for store-operated Ca2+ entry of 1 µM, 
in the presence of 1 mM extracellular Ca2+, did not give rise to a noticeable increase in 
cytosolic Ca2+ (figure 3.2 A and B), contrasting with the action of 2-APB at the relevant 
concentration for inhibiting Ca2+ entry. 1 µM ACh was applied to cells after the application 
of 1 µM DPB163-AE as a positive control in figure 3.2 B, to confirm that it was possible to 
mobilise Ca2+ from ER stores, confirming that the stores were not Ca2+ depleted and were 
metabolically capable of subsequently pumping Ca2+ from the cytosol, across the plasma 
membrane.  
Unlike in CHO, HeLa and DT40 cells 1 µM DPB163-AE had no effect on SOCE in 
pancreatic acinar cells – figure 3.2 C. When applied in the presence of a sustained elevation 
in cytosolic Ca2+, due to Ca
2+influx, 1 µM DPB163-AE did not decrease cytosolic Ca2+ levels. 
The sustained elevation in cytosolic Ca2+ persisted until Ca2+ was removed from the 
extracellular solution. Increasing the concentration of DPB163-AE to 3 µM resulted in a 
dramatic decrease in cytosolic Ca2+ levels. 3 µM DPB163-AE reduced cytosolic Ca2+ levels 
by 73 ± 3.1%, when applied acutely in the presence of a sustained elevation in cytosolic Ca2+. 





Figure 3.2- DPB163-AE did not release Ca2+ from ER stores but can inhibit store-operated Ca2+ 
entry in a concentration-dependent manner 
Average traces ± SEM from Fura-2 loaded pancreatic acinar cells. 
A – 1 µM DPB163-AE was applied to cells in presence of 1mM extracellular Ca2+ (n=17). B – 1 µM 
DPB163-AE was applied to cells in the presence of 1 mM extracellular Ca2+. 1 µM Ach was then 
applied to cells as a positive control (n=32). C- Cells were treated according to the protocol in section 
2.5.3, 1 µM DPB163-AE was applied on top of a sustained elevation in cytosolic Ca2+, due to re-
introduction of 5 mM extracellular Ca2+ (n=19) D- Cells were treated according to the protocol in 
section 2.5.3, 3 µM DPB163-AE was applied on top of a sustained elevation in cytosolic Ca2+, due to 
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Removal of Ca2+ and DPB63-AE from the extracellular solution resulted in a further decrease 
of cytosolic Ca2+ back to baseline levels. 
As 1 µM DPB163-AE had no effect on reducing SOCE, this concentration was not utilised 
for further experiments. In a pre-incubation protocol, as described in section 2.5.2, cells were 
pre-incubated with 3 µM DPB163-AE during store-depletion for ten minutes, before the re-
introduction of Ca2+ to the extracellular solution (figure 3.3 A). The subsequent amplitude of 
Ca2+ influx was significantly reduced by 51.1 ± 4.9% compared to the Ca2+ influx in control 
cells (p = 0.0005) (figures 3.3 B). The half time of Ca2+ influx in cells pre-treated with 3 µM 
DPB163-AE was significantly faster when compared with the half time of Ca2+ influx in 
control cells (p = 0.0335) (figure 3.3 C). In a similar manner, the half time of Ca2+ efflux was 
significantly faster in DPB163-AE pre-treated cells compared with control cells (p = 0.0017).  
Other inhibitors of Orai1 such as GSK-7975A maximally inhibited Orai1-mediated SOCE in 
pancreatic acinar cells at 10 µM, so this concentration of DPB163-AE was also used on 
pancreatic acinar cells to determine if increasing the concentration of inhibitor would result in 
a further inhibition of Ca2+ influx. In figure 3.3 D cells were treated according to section 
2.5.2, with a ten minute pre-incubation with 10 µM DPB163-AE during the store depletion 
phase. After approximately five minutes pre-incubation, a plateau in cytosolic Ca2+ was 
attained that was elevated above resting Ca2+ levels, cytosolic Ca2+ levels then slowly started 
to increase before the re-introduction of Ca2+ to the extracellular solution.





Figure 3.3 - Pre-incubation with DPB163-AE had a bimodal effect on Ca2+ influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A- Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 
3 µM DPB163-AE for 10 minutes before 5 mM Ca2+ was subsequently re-introduced to the 
extracellular solution. Blue trace represents control cells (n=16). Red trace represents 3uM 
DPB163-AE (n=22). B- graph summarising the changes in ratio amplitude due to Ca2+ influx 
(from A) from control cells (blue bar) and cells pre-incubated with 3 µM DPB163-AE (red 
bar) (p = 0.0005). C- Graph summarising the half time of influx (lower bars: blue bar– 
control cells and red bar – 3 µM pre-incubated cells) (p = 0.0335) and efflux (upper bars blue 
– control cells and red – 3 µM pre-incubated cells) (p = 0.0017). D- Cells were treated 
according to the protocol in section 2.5.2, cells were pre-incubated with 10 µM DPB163-AE 
before 2 mM Ca2+ was subsequently re-introduced to the extracellular solution. The blue trace 
represents control cells (n=25). Red trace represents cells pre-treated with 10 µM DPB163-
AE (n=17.). E- Graph summarising the changes in ratio amplitude due to Ca2+ influx (from 
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The amplitude of Ca2+ influx in cells pre-incubated with 10 µM DPB163-AE was more than 
double the amplitude compared to control cells (figure 3.3 E). Furthermore, unlike in figure 
3.3 A, when Ca2+ was removed from the extracellular solution, in figure 3.3 D, cytosolic Ca2+ 
levels continued to increase and remained significantly elevated above baseline levels, even 
when DPB163-AE was removed from the extracellular solution. 
DPB162-AE, the structural isomer of DPB163-AE, was also used to inhibit Ca2+ entry in 
pancreatic acinar cells. 3 µM DPB162-AE was applied to cells according to the protocol in 
section 2.5.2 during store depletion for ten minutes before the re-introduction of 5 mM Ca2+ 
to the extracellular solution. This was sufficient to significantly inhibit the amplitude of Ca2+ 
influx by 83.9 ± 2.2 % compared to SOCE in control cells (figure 3.4 B). The half time of 
SOCE in cells pre-incubated with 3 µM DPB162-AE was significantly slower compared to 
control cells (figure 3.4 C), whereas the half time of Ca2+ efflux in the pre-treated cells was 
significantly faster than in control cells.  
As with DPB163-AE, 10 µM DPB162-AE was also used on pancreatic acinar cells, figure 3.4 
D demonstrates a ten minute pre-incubation with 10 µM DPB162-AE before the re-
introduction of 5 mM Ca2+ to the extracellular solution. Conversely to pre-incubation with 
DPB163-AE, in which there was an increase in cytosolic Ca2+ levels and subsequent 
sustained elevation of cytosolic Ca2+ when compared with control cells,  with DPB162-AE 
the amplitude of Ca2+ influx was significantly reduced when compared with control (figure 
3.4 E). The half time of SOCE in cells pre-incubated with 10 µM DPB162-AE was 
significantly inhibited compared with control cells, as was the half time of Ca2+ efflux (figure 
3.4 F). As with DPB163-AE in figure 3.2 D, 3 µM DPB162-AE was applied to cells 
according to the protocol in section 2.5.3, in figure 3.4 G; there was an immediate reduction 
in cytosolic Ca2+ levels and after five minutes a new lower plateau in cytosolic Ca2+ was 
established. This acute application of 3 µM DPB162-AE was sufficient to reduce Ca2+ entry 
by 62.9 ± 3.0. The acute application of DPB162-AE was less inhibitory when applied to cells 
in an acute protocol (figure 3.4 G) compared to when cells were pre-treated with the same 
concentration (figure 3.4 A), this is different to the data from cells treated acutely with 
DPB163-AE (figure 3.2 D) and cells pre-treated with the same concentration of DPB163-AE 
(3 µM in figure 3.3 A), where acute application was more effective. 













Figure 3.4 Pre-incubation with DPB162-AE had solely an inhibitory effect on Ca2+ influx  
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells. 
A - Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 3 µM DPB162 
for 10 minutes before 5 mM Ca2+ was subsequently re-introduced to the extracellular solution. Control – Blue 
(n=14). 3uM DPB162 - red (n=8.). B- Summary of ratio amplitude changes due to Ca2+ influx (from A) from 
control (blue bar) and DPB162 treated cells (red bar p<0.0001). C- Summary of the half time of influx (lower 
bars p=0.0006) and efflux (upper bars p=0.0151) blue – control cells and red – DPB162 treated cells. D- 
Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 10 µM DPB162-
AE before 5 mM Ca2+ was subsequently re-introduced to the extracellular solution. Control - blue (n=5). 10 
µM DPB162 - red (n=10). E- Summary of ratio amplitude changes due to Ca2+ influx (from D) in control 
cells (blue bar) and DPB162-AE treated (red bar p = 0.0068). F- Summary of the half time of influx (lower 
bar p < 0.0001) and efflux (upper bar p < 0.0001) blue – control cells. G- Cells were treated according to the 
protocol in section 2.5.3, 3 µM DPB162 was applied on top of a sustained elevation in cytosolic Ca2+, as a 
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1.1.1. Roche inhibitor - RO2959.  
RO2959 is an Orai1 specific inhibitor developed by Roche and was initially shown to inhibit 
endogenous CRAC channel mediated SOCE in RBL-2H3 cells, a rat basophilic leukaemia 
cell line (305). In addition, RO20959 was shown to inhibit human Orai1, Orai2 and Orai3 
mediated SOCE in a stable expression system in CHO cells (305). However, it was much less 
potent at inhibiting Orai2 and Orai3 in this system. An IC50 of 402 ± 129 nM in RBL-2H3 
was obtained for RO2959 action on endogenous CRAC current. In order to achieve such low 
IC50 values, cells were pre-incubated with RO2959 for 30 to 60 minutes before the SOCE 
protocol  was undertaken (209). One more recent study utilised RO2959 and found the IC50 to 
be much higher than the initial study for example in HEK293T; cells it was approximately 
2.5 µM (306) 
Figure 3.5 demonstrates the dose-dependent inhibitory effect RO2959 had on pancreatic 
acinar cells. In light of the IC50 obtained for RO2959 in the aforementioned study, 1 µM 
RO2959 was the first concentration to be tested on pancreatic acinar cells. Figure 3.5 A 
shows acute application of this concentration to pancreatic acinar cells according to the 
protocol in section 2.5.3 in the continued presence of 2 mM extracellular Ca2+. In control 
cells, in the continued presence of extracellular Ca2+ and in the absence of inhibitor there is a 
decline of the plateau in cytosolic Ca2+ of 20.7 ± 5.5%; in cells where 1 µM RO2959 was 
present in the extracellular solution the plateau in cytosolic Ca2+ slowly decreased by 38.3 ± 
2.1 %. 1 µM RO2959 reduced cytosolic Ca2+ by 17.6% compared to control. The efficacy of 
this inhibitor in other cells was much greater, at the same concentration, than was 
demonstrated in pancreatic acinar cells, which is similar to the efficacy of inhibition observed 
with the 2-APB analogues.  
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A B 
D C 
Figure 3.5 RO2959 had a dose-dependent inhibitory effect on Orai1-mediated Ca2+ influx, 
when applied to cells acutely. 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells. 
A – 1 µM RO2959 was applied to cells according to the protocol in section 2.5.3, in the continued 
presence of 2 mM extracellular Ca2+ (control – blue n=9 1 µM RO2959 – red n=5.). B – 5 µM 
(control n=2. 5 µM RO2959 n=11); C- 10 µM (control = 15. 10 µM RO2959 n= 12) and D- 20 
µM RO2959 (control = 8. 20 µM RO2959 n=7.) was applied to cells in an identical manner to 
panel A. E –Graph of percentage of inhibition against concentration of RO2959 (±SEM).  
E 
2 
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The concentration of RO2959 was increased to 5 µM (figure 3.5 B), this concentration was 
significantly more effective in inhibiting SOCE than 1 µM. When applied acutely, in exactly 
the same experimental protocol as in figure 3.5 A, 5 µM was sufficient to inhibit SOCE and 
as such reduce cytosolic Ca2+ by 91.9 ± 0.9 %. A further increase of inhibitor to 10 µM 
(figure 3.5 C) gave rise to a further inhibition of SOCE, and thereby reduced cytosolic Ca2+ 
by 96.6 ± 1.5 %. Increasing the concentration further to 20 µM (figure 3.5 D) did not further 
inhibit Ca2+influx compared to 10 µM, when applied in an identical protocol, 20 µM reduced 
SOCE by 89.2 ±1.9 %. Figure 3.5 E summarises the percentage inhibition of RO2959 at 4 
different concentrations when applied acutely to pancreatic acinar cells in the continued 
presence of 2 mM Ca2+ in the extracellular solution and an elevation in cytosolic Ca
2+ levels. 
From this dose-response graph an IC50 of 2 µM RO2959 was obtained. This is more than 
double the IC50 for RO2959 in RBL-2H3 cells, inhibiting the endogenous CRAC current. 
However, the IC50 in that study was measured using whole-cell patch clamp as opposed to 
fluorescent Ca2+ imaging and as such is likely to be more sensitive.  
The experiments undertaken in figure 3.5 provide additional vital evidence that CRAC 
channel inhibition is sufficient to decrease elevated cytosolic Ca2+ levels caused by store-
operated Ca2+ influx, without any pre-incubation required. However, as in previous studies 
(130) and in line with other experiments in this chapter RO2959 was also utilised in a pre-
incubation protocol according to section 2.5.2. Pancreatic acinar cells were pre-incubated 
with increasing concentrations of RO2959 for ten minutes before the re-introduction of 2 mM 
Ca2+ to the extracellular solution. Figure 3.6 A demonstrates the effect of pre-incubating cells 
with 1 µM RO2959 on Ca2+ influx. In those cells pre-incubated with RO2959, after store 
depletion with CPA, cytosolic Ca2+ levels dropped below baseline levels, which is sometimes 
seen during store depletion of pancreatic acinar cells. Pre-incubation with 1 µM did not 
significantly reduce the amplitude of Ca2+ influx compared with control cells (figure 3.6 B). 
In figure 3.6 C the time taken to reach both half maximal Ca2+ influx and half maximal Ca2+ 
efflux are shown, indicating the rate of influx and efflux. Pre-incubating cells with 1 µM 
RO2959, despite not reducing the amplitude of Ca2+, resulted in a significant slowing in the 
rate of Ca2+ influx compared with control cells (p < 0.0001) but the rate of Ca2+ efflux was 
not significantly affected by this concentration of RO2959 (p = 0.1524). As the rate of Ca2+ 
influx is more influenced by Ca2+ influx mechanisms than efflux mechanisms, the half time 
of influx is a good indicator of inhibitors effect on Ca2+influx. 
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A B 
C 
Figure 3.6 Pre-incubation of cells with 1 µM RO2959 did not significantly inhibit the amplitude of 
Ca2+ influx but did significantly prolong the rate of Ca2+ influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A – 1 µM RO2959 was applied to cells according to the protocol in section 2.5.2 before the re-
introduction of 2 mM Ca2+ to the extracellular solution (control – blue n=12 and 1 µM RO2959 – red 
n=9).B - Summary of changes in ratio amplitude due to Ca2+ influx from figure A in control cells (blue) 
and cells pre-incubated with 1 µM RO22959 (red) (p = 0.4072). C – Summary of the changes in half time 
of Ca2+influx in control – blue and RO2959 treated – red (lower bars) (p < 0.0001) and half time of Ca2+ 
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A B 
C 
Figure 3.7 Pre-incubation of cells with 5 µM RO2959 resulted in a reduction in the amplitude of Ca2+ 
influx and the rate of Ca2+ influx  
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells. 
A- 5 µM RO2959 was applied to cells according to the protocol in section 2.5.2 before the re-introduction 
of 2 mM Ca2+ to the extracellular solution (control – blue  n=21 and 5 µM RO2959 n= 16). B - Summary 
of changes in ratio amplitude due to Ca2+ influx from figure A in control cells (blue) and cells pre-
incubated with 5 µM RO22959 (red) (p = 0.1964). C – Summary of the changes in half time of Ca2+influx 
in control – blue and RO2959 treated – red (lower bars) (p < 0.0001) and half time of Ca2+ efflux in control 
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Figure 3.7 A shows that increasing the concentration of RO2959 to 5 µM and pre-incubating 
cells for the same duration still did not significantly decrease the amplitude of Ca2+ influx (p= 
0.1964). The changes in ratio amplitude due to Ca2+ influx are summarised in figure 3.7 B. 
However, this is in contrast to the data in figure 3.5 B, where an acute application of 5 µM 
RO2959 resulted in a reduction of Ca2+ influx by 92%. Pre-incubation with 5 µM RO2959 
was sufficient to significantly slow the rate of Ca2+ influx (p < 0.0001) compared with control 
cells and furthermore, this concentration resulted in a significantly slower rate of Ca2+ efflux 
(figure 3.7 C). The effect of 5 µM RO2959 pre-incubation on Ca2+ efflux was not observed 
with 1 µM RO2959 pre-incubation (figure 3.6 C).  
The effect of further increasing the concentration of RO2959 to 10 µM and pre-incubating 
cells for the same duration as the previous two experiments is demonstrated in figure 3.8 A. 
This pre-incubation was sufficient to significantly reduce the amplitude of Ca2+ influx (p < 
0.0001), compared to control cells. The changes in ratio amplitude due to Ca2+ influx are 
summarised in figure 3.8 B. When comparing acute application of RO2959 (figure 3.5 C) 
with pre-incubation with RO2959 (figure 3.8 C) 10 µM acutely reduced Ca2+ influx by 96.6 ± 
1.5% whereas when it was applied in a pre-incubation experiment 10 µM reduced SOCE by 
67.3 ± 2.7%.  
Pre-incubation of cells with 20 µM RO2959 for the same duration as previous experiments, 
figure 3.9 A, was sufficient to significantly inhibit Ca2+ influx by 89.5 ± 2.9% (p=0.0095), 
compared with the amplitude of Ca2+ influx in control cells. The changes in ratio amplitude 
due to Ca2+ influx are summarised in figure 3.9 B. The same concentration of RO2959, when 
applied acutely resulted in a 89.2 ± 1.9% reduction in Ca2+ influx (figure 3.5 D). Although 
the amplitude of Ca2+ influx is significantly reduced by pre-incubation with 20 µM RO2959 
the half time of Ca2+ influx between pre-incubation and control cells was not significantly 
changed (p = 0.1143). The time taken to reach half maximal Ca2+ efflux was significantly 
longer in RO2959 pre-incubated cells compared with control cells (p = 0.0095). The changes 
to the half time of Ca2+ influx and efflux are summarised in figure 3.9 C.
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A B 
C 
Figure 3.8 Pre-incubation of cells with 10 µM RO2959 significantly inhibited both the 
amplitude and rate of Ca2+ influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells. 
A- 10 µM RO2959 was applied to cells according to the protocol in section 2.5.2 before the re-
introduction of 2 mM Ca2+ to the extracellular solution (control – blue  n=24 and 10 µM 
RO2959 n= 17). B - Summary of changes in ratio amplitude due to Ca2+ influx from figure A in 
control cells (blue) and cells pre-incubated with 10 µM RO22959 (red) (p < 0.0001). C – 
Summary of the changes in half time of Ca2+influx in control – blue and RO2959 treated – red 
(lower bars) (p = 0.0004) and half time of Ca2+ efflux in control – blue and RO2959 treated 
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Figure 3.9 20 µM RO2959 significantly inhibited the amplitude of Ca2+ influx but resulted in an 
increase in cellular necrosis 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells. 
A- 20 µM RO2959 was applied to cells according to the protocol in section 2.5.2 before the re-
introduction of 2 mM Ca2+ to the extracellular solution (control – blue  n=4 and 10 µM RO2959 n= 
6). B - Summary of changes in ratio amplitude due to Ca2+ influx from figure A in control cells (blue) 
and cells pre-incubated with 20 µM RO22959 (red) (p = 0.0095). C – Summary of the changes in 
half time of Ca2+influx in control – blue and RO2959 treated – red (lower bars) (p = 0.1143) and half 
time of Ca2+ efflux in control – blue and RO2959 treated cells – red (upper bars) (p = 0.0095). D- 
Cellular necrosis measurements were made according to section 2.6, 1 hour incubation with 200 µM 
TLC-S resulted in an increase in cellular necrosis as measured by staining with propidium iodide. 
Cells were pre-incubated with 20 µM RO2959 before an hour long incubation with TLC-S, which 
resulted in a further increase in cellular necrosis (control = 79. TLC-S = 147. TLC-S + RO2959 = 
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In order to be an effective treatment for acute pancreatitis a CRAC channel inhibitor is 
required to be effective at inhibiting Ca2+ influx, and thereby reducing cytosolic Ca2+ 
overload, as well as reducing the amount of cellular necrosis – two key hallmarks of acute 
pancreatitis. This is not always the case for agents known to inhibit CRAC channels; 2-APB 
has been demonstrated to cause cellular necrosis (130). Figure 3.9 D demonstrates the effect 
of an RO2959 cell death assay undertaken according to the protocol in section 2.6. Cells were 
incubated with the bile salt TLC-S for one hour, as a method of causing cellular necrosis 
mimicking biliary acute pancreatitis. In order to protect cells from cellular necrosis, cells 
were pre-incubated with 20 µM RO2959 for ten minutes before the hour long incubation with 
TLC-S. The results in figure 3.9 D demonstrate that the combined incubation with TLC-S 
significantly increased the percentage of necrosis compared with control (p = 0.05) and 
combined incubation of RO2959 and TLC-S resulted in a further increase in percentage of 
necrosis compared with TLC-S treatment alone (p = 0.05).  RO2959 treatment alone did not 
significantly increase necrosis compared to control, but perhaps sensitised cells making them 
more vulnerable to cell death. 
1.1.2. Pyr6  
A recent paper described tools that were generated to distinguish between TRPC3-mediated 
Ca2+ entry and Orai1-mediated Ca2+ entry pharmacologically (195). The specificity of Pyr3 as 
a TRPC3 specific antagonist has been questioned. The authors tested Pyr2/BTP2, Pyr3, Pyr6 
and newly generated Pyr10 for their ability to inhibit TRPC3 or Orai1. Pyr6 (307,308) was 
determined to be Orai1 specific inhibitor. Pyr10 was determined to be a TRPC3 inhibitor and 
is discussed in the TRPC3 section of this chapter (section 3.3). 
 Pyr6 had a maximal inhibitory effect in native RBL-2H3 cells at 10 µM. These cells were 
utilised in this paper to study endogenous SOCE, similar to other studies in this field (195).  
In pancreatic acinar cells, in a pre-incubation protocol (according to section 2.5.3) 10 µM 
Pyr6 (figure 3.10 A) was applied to cells for ten minutes before the re-introduction of 2 mM 
Ca2+ to the extracellular solution, this concentration was sufficient to significantly inhibit 
SOCE by 83.3 ± 1.1% compared to control (figure 3.10 B). The pre-incubation of cells with 
Pyr6 did not significantly reduce the time taken to reach half maximal Ca2+ influx but did 
significantly slow the time to half maximal Ca2+ efflux (figure 3.10 C). Figure 3.10 D shows 
the effect of acute application of 10 µM Pyr6 in the continued presence of 2 mM extracellular 
Ca2+ during a sustained plateau in cytosolic Ca2+, this concentration was sufficient to reduce 
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SOCE by 83.3 ± 5.4%, a significant reduction. Upon removal of Ca2+ and Pyr6 from the 
extracellular solution, cytosolic Ca2+ levels returned to baseline levels. Both the pre-
incubation protocol and acute application protocol with 10 µM Pyr6 inhibited SOCE by the 
same percentage. 
When Pyr6 was pre-incubated with AR42J cells, a pancreatic acinar cell-like cell line, the 
resultant Ca2+ influx was of a different magnitude compared with the same length pre-
incubation, with the same concentration of Pyr6, in primary pancreatic acinar cells (figure 
3.7). Figure 3.11 A demonstrates that pre-incubation of AR42J cells with 10 µM Pyr6 pre-
incubation for ten minutes resulted in a reduction in the amplitude of Ca2+ influx, compared 
with control cells (figure 3.11 B). The time taken to reach half maximal Ca2+ influx was 
significantly slowed in cells pre-incubated with Pyr6 compared with control cells (p = 
0.0001) but the time taken to reach half maximal Ca2+ efflux was significantly faster in cells 
pre-incubated with Pyr6 compared with control cells; the changes in half time of Ca2+ influx 
and efflux are summarised in figure 3.11 C. The difference in the magnitude of the inhibition 
in primary acinar cells compared with the pancreatic cell line was marked, in acinar cells 
Pyr6 reduced Ca2+ influx by 83.3 ± 1.6 % (figure 3.10), whereas in AR42J cells Ca2+ influx 
was reduced by 49.4 ± 5.0 % under identical conditions (figure 3.11). Functionally, this 
suggests a difference in expression levels of Orai1 in pancreatic acinar cells compared with 
AR42J cells, due to the difference in the magnitude of inhibition seen between the two cell 
types.  
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Figure 3.10 Pyr6 inhibited Orai1 mediated SOCE in both pre-incubation and acute 
treatments 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- 10 µM Pyr6 was pre-incubated with cells according to the protocol in section 2.5.2, before the 
re-introduction of 2mM Ca2+ to the extracellular solution (control – blue n=28. 10 µM Pyr6 – red 
n=33.). B- Summary of changes in ratio amplitude due to Ca2+ influx from figure A in control cells 
(blue) and cells pre-incubated with 10 µM Pyr6 (red) (p < 0.0001). C – Summary of the changes in 
half time of Ca2+influx in control – blue and Pyr6 treated – red (lower bars) (p = 0.2108)and half 
time of Ca2+ efflux in control – blue and Pyr6 treated cells – red (upper bars) (p = 0.003).  D - 10 
µM Pyr6 was acutely applied to cells, according to the protocol in section 2.5.3, in the continued 
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Figure 3.11 Pyr6 an Orai1 channel inhibitor, reduced store-operated Ca2+ influx in AR42J cells 
Average traces (±SEM) from Fura-2 loaded AR42J cells 
A- ER stores were depleted according to the protocol in section 2.5.2 and then cells were pre-incubated with 
10 µM Pyr6 for ten minutes before 2 mM Ca2+ was subsequently re-introduced to the extracellular solution. 
Blue trace represents control cells (n = 52). Red trace represents 10 µM Pyr6 (n = 41). B- Summary of the 
changes in the ratio amplitude due to Ca2+ influx (from cells in figure A) control (blue bar) and Pyr6 treated 
(red bar) (p = 0.0001). C- Summary of the changes in the half time of Ca2+ influx (bottom bars) control – 
blue, Pyr6 treated – red (p = 0.0001). Half time of Ca2+ efflux (upper bars) control – blue, Pyr6 treated – red 
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1.2. Inhibition of TRPC3 mediated Ca2+ entry 
1.2.1. Pyr3 
Pancreatic acinar cells also express TRPC3 channels, non-specific cation channels that 
contribute to Ca2+ influx but whether this Ca2+ influx channel is store-dependent is still 
debated in the field. In all instances application of Orai1 inhibitors, GSK-7975A (130), 
DPB163-AE, DPB162-AE, RO2959 and Pyr6, was effective at inhibiting Ca2+ entry, . 
However, concerns have been raised over the remaining small percentage of Ca2+ influx 
observed, a possible explanation is that there is contribution by other channels, such as 
TRPC3, to Ca2+ influx. Pyr3 was reported to be specific for TRPC3 but not for other 
members of the TRPC subfamily (309). Further to the study on pancreatic acinar cells 
isolated from TRPC3 knock out mice (220), Pyr3 was utilised in identical experiments also 
on pancreatic acinar cells in a later paper, where the authors saw a similar magnitude of 
inhibition on Ca2+ entry in cells treated with Pyr3 and cells deficient in TRPC3 (221). The 
reported maximal inhibitory effect seen with Pyr3 in pancreatic acinar cells was at 3 µM 
(221), resulted in approximately 50% reduction in SOCE. 
In order to ensure maximal inhibition of TRPC3 channels in pancreatic acinar cells 10 µM 
Pyr3 was used in a pre-incubation protocol according to section 2.5.2, cells were pre-
incubated for ten minutes before the re-introduction of 5 mM Ca2+ to the extracellular 
solution, as seen in figure 3.12 A. Figure 3.12 B demonstrates the effect of acute application 
of 10 µM Pyr3 on Ca2+ influx when applied to cells in the continued presence of 5 mM Ca2+. 
The initial phase of Ca2+ influx from figure 3.12 B can be used as a control for Ca2+ influx in 
pre-incubation protocol (figure 3.12 A) as the experiments were undertaken on the same day. 
The changes in Ca2+ influx for figure 3.12 A and B are summarised in figure 3.12 E, on the 
left the blue bar represents the change in ratio amplitude due to Ca2+ influx in figure 3.12 B 
(acute application) and the red bar represents the change in ratio amplitude due to Ca2+ influx 
in figure 3.12 A (pre-incubation). Pre-incubation with 10 µM Pyr3 for ten minutes 
significantly inhibited Ca2+ influx by 86.3 ± 14.8 % compared to Ca2+ influx in control cells 
(p= 0.0007) (figure 3.12 A). 





Figure 3.12 Pyr3, inhibitor of TRPC3 channels, inhibits Ca2+ entry in pancreatic acinar cells 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells.  
A- Cells were treated according to the protocol in section 2.5.2 and pre-incubated with 10 µM for ten 
minutes before the re-introduction of 5 mM of Ca2+ to the extracellular solution (n = 9). B- Cells were 
treated according to the protocol in section 2.5.3, 10 µM Pyr3 was applied to cells in the continued 
presence of 5 mM extracellular Ca2+ on top of a sustained plateau in cytosolic Ca2+ (n = 10). C- Cells 
were treated identically to A with the exception of the re-introduction of 2 mM Ca2+ to the extracellular 
solution (n = 8). D- Cells were treated identically to B with the exception that 10 µM Pyr3 was applied 
in the continued presence of 2 mM extracellular Ca2+(n = 9). E- Summary of the changes in ratio 
amplitude in acute application experiments (blue bars) with 5 mM extracellular Ca2+ (right) and 2 mM 
Ca2+(left) and in pre-incubation experiments (red bars) with 5mM extracellular Ca2 (right, p = 0.0007) 
and 2mM extracellular Ca2+(left, p < 0.0001). 
**** 
*** 
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The experiments were repeated using 2 mM Ca2+ extracellular calcium, in line with 
experiments undertaken in (221). Figure 3.12 C utilised an identical protocol to figure 3.12 A 
using 2 mM Ca2+ in the extracellular solution, the same concentration of Pyr3 was able to 
inhibit Ca2+ influx presumably due to the somewhat reduced driving force for Ca2+ into the 
cell. Figure 3.12 D utilised an identical protocol to figure 3.12 B, again substituting 5 mM for 
2 mM extracellular Ca2+. The effect of the same concentration of Pyr3 in the continued 
presence of a reduced extracellular Ca2+ concentration was greater than in figure 3.12 B. Pre-
incubation with 10 µM Pyr3 for ten minutes inhibited Ca2+ influx, induced by 2 mM 
extracellular Ca2+, by 96.3 ± 15.9 % compared to Ca
2+ influx in control cells (figure 3.12 D). 
In both acute and pre-incubation protocols 10 µM Pyr3 had a more inhibitory effect on Ca2+ 
influx and therefore reduced cytosolic Ca2+ levels more in protocols in which Ca2+ influx was 
driven by 2 mM Ca2+ in the extracellular solution. 
Ba2+ is often used to study SOCE, as it gives rise to a unidirectional flux of ions. Ba2+ binds 
Fura-2 much the same as Ca2+ and can enter cells across the plasma membrane, through Ca2+ 
permeable channels such as CRAC channels. However, it is not possible for Ba2+ to be 
sequestered into stores or extruded back across the plasma membrane, as it cannot be actively 
transported by ATP-dependent pumps (310–312). In figure 3.13 unidirectional Ba2+ flux was 
used to study the efficacy of Pyr3 in inhibiting Ba2+ influx in cells after store depletion. In 
figure 3.13 A, cells were treated according to the protocol in section 2.5.2 and were pre-
incubated with 10 µM Pyr3 for 400 seconds before the introduction of 10 mM Ba2+ to the 
extracellular solution, in order to maximally activate Ba2+ entry through channels. The pre-
incubation with Pyr3 significantly inhibited Ba2+ entry by 54.5 ± 4.6% compared to control 
cells (figure 3.13 B). The half time of influx was significantly slowed in Pyr3 pre-incubated 
cells compared to control cells (figure 3.13 C).
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Figure 3.13 Pyr3 inhibited Ba2+ influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells. 
A- Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 10 µM 
Pyr3 for 400 seconds before the re-introduction of 10 mM Ba2= to the extracellular solution. Control-
blue n=12. 10 µM Pyr3 – red n=13. B- Summary of the changes in ratio amplitude due to Ba2+influx in 
control (blue) and 10 µM Pyr3 (red p = 0.0002). C- Summary of the changes in the half time of Ba2+ 
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1.2.2. Pyr10 
As mentioned in section 3.2.3, a novel TRPC3 channel inhibitor was developed and utilised 
in experiments to determine the specificity of Pyr6 and Pyr3 for TRPC3 and Orai1 channels. 
Alongside Pyr3, Pyr10 was used to specifically inhibit TRPC3 channels (195). Pyr10 was 
found to be 18 times more specific for TRPC3 channels than for native CRAC channels, 
largely thought to mediate Ca2+ entry through Orai1. Pyr10 was able to inhibit Orai1 but was 
demonstrated to less effective at inhibiting Orai1-mediated Ca2+ influx and needed to be used 
at much greater concentrations than were effective to inhibit TRPC3 channels (195).  
In HEK293 cells expressing YFP-TRPC3, 10 µM Pyr10 was sufficient to near maximally 
inhibit Ca2+ entry as measured by Fura-2 in Ca2+ imaging experiments, as such this 
concentration was used in the experiment in figure 3.14 A. Cells were pre-incubated with 10 
µM Pyr10 for ten minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution, according to the protocol in section 2.5.2. When applied to cells during the store 
depletion part of the protocol, 10 µM Pyr10 affected the Ca2+ clearance from the cytosol. In 
control cells the application of CPA in the absence of extracellular Ca2+ resulted in a transient 
increase in cytosolic Ca2+ that was rapidly extruded across the plasma membrane by the 
PMCA, ensuring that cytosolic Ca2+ levels return to baseline. However, cytosolic Ca2+ levels 
in cells pre-incubated with 10 µM Pyr10 did not return to baseline levels during the same 
time course as control cells. It is possible that if the time course of store depletion and pre-
incubation were extended, cytosolic Ca2+ levels would have returned to baseline. As such, at 
the time point at which extracellular Ca2+ was re-introduced cytosolic Ca
2+ level were 
significantly different compared to control (p= 0.0025). Despite this, the pre-incubation of 
cells with Pyr10 significantly inhibited the amplitude of Ca2+ entry (p= 0.012), as 
summarised in figure 3.14 B. The rate of Ca2+ influx in cells pre-incubated with 10 µM Pyr10 
was significantly slower (p= 0.0075) compared to in control cells. The time take to reach half 
maximal Ca2+ efflux not significantly different in cells pre-incubated with Pyr10 compared to 
control cells (p= 0.1373). 
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Figure 3.14 The novel TRPC3 inhibitor Pyr10 had an inhibitory effect on Ca2+ influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A- Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 10 
µM Pyr10 for ten minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution. 
Control – blue (n= 20) 10 µM pre-incubated – red (n=17). B- Summary of the change in ratio 
amplitude due to Ca2+ influx, from A, in control (blue) and 10 µM Pyr10 treated cells (red p= 
0.012). C- Summary of half time of influx in control -blue and Pyr10 treated cells - red (lower bars 
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The Ca2+ influx and efflux half times are summarised in figure 3.14 C. Upon removal of Ca2+ 
from the extracellular solution cytosolic Ca2+ levels returned to baseline levels in control 
cells, however, in cells pre-incubated with Pyr10, cytosolic Ca2+ levels did not return to 
baseline levels, nor did they return to the level of pre-Ca2+ re-introduction. It is likely that this 
concentration of Pyr10 has non-specific and off-target effects. Based on the impaired 
clearance of Ca2+ from the cytosol in all repeats of the experiment in figure 3.14 A one of 
these non-specific targets is PMCA.  
When AR42J cells were pre-incubated with Pyr6 the reduction in Ca2+ influx observed was 
significantly smaller than the same pre-incubation in primary acinar cells, therefore, it was 
sought to determine if this was the same case with Pyr10, which is reported to be more 
specific for Orai1 over TRPC3. When applied to AR42J cells, 10 µM Pyr10 incubation for 10 
minutes (figure 3.15 A) resulted in a significant inhibition of Ca2+ influx compared with 
control cells (p < 0.0001). Furthermore, the magnitude of inhibition in AR42J cells due to 
Pyr10 pre-incubation (figure 3.15 A) was different to the magnitude of inhibition 
demonstrated in pancreatic acinar cells (figure 3.14 A). Pyr10 resulted in a 36.9 ± 9.1 % 
decrease in Ca2+ influx in pancreatic acinar cells, whereas in AR42J cells there was a 
decrease of 76.8 ± 5.1 % in Ca2+ influx. Figure 3.15 B summarises the changes in ratio 
amplitude due to Ca2+ influx in AR42J cells. The rate of Ca2+ influx was significantly slowed 
in cells pre-incubated with Pyr10 compared with control cells (p < 0.0001) and in addition 
rate of Ca2+ efflux was also significantly slowed in cells pre-incubated with Pyr10 (p < 
0.0001) compared with control cells (figure 3.15 C).  
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Figure 3.15 Pyr10, a TRPC3 channel inhibitor, reduced store-operated Ca2+ 
influx in AR42J cells 
Average traces (±SEM) from Fura-2 loaded AR42J cells 
A- ER stores were depleted according to the protocol in section 2.5.2 and then cells 
were pre-incubated with 10 µM Pyr10 for ten minutes before 2 mM Ca2+ was 
subsequently re-introduced to the extracellular solution. The blue trace represents 
control cells (n = 55). The red trace represents 10 µM Pyr10 (n = 45). B- Summary of 
the changes in the ratio amplitude due to Ca2+ influx (from cells in figure A) control 
(blue bar) and Pyr10 treated (red bar) (p = 0.0001). C- Summary of the changes in the 
half time of Ca2+ influx (bottom bars) control – blue, Pyr10 treated – red (p = 0.0001). 















  98 
1.3. Inhibition of Orai1 and TRPC3-mediated Ca2+ entry 
Although the application of Orai1 channel inhibitors alone and TRPC3 channel inhibitors 
alone was particularly effective at inhibiting Ca2+ influx, in each instance there was always a 
small percentage of Ca2+ influx that remained; presumably because the other entry channel 
remained uninhibited.  At the time it seemed pragmatic to inhibit both entry channels 
simultaneously.  
1.3.1. GSK-7975A and Pyr3 
The use of both an Orai1 channel inhibitor and a TRPC3 channel inhibitor should be 
sufficient to inhibit Ca2+ entry entirely, as these are the major entry pathways in pancreatic 
acinar cells. As 10 µM GSK-7975A (130) and 10 µM Pyr3 (section 3.3.1) were used in single 
application experiments, they were the concentrations utilised in this dual inhibitor 
application experiment. Figure 3.16 A demonstrates the pre-incubation of cells with 10 µM 
GSK-7975A and Pyr3, according to the protocol in section 2.5.2, for ten minutes before the 
re-introduction of 10 mM Ca2+ to the extracellular solution. Figure 3.16 B shows the effect of 
acute application of 10 µM GSK-7975A and Pyr3 in the continued presence of 10 mM Ca2+ 
to the extracellular solution, on top of an elevation in cytosolic Ca2+ levels. In a similar 
manner to figure 3.12, the initial phase of Ca2+ influx from figure 3.16 B was used as a 
control in order to compare the pre-incubation of inhibitors from figure 3.16 A; this pre-
incubation was sufficient to significantly inhibit Ca2+ influx and thereby reduce cytosolic 
Ca2+ levels by 81.3 ± 5.8% ( figure 3.16 C). In figure 3.16 B the acute application of 
inhibitors was sufficient to significantly reduce Ca2+ -influx and cytosolic Ca2+ levels by 76.8 
± 1.8 % (p< 0.0001). Removal of extracellular Ca2+ and inhibitors from the extracellular 
solution resulted in a further decrease in cytosolic Ca2+ levels back to baseline levels.  
Experiments using GSK-7975A (130) used 5 mM Ca2+in the extracellular solution in the re-
introduction protocol; in experiments using Pyr3, figure 3.12 A, 5 mM Ca2+ was also used. 
Figure 3.17 A shows the effect of pre-incubating cells with 10 µM GSK-7975A and 10 µM 
Pyr3 before the re-introduction of 5 mM Ca2+ to the extracellular solution. This pre-
incubation was sufficient to significantly inhibit Ca2+ influx by 78.1 ± 4.2 % (figure 3.17 B). 
Figure 3.17 C shows the acute application of 10 µM Pyr3 and GSK-7975A in the continued 
presence of 5 mM extracellular Ca2+, during a sustained elevation in cytosolic Ca2 levels. 




Figure 3.16 GSK-7975A and Pyr3 applied together to inhibited Orai1 and TRPC3-mediated 
Ca2+ entry 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells.  
A- Cells were treated according to the protocol in section 2.5.2, cells were pre-incubated with 10 µM 
GSK-7975A and 10 µM Pyr3 for ten minutes before the re-introduction of 10 mM Ca2+ to the 
extracellular solution (n=13.). B- Cells were treated according to the protocol in section 2.5.3, 10 µM 
GSK-7975A and 10 µM Pyr3 was applied in the continued in presence of 10 mM extracellular Ca2+on 
top of an increase in cytosolic Ca2+ levels (n =  4. p= 0.0008). C- Summary of the changes in ratio 
amplitude due to Ca2+ influx from acute application (used as control influx B blue bar) and from cells 
pre-incubated with GSK-7975A and Pyr3 (red bar p< 0.0001).  
**** 
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C 
Figure 3.17 GSK-7975A and Pyr3 inhibited Orai1 and TRPC3 mediated Ca2+ influx induced by 
5 mM Ca2+ 
Average traces (± SEM) from Fura-2 loaded cells 
A – Cells were treated according to the protocol in section 2.5.2. they were pre-incubated with 10 µM 
Pyr3 and 10 µM GSK-7975A for ten minutes before the re-introduction of 5 mM Ca2+ to the 
extracellular solution (control – blue n=5. 10 µM Pyr3 + 10 µM GSK-7975A – red n= 16.). B- Graph 
summarising the changes in ratio amplitude due to Ca2\= influx from A in control cells (blue bar) and 
cells pre-incubated with Pyr10 and GSK-7975A (red bar, p < 0.0001). C- Cells were treated 
according to the protocol in section 2.5.3, 10 µM Pyr3 and 10 µM GSK-7975A was applied to cells in 
the continued presence of 5 mM Ca2+, on top of an elevation in cytosolic Ca2+ levels ( n= 8 p = 
0.0018). 
**** 
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Upon addition of inhibitors to the extracellular solution, there was an initial small increase in 
cytosolic Ca2+ levels followed by a gradual decrease in cytosolic Ca2+ until a new plateau was 
reached. This acute application of GSK-7975A and Pyr3 was sufficient to significantly 
inhibit Ca2+ entry, and thereby to reduced cytosolic Ca2+ by 50.8 ± 6.1 % (p= 0.0018). 
In figure 3.12 C and D, 2 mM extracellular Ca2+ was used to induce Ca2+ influx in order to 
study the inhibitory effect of Pyr3 alone , in figure 3.18 2 mM extracellular Ca2+ was also 
used to induce Ca2+ influx. Figure 3.18 A shows the effect of pre-incubating cells with 10 µM 
GSK-7975A and 10 µM Pyr3 for ten minutes before the re-introduction of 2 mM Ca2+ to the 
extracellular solution. This pre-incubation was sufficient to significantly inhibit Ca2+ entry by 
87.9 ± 2.0 % (figure 3.13 B). Figure 3.18 C demonstrates the effect of acute application of 10 
µM of both GSK-7975A and Pyr3 in the continued presence of 2 mM extracellular Ca2+, on 
top of an elevation in cytosolic Ca2+. Unlike in figure 3.17 C there was no increase in 
cytosolic Ca2+ after the addition of inhibitors, but rather a decrease in cytosolic Ca2+, this 
continued until a new and lower plateau in cytosolic Ca2+ was attained. Ca2+ influx, and 
thereby cytosolic Ca2+, was significantly inhibited by 65.0 ± 3.3% (p= 0.0002).  
Pyr6 and Pyr10, inhibitors of Orai1 channels and TRPC3 channels respectively, were both 
used at 10 µM in a pre-incubation protocol (as described in section 2.5.2) for ten minutes 
before the re-introduction of 2 mM Ca2+ to the extracellular solution, as demonstrated in 
figure 3.18 D. The application of these two inhibitors during the store depletion step of the 
protocol resulted in incomplete clearance of Ca2+ from the cytosol after release from the ER. 
Ca2+levels did not return to baseline levels and began to increase before Ca2+ was even re-
introduced to the extracellular solution. Upon re-introduction of Ca2+ to the extracellular 
solution, the increase in cytosolic Ca2+ continued, the removal of extracellular Ca2+did little 
to prevent the increase. The removal of Pyr6 and Pyr10 from the extracellular solution did 
result in the start of a declining phase of cytosolic Ca2+. The effect of 10 µM Pyr10, in figure 
3.14, was somewhat similar to that observed in figure 3.18 D. The cell’s ability to clear Ca2+ 
from the cytosol was impaired during the store depletion by incubation with Pyr10, likely due 
to off-target effects on PMCA. This impaired clearance was exaggerated in experiments 
where Pyr6 and Pyr10 were incubated with cells together, in the absence of extracellular 
Ca2+, cytosolic Ca2+ started to increase.
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Figure 3.18 The inhibition of Orai1 and TRPC3 mediated Ca2+ influx induced by 2mM Ca2+ 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells.  
A- Cells were treated according to the protocol in section 2.5.2, pre-incubated with 10 µM GSK-
7975A and 10 µM Pyr3 before the re-introduction of 2 mM Ca2+ to the extracellular solution 
(control – blue n= 4. GSK-7975A + Pyr3 – red n= 1). B-  Graph summarising the changes in ratio 
amplitude due to Ca2+ influx in control cells (blue bar) and cells pre-incubated with GSK-7975A + 
Pyr3 (red bar p= 0.0007). C – Cells were treated according to the protocol in section 2.5.3, 10 µM 
of both GSK-7975A and Pyr3 was applied to cells in the continued presence of 2 mM Ca2+in the 
extracellular solution. (n= 5 p= 0.0002). D – Cells were treated according to the protocol in section 
2.5.2, pre-incubated with 10 µM Pyr6 and 10 µM Pyr10 for ten minutes before the re-introduction 
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In figure 3.14 A the re-introduction of Ca2+ to the extracellular solution resulted in Ca2+ 
influx of a similar dynamic to that of control, although smaller in amplitude; unlike in figure 
3.18 D. The removal of extracellular Ca2+ in figure 3.14 A resulted in a subsequent decrease 
in cytosolic Ca2+, this was not the case in figure 3.18 D, in which it was necessary to remove 
Ca2+ and inhibitors from the extracellular solution in order to start to reduce cytosolic Ca2+ 
levels.  
1.4. Discussion 
During the time course of publication of the second two papers, the work in this chapter was 
undertaken using the various different inhibitors of Orai1 - DPB162-AE, DPB163-AE, 
RO2959 and Pyr6. The pharmacology in this chapter contributes towards the acceptance of 
CRAC channels as a drug target for acute pancreatitis. The use of Orai1 inhibitors in human 
pancreatic acinar cells and clinically relevant mouse models of acute pancreatitis confirms the 
viability of targeting these channels therapeutically (253).  
There are undoubtedly wider therapeutic advantages to the inhibition of Orai1-mediated Ca2+ 
entry in this inflammatory disease, as SOCE plays a role in immune cells such as mast cells, 
macrophages and T-cells. If immune cells have a diminished ability to launch an immune 
response, due to inhibition of Orai1-mediated Ca2+ entry, there would be a resultant reduction 
in the severity of inflammation and therefore a reduced chance of the disease progressing to a 
more severe form (253,281,282). A recent report indicates that phagocytosis and cytokine 
production by macrophages, known to be recruited to the site of pancreatic acinar cell injury 
(313), is dependent on Ca2+ signalling in general but not specifically dependent on SOCE 
(314). This supports the point made in (253) that the principal effect of CRAC channel 
inhibition is due to the effect of the inhibitor on pancreatic acinar cells, which express the 
Orai11 isoform (80,129); as although inhibition of SOCE in innate immune cells prevents 
some of their functionality, neutrophils and macrophages are not entirely inhibited and can 
still launch an immune response thus contributing towards the severity of acute pancreatitis. 
T-cells would be inhibited by CRAC channel inhibition, although they are recruited to the 
site of pancreatic injury in significantly smaller numbers (282).  
1.4.1. 2-APB analogues 
2-APB, originally thought to be an IP3R antagonist, is now known to have a biphasic action 
on CRAC channel mediated-Ca2+entry. When 2-APB was applied to pancreatic acinar cells at 
100-300 µM it gave rise to an increase in intracellular Ca2+ (130,315). As the 2-APB 
  104 
analogues are reported to be 100 times more potent, the analogous concentration of the DPB 
compounds that would elicit an increase in intracellular Ca2+ would be 1 µM. However, at 
least in pancreatic acinar cells there was no noticeable increase in Ca2+ observed (figure 3.2A 
and B) when DPB163-AE was applied at this concentration, in the presence of extracellular 
calcium. 3 µM DPB163 and DPB162 was shown to be effective in markedly reducing Ca2+ 
influx, as such this concentration should have been tested to determine if there were any 
effects on Ca2+ release.  
DPB163-AE and DPB162-AE, are structural isomers that are analogues of 2-APB developed 
by Dr Mikoshiba’s group, they were not found to be as potent in inhibiting SOCE in 
pancreatic acinar cells as they were in their study (295). 1 µM of both analogues was found to 
completely inhibit Orai1-STIM1 mediated Ca2+ entry in HEK293 cells within 3 minutes, 
however in this chapter 1 µM was found to be largely ineffective. 3 µM of DPB162-AE and 
DPB163-AE was found to be more inhibitory than 1 µM, similar to the effect seen on 
HEK293 cells expressing STIM1-Orai2. This result, the authors might suggest, indicates that 
in pancreatic acinar cells the native CRAC current is mediated by Orai2, though not 
necessarily as a homomeric channel. DPB163-AE was found to potentiate Ca2+ entry in HeLa 
cells when used at lower concentrations (10-300 nM), this effect was not investigated in 
pancreatic acinar cells as 1 µM was not inhibitory as it was reported to be in (295).  
When applied in a store-depletion protocol to activate SOCE, high concentrations of 
DPB163-AE (10 µM) resulted in incomplete clearance of Ca2+ from the cytosol (figure 3.3). 
It is likely that DPB163-AE interferes with a Ca2+ clearance mechanism, such as the PMCA, 
which during store depletion protocols is the predominant Ca2+ extrusion pathway. DPB163-
AE at 10 µM potentiated Orai3 mediated Ca2+ entry initially, this was followed by 100 
seconds of decreased current, however the current slowly increased towards the end of the 
recording (295). However, this seems to be a less than likely explanation for the observed 
effect of DPB163-AE in figure 3.3. 
1.4.2. RO2959 
It is known the pancreatic acinar cells express Orai1, but there is no evidence indicating if 
this is the only Orai isoform expressed in these cells (2,55,56). If in pancreatic acinar cells 
Orai1 forms heteromultimers with Orai2 and Orai3, as it is known to do in other cell types 
(317–319) then this would provide an explanation for why all the variety of Orai1 specific 
inhibitors are less potent in pancreatic acinar cells than in CHO, HeLa, RBL cells and 
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HEK293 (305). It is still unclear if heteromultimers of Orai form endogenously or just in an 
overexpression system (317–319). Orai1-Orai2 or Orai1-Orai3 heteromultimer formation has 
been suggested as a hypothesis for why the IC50 for RO2959 in CD4 T cells is much lower 
than the IC50 of RO2959 in RBL-2H3 cells, as potentially heteromultimers of Orai form in 
RBL-2H3 cells. The IC50 for RO2959 is lower for endogenous CRAC currents than for 
STIM1 and Orai1 overexpression systems (127,296,305). The same concentration of RO2959 
(200 nM) inhibited Orai1 by 88%, Orai2 by 14% and Orai3 by 32%. If native CRAC 
channels can be formed of Orai1-Orai2 or Orai1-Orai3 heteromultimers then RO2959 will be 
a less potent inhibitor than in cells where the CRAC channels are formed from Orai1 
homomultimers.  
There were reported solubility issues with RO2959 (305). The authors of this study used 
RO2959 at a maximal concentration of 1 µM for this reason. In this chapter there was no 
notable effect of 1 µM RO2959 on SOCE when applied acutely (figure 3.5A) or when pre-
incubated with cells during store depletion (figure 3.6 A). Furthermore, there were no 
noticeable solubility issues upon dissolving RO2959 in DMSO, therefore this would not be a 
contributing factor to the lack of efficacy observed with 1 µM RO2959 in the aforementioned 
figures. The authors in this study utilised a pre-incubation protocol, similar to the protocol in 
section 2.5.2; RBL-2H3 cells were pre-incubated with RO2959 for thirty minutes before 
activation of CRAC channels to allow for the compound to reach equilibrium, which they 
stated was important particularly for the low concentrations used (305); as acute pancreatitis 
is by its very nature an acute disease, any therapy needs to be effective when applied to cells 
already undergoing cytosolic Ca2+ overload and necrosis and not in advance. 
An IC50 of approximately 2 µM was obtained from the graph in figure 3.5. Notably there is a 
steep concentration dependence of inhibition observed between 1 µM RO2959 and 5 µM 
RO2959. Further intermediate concentrations should be tested and added to the dose response 
curve to more accurately determine the IC50. Calculating the IC50 of inhibitors using data 
generated by fluorescent Ca2+ imaging is likely not the most accurate method, as it is not a 
direct measurement of channel conductance; using patch clamp would result in more accurate 
measurements of the extent to which each concentration inhibits the channel current.  Lastly, 
data demonstrated in figure 3.9 D indicates that rather than protecting cells from necrosis 
induced by bile salts, mimicking biliary acute pancreatitis, RO2959 increased the percentage 
of cell death. There is evidence that the balance between necrosis and apoptosis influences 
the severity of acute pancreatitis (320–322). RO2959 when pre-incubated with cells affected 
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the half time of Ca2+ efflux, which is dependent on the PMCA. If RO2959 impairs the 
clearance capacity of the PMCA, then cytosolic Ca2+ overload is likely. Cytosolic Ca2+ 
overload is one of the key causes of cellular necrosis. 200 µM TLC-s results in high levels of 
apoptosis, due to the production of reactive oxygen species (270), it is possible that RO2959 
tilts the delicate balance between apoptosis and necrosis more towards the necrosis end of the 
scale.  
1.4.3. Pyr6 
Pyr6 is an Orai1 specific inhibitor of Ca2+entry that preferentially inhibits Orai1 over TRPC3 
(195); it was reported to have a 37-fold higher potency for Orai1 mediated Ca2+ entry over 
TRPC3 mediated Ca2+ entry. The work in this chapter utilised 10 µM Pyr6 to inhibit SOCE in 
pancreatic acinar cells, as this was the maximal inhibitory concentration used in RBL-2H3 
cells (195). Ca2+ entry was significantly inhibited by this concentration of Pyr6 when it was 
pre-incubated with cells before the re-introduction of extracellular Ca2+ and furthermore 
when acutely applied to cells in the presence of elevated cytosolic Ca2+ levels (figure 3.10 A 
and C). When compared with GSK-7975A, which when pre-incubated with cells for ten 
minutes at 10 µM inhibited Ca2+ entry by 93.4 ± 5%, Pyr6 was less effective at inhibiting 
Ca2+ entry; when used for the same duration of pre-incubation and the same concentration, it 
inhibited Ca2+ entry by 83.3 ± 1.1%. Pyr6 was more effective at inhibiting Orai1-mediated 
Ca2+ entry than TRPC3-mediated Ca2+ entry (195) but GSK-7975A was more effective at 
inhibiting Ca2+entry in pancreatic acinar cells than Pyr6, which is thought to be mediated by 
Orai1 (80,129,316). If in acinar cells the native CRAC channel is only formed by Orai1 
homomultimers, this data then indicates that GSK-7975A is a more potent inhibitor of Orai1 
than Pyr6. Data from experiments on AR42J cells, in which GSK-7975A was ineffective at 
inhibiting Ca2+ influx (130) contrasted with experiments using Pyr6 on AR42J cells. Pyr6 
significantly inhibited Ca2+ influx. It is unlikely that they are targeting the same protein, there 
may be a possibility that Pyr6 indirectly inhibits Orai1. The isoform specific molecular 
identity of the Ca2+ influx in AR42J cells has yet to be determined, but from the work in this 
chapter it   
1.4.4. Pyr3 
TRPC3 channels are non-specific cation channels that are ubiquitously expressed in almost 
all tissues including pancreatic acinar cells. Although the store-operated nature of TRPC3 
channels is still somewhat debated, TRPC3 has now been shown to bind to STIM1 (222,323). 
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The STIM1 Orai1-activating region (SOAR) domain of STIM1 binds to the coiled-coil 
domain in the C-terminus of TRPC3. Whereas previously it was shown that TRPC1 directly 
binds STIM1 and it is known to form heteromultimers with TRPC3, it was thought that in 
this way TRPC1 conveyed STIM1 dependence to TRPC3 (214). The binding of the channel 
to STIM1 meets one of the criteria of a store-operated channel (222).  
Deletion of TRPC3 from pancreatic acinar cells resulted in a 50% reduction in the amplitude 
of SOCE (220) and pharmacological inhibition using Pyr3 resulted in a reduction of SOCE of 
a similar amplitude (with no further reduction in SOCE seen when Pyr3 was applied to 
TRPC3-deficient acinar cells) (221). This previously published study used Pyr3 at 3 µM and 
stated that this concentration had near maximal inhibition, with no further inhibition of SOCE 
seen at higher concentrations such as 10 or 50 µM, however, no dose-response in pancreatic 
acinar cells was demonstrated. In figure 3.12 and 3.13 Pyr3 was applied to acinar cells at 10 
µM, the maximal inhibitory concentration as reported previously (309). The effect of 
increasing Pyr3 concentration from 3 µM (221) to 10 µM was a stronger inhibition of Ca2+ 
influx (96%) in pancreatic acinar cells. This is similar to the percentage of inhibition seen 
when CRAC channel inhibitor GSK-7975A was used to inhibit Ca2+ entry in pancreatic 
acinar cells (130). The specificity of Pyr3 for the inhibition of TRPC3-mediated Ca2+ entry 
over Orai1-mediated Ca2+ entry was tested using HEK293 cells overexpressing TRPC3 and 
RBL-2H3 cells, which endogenously express Orai1 (195). Pyr3 was found to lack specificity 
for TRPC3 over Orai1, the IC50 of Pyr3 for TRPC3 and Orai1 was 0.54 µM in both instances. 
Whereas the SOCE inhibitor Pyr2 (BTP2) had a lower IC50 for Orai1 (0.59 µM) over TRPC3 
(4.21 µM). At the concentration used in this study it is likely that both TRPC3-mediated and 
Orai1-mediated Ca2+ entry are inhibited, thus resulting in a 96% inhibition of the Ca2+influx 
into pancreatic acinar cells via both channels. Even at 3 µM used previously (221) there 
would have been no discrimination between Orai1 and TRPC3 channels using Pyr3. In order 
to specifically target TRPC3 and not Orai1 Pyr3 is not a suitable tool, but it may be useful if 
it is experimentally necessary to indiscriminately target Ca2+ entry. 
1.4.5. Pyr10 
Pyr10 was designed by the authors of the aforementioned paper and was found to more 
potently inhibit TRPC3 (195). The maximal inhibitory effect on TRPC3 was observed at 
approximately 50 µM, whereas for Orai1 it was approximately 500 µM, as measured in Fura-
2 loaded YFP-TRPC3 expressing HEK293 cells. In figure 3.14, 10 µM Pyr10 was used in 
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similar experiments to those utilising Pyr3 and Pyr6. Pre-incubation with this concentration 
(figure 3.14 A) resulted in an altered and incomplete Ca2+ clearance from the cytosol during 
the store-depletion phase of the protocol. Typically upon CPA or thapsigargin application, in 
nominally Ca2+ free extracellular solution, Ca2+ is released from ER stores giving rise to a 
transient increase in cytosolic Ca2+ concentration; this is followed by Ca2+ extrusion across 
the plasma membrane via PMCA and therefore there is a subsequent decrease in cytosolic 
Ca2+ concentration back to pre-stimulation levels. In figure 3.14 A cytosolic Ca2+ 
concentration did not return to pre-stimulation levels after the addition of Pyr10 to the 
extracellular solution, in the maintained absence of extracellular Ca2+. Cytosolic Ca2+ 
concentrations remained significantly elevated compared with control cells at the point at 
which Ca2+ was re-introduced to the extracellular solution, this is likely due to non-specific 
effects of Pyr10 on Ca2+ clearance mechanisms, such as the PMCA.  
Pyr10 has been used recently in a paper investigating the role of TRPC3 in human coronary 
artery endothelial cells. The slight elevation in cytosolic Ca2+ levels after store depletion 
observed in figure 3.14 was also observed in their store-depletion protocol, but to a lesser 
extent, despite using 2 µM Pyr10 and not 10 µM (324). A second recent paper studying the 
contribution of TRPC3 to SOCE in primary nociceptors also utilised Pyr10 at 10 µM, the 
authors did not demonstrate any obvious changes in the dynamics of Ca2+ handling by dorsal 
root ganglion cells (325). If Pyr10 has off-target effects on the PMCA then it is less likely to 
negatively impact the Ca2+ handling in an excitable cell, which also possess the NCX that can 
remove Ca2+ from the cytosol.  
2 µM Pyr10 had no inhibitory effect on SOCE in human coronary artery endothelial cells and 
10 µM Pyr10 had no effect on SOCE in dorsal root ganglion cells, when measured using 
Fura-2 loaded cells in both instances. There is a full dose response curve for the effect of 
Pyr10 on RBL-2H3 cells in (195), with 10 µM inhibiting Ca2+ entry by approximately 40%. 
In pancreatic acinar cells 10 µM Pyr10 inhibited Ca2+ entry by 36.9 ± 5.7% despite the 
disturbances in cytosolic Ca2+ clearance. There is insufficient data to determine whether 
Pyr10 can specifically inhibit TRPC3 in pancreatic acinar cells.   
1.4.6. GSK-7975A and Pyr3 
As both Orai1 and TRPC3 contribute to Ca2+entry in pancreatic acinar cells 
(80,129,130,220,221) an inhibitor that blocks both channels would be useful as a potential 
therapeutic to treat acute pancreatitis. At the point the experiments in figure 3.16 and 3.17 
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were conducted, the lack of specificity of Pyr3 for TRPC3 was not known (195). The aim of 
these figures when the experiments were performed was to use Pyr3 to target TRPC3 
mediated Ca2+ entry and GSK-7975A to target Orai1-mediated Ca2+ entry. The combined pre-
incubation of 10 µM Pyr3 and GSK-7975A for ten minutes reduced Ca2+ entry by 78.3 ± 1.1 
% (in the presence of 5mM extracellular Ca2+, figure 3.17) and by 81.3 ± 2.9 % (in the 
presence of 10 mM extracellular Ca2+. Figure 3.16). There was no further inhibition of Ca2+ 
entry compared to the inhibition of Orai1 alone, this could be due to the lack of specificity of 
Pyr3 for TRPC3 and therefore non-specific inhibition of Orai1. The trend is true for 
experiments in which Pyr3 and GSK-7975A were applied acutely, in the presence of a 
sustained elevation in cytosolic Ca2+ levels, there was no further inhibition of Ca2+ entry 
compared to cells where only Orai1 was inhibited; a 50.8 ± 6.2 % reduction in the presence 
of 5 mM extracellular Ca2+ and 76.8 ± 1.8 % reduction in the presence of 10 mM extracellular 
Ca2+.  
One of the discrepancies between experiments studying SOCE is that different labs use 
slightly different concentrations of Ca2+ in their extracellular solutions to re-admit Ca2+ to the 
cell, by increasing the extracellular concentration the extent of inhibition by a particular 
inhibitor is reduced (183). In figure 3.16 10 mM extracellular Ca2+ is used to re-admit Ca2+ to 
the cells and in figure 3.17 5 mM Ca2+ is used, therefore it would be expected that the 
combined application of Pyr3 and GSK-7975A to be less effective in figure 3.16 than in 
figure 3.17, but the converse is observed. In pre-incubation experiments utilising 2 mM 
extracellular Ca2+, Pyr3 and GSK-7975A were the most effective at inhibiting Ca2+ entry 
(88.0 ± 6.5 %) although in acute application the results did not follow the expected trend and 
Ca2+ entry was only reduced by 65 ± 3.2 %.  
The motivation behind the experiment shown in Figure 3.18 D was to utilise Pyr6 and Pyr10 
in an attempt to more specifically target Orai1 and TRPC3. However, the application of 10 
µM of both inhibitors resulted in a disturbance in the clearance of Ca2+ from the cytosol, 
likely due to an effect on PMCA activity, similar to that seen in figure 3.14 A with Pyr10 
application alone. In figure 3.18 D cytosolic Ca2+ levels had already increased to levels 
comparable with peak Ca2+ influx in control cells at the time point when Ca2+ was re-
admitted to the extracellular solution. Only when both the inhibitors were removed from the 
extracellular solution did cytosolic Ca2+ levels begin to decrease, suggesting that the effects 
of Pyr6 and Pyr10 may be reversible.  
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The theory behind an attempt at dual inhibition of the two Ca2+ influx channels was based on 
a study in which two inhibitors of two targets implicated in nasal polyps – the leukotriene 
receptor and CRAC channels. The authors of the study utilised the two inhibitors at 
individual submaximal concentrations and found that this combination was as effective as 
using either inhibitor at their maximal concentration (326). The benefit of using submaximal 
concentration of any agent is that there is an improved therapeutic index of that agent and 
therefore a reduction in side effects. However, the combined treatment of acinar cells with 
both Orai1 inhibitors and TRPC3 inhibitors was not at submaximal concentrations, as such 
was not very well designed and no conclusions can be drawn from the data. It would be very 
interesting to observe the effects of submaximal concentrations of both inhibitors on both the 
amplitude of Ca2+ influx when treated in an acute manner, but also their effects on cellular 
necrosis and apoptosis.  
1.4.7. Pancreatic acinar cells vs AR42J cells 
The difference in the magnitude of inhibition observed in both pancreatic acinar cells and 
AR42J cells when exposed to the Orai1 specific inhibitor - Pyr6 and the TRPC3 channel 
specific inhibitor - Pyr10 could be due to different levels of expression of Orai1 and TRPC3 
channels in the two different cell types. AR42J cells are used as a model pancreatic acinar 
cell line as they are the most similar cells to primary acinar cells that are commercially 
available. Primary pancreatic acinar cells are viable for several hours after isolation, but the 
more time they are left after isolation the higher the levels of cellular necrosis observed. 
Primary acinar cells are notoriously difficult to culture, although newer methods have been 
developed that report successful culture of pancreatic acinar cells for up to 10 days in vitro 
(327). Due to the difficulty in culturing primary acinar cells researchers have tended to look 
towards model cell lines, such as AR42J cells to do experiments that require extensive 
incubations such as transfections of plasmid DNA or knockdown with siRNA (328). From 
the functional data generated in this chapter, from primary acinar cells and AR42J cells, it 
can be hypothesised that the expression levels of Orai1 and TRPC3 are very different 
between the two cell types, with Ca2+ influx in pancreatic acinar cells primarily mediated by 
Orai1 channels and to a lesser extent TRPC3 channels; with the converse true in AR42J cells 
as TRPC3 inhibition resulted in a greater magnitude of inhibition than Orai1 inhibition. In 
order to quantitatively assess if the functional difference observed with pharmacological 
agents is due to a difference in expression levels of channels it would be prudent to run a 
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qPCR to determine the expression levels of mRNA for each channel and a western blot to 
determine relative protein levels. 
AR42J cells are derived from a pancreatic exocrine tumour taken from a rat. AR42J cells are 
non-polarised cells that unless differentiated, by dexamethasone treatment, do not have 
substantial number of zymogen granules (329,330) and are not secretory in response to 
physiological stimuli of pancreatic acinar cells such as CCK (331). Although a useful tool to 
have, AR42J cells should not be studied in isolation from pancreatic acinar cells due to these 
differences, thereby a difference in which ion channels are primarily responsible for 
mediating Ca2+ influx in response to store depletion is highly likely. There is a lot of evidence 
for the role of TRP channels in tumorigenesis, with members of the TRPC, TRPM and TRPV 
family of channels implicated in proliferation and apoptosis (332). Targeting TRPC3 
channels could provide a way of differentially targeting pancreatic cancer cells over normal 
acinar cells as a potential therapeutic strategy, as normal acinar cells seem to be more 
dependent on Orai1 for SOCE.  
Future work 
It remains to be determined whether there is expression of the Orai2 and Orai3 isoforms in 
pancreatic acinar cells. Such information could possibly provide an explanation for the 
different efficacy of CRAC channel inhibitors when used in pancreatic acinar cells as 
compared to cell lines or other primary cell types, such as with inhibitors including 2-APB 
analogues, RO2959 (295,305). This data should be obtained by running PCR experiments to 
determine the presence of Orai2 or Orai3 isoform mRNA. Western blots and immunostaining 
techniques should then be undertaken to confirm expression of the Orai2 and Orai3 protein, 
antibodies for both proteins are commercially available. Co-immunoprecipitation 
experiments can be done to determine if Orai2 and Orai3 do form heteromultimers with Orai1 
endogenously, similar to the experiments undertaken studying TRPC channel 
heteromultimerisation in (214) and FRET based experiments such as those studying Orai 
heteromultimerisation (317). Confirmation of the formation of Orai heteromultimers would 
give rise to an explantion for altered channel kinetics and pharmacological response to 
antagonists (317).  
A full dose-response study of Pyr10 is currently lacking in pancreatic acinar cells and would 
be necessary in order to determine a usable concentration to discriminate between Orai1 and 
TRPC3 mediated Ca2+ signals. Furthermore, as it is necessary for a therapeutic for acute 
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pancreatitis to have the capacity to reduce Ca2+ entry when applied in the presence of a 
sustained elevation in cytosolic Ca2+ levels, it is necessary to test whether Pyr10 is effective 
in inhibiting TRPC3-mediated Ca2+ entry in an acute manner. The same is true of Pyr6, a full 
dose-response study in pancreatic acinar cells is also lacking. However, at the same 
concentration as GSK-7975A (10 µM), Pyr6 is less effective in reducing cytosolic Ca2+ 
overload, due to Ca2+ influx; as such it may not be worthwhile investing more time 
investigating such an agent. The levels of apoptosis and necrosis measurements should be 
undertaken to determine the effect of Pyr6 and Pyr10 on cell fate. It is worthwhile noting, that 
in order to produce meaningful necrosis measurements all cell counting ought to be double-
blinded to prevent inherent experimenter bias. 
The development of specific CRAC channel inhibitors have been a focus in the field for 
many years (127,183) and binding site and mechanism of action of most SOCE inhibitors is 
largely unknown (127). Improving the specificity and potency of an inhibitor for a particular 
channel by making new analogues and undertaking structure-function studies becomes 
problematic when the binding site of the drug is unknown. Improved channel specificity of a 
drug is necessary, as is an improved potency of the drug, in order to be able to reduce the 
therapeutically viable concentrations delivered to patients and reduce the concentration of 
unbound drug found in plasma, as this unbound drug is available to bind non-specifically to 
other proteins resulting in off-target effects(333). In order to improve these factors it is 
important to know whether an inhibitor binds directly to the channel in question, or indirectly 
via an accessory protein. A recent study using minimal functional domains of channels in 
order to determine binding of inhibitors to functional channel domains provides a high-
throughput way to test compounds and thereby improve drug design (209). 
Once a new inhibitor has been identified, that is potent and specific for Orai1, it will be 
necessary to ensure it will target all hallmarks of acute pancreatitis. An ideal therapeutic for 
acute pancreatitis will need to: inhibit SOCE, prevent premature intracellular trypsinogen 
activation, reduce vacuolisation, reduce release of cytokines and recruitment inflammatory 
cells to the injured pancreas and ultimately reduce the extent of cellular necrosis. All 
hallmarks of acute pancreatitis need to be ameliorated and ideally the potential therapeutic 
candidate needs to be tested in multiple models of acute pancreatitis.  
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4 Modulation of Calmodulin to reduce cytosolic Ca2+ overload 
4.1  Introduction 
There is a superfamily of Ca2+ binding proteins called the Calmodulin superfamily, in which 
there are over 600 proteins that can sense or buffer intracellular Ca2+ (334). Calmodulin itself 
is part of this superfamily, it is a Ca2+ binding protein found at micromolar concentration 
(335) and is dispersed throughout the cytosol (336) of most eukaryotic cells (335). There is 
further evidence for the expression of calmodulin in the nucleus of cells (35,337). The amino 
acid sequence of calmodulin is highly conserved from yeast to humans, the only proteins 
more highly conserved are histones, β-actin and ubiquitin (338). A feature that all members 
of the calmodulin superfamily have in common is that they all possess a Ca2+ binding motif 
known as an EF hand (334). 
Calmodulin is a protein of 148 amino acids, it has four EF-hands, allowing one molecule of 
calmodulin to bind with four molecules of Ca2+ (35,335). The first two EF hands are located 
in the N-terminal domain of calmodulin and the third and fourth EF hands make up the C-
terminal domain; the two domains are separated by a short but flexible linker region (35). The 
EF-hands contain a 12 amino acid acidic group in the centre of a helix-loop-helix region and 
two alpha helices linked by a short loop region, and are known to bind to Ca2+ ions (35,334). 
The Ca2+ affinity for calmodulin makes it an efficient cytosolic Ca2+ sensor, as its affinity for 
Ca2+ falls within the intracellular free Ca2+ concentration range. Furthermore, the two separate 
domains of calmodulin have two different Ca2+ affinities, the C-terminus has a three to five 
fold higher affinity for Ca2+ than the N-terminus, and thereby the C-terminus binds Ca2+ 
before the N-terminus. Within each terminus Ca2+ ions will bind co-operatively to the EF 
hands, whereas the two domains bind Ca2+ independently of each other (35). The different 
domains of calmodulin have different conformational states depending whether Ca2+ is bound 
or unbound (apo-calmodulin). When no Ca2+ is bound the N-terminal EF hands are 
inaccessible and are tightly packed in a closed conformation, whereas the C-terminal is in a 
semi-open conformation; this may enable the C-terminal domain to bind to target proteins 
(339), such as the calmodulin binding sites on ion channels e.g. voltage gated Ca2+ channels 
(161). 
Calmodulin mediates many Ca2+ dependent processes in cells, such as protein 
phosphorylation, cell proliferation and ion transport. It does this through binding with the 
many target proteins that it regulates. There are so many targets that scientists created a 
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database of them (340). A few examples of calmodulin targets are: calmodulin Kinase I 
(CaMKI), phosphatases such as calcineurin (CaN) (35,335), voltage gated Ca2+ channels 
(161), the PMCA pump (341), IP3R, RyR (342) and lastly STIM (176) and Orai proteins 
(159). Calmodulin has been demonstrated to regulate all the above proteins in both negative 
and positive feedback loops, meaning it can activate or inactivate certain targets. This can 
depend on the target protein in question, and whether or not calmodulin is in its Ca2+-bound 
or Ca2+-free/apo-calmodulin state (343).  
4.1.1 Inhibition of Calmodulin  
Calmidazolium is a well characterised inhibitor of calmodulin. It was synthesised in 1981 
(344) and was found to be more potent and selective for calmodulin than drugs at the time 
that had antagonistic effects on calmodulin, such as fungicides and insecticides (345). W-7 is 
also an inhibitor of calmodulin (346,347) which is reported to be less specific and less potent 
than calmidazolium (348).  
W-7 was shown to inhibit amylase secretion from pancreatic acinar cells (349,350), which is 
known to be stimulated by local elevations in cytosolic Ca2+ concentrations.  Furthermore, 
calmodulin antagonism, achieved using W-7 and other inhibitors, inhibited the volume of bile 
flow in isolated liver and also inhibited bile acid secretion (351).  
Calmidazolium has been demonstrated to induce cytosolic Ca2+ signals in cells when applied 
in low micromolar concentration (2-5 µM) to Madin Darby Canine Kidney (MDCK) cells 
(352). W-7 has also been shown to induce Ca2+ signals in MDCK cells (353). It was found 
that removing extracellular Ca2+ only partially reduced the increase in cytosolic Ca2+ induced 
by both calmidazolium and W-7 (352,353), suggesting that in part this elevation in cytosolic 
Ca2+ is mediated by Ca2+ influx but part of the Ca2+ signal that is mediated by release from 
intracellular Ca2+ stores.  
It was demonstrated that the binding of calmodulin to PMCA resulted in the sensitisation of 
PMCA to increased cytosolic Ca2+ concentrations (354) allowing for enhanced extrusion of 
Ca2+ from the cytosol across the plasma membrane. In pancreatic acinar cells it was 
demonstrated that inhibiting calmodulin prevented Ca2+ efflux by PMCA (355). This was 
replicated in RBL-1 cells, where calmidazolium slowed the rate of Ca2+ clearance from the 
cytosol as mediated by PMCA (177). In addition to its effects on PMCA pumps 
calmidazolium has also been reported to inhibit Ca2+ entry in cells such as cardiac myocytes 
(356) and smooth muscle cells (357). Ca2+ influx in these two cell types is largely mediated 
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by voltage gated Ca2+ cells. Calmodulin binds the C-terminus of voltage gated Ca
2+ channels 
and regulates facilitation of the channel and mediates the fast Ca2+-dependent inactivation of 
the channel (161,358). For further information on the role of calmodulin in the Ca2+ 
dependent inactivation of CRAC channels see section 4.1.3. 
4.1.2 Activation of CaM 
In pancreatic acinar cells there has been some success in targeting cytosolic Ca2+ overload by 
utilising activators of calmodulin (359). Ca2+-like peptides (CALP) are activators of 
calmodulin that bind to EF hands and activate calmodulin in much the same way as Ca2+. 
They are Ca2+ like mimetics that were designed to competitively bind to Ca2+ binding sites on 
target proteins to allow for modulation of the downstream cellular functions of Ca2+ 
signalling, such as excitation-contraction coupling (360). The EF hands found on troponin C 
and calmodulin have very similar amino acid sequences, as they are believed to have evolved 
from one common ancestral Ca2+ binding site. The ancestral Ca2+ binding site was used as a 
template to create a peptide with an amino acid sequence that has an opposite hydropathy 
score, in an attempt to design a final peptide with affinity for the Ca2+ binding sites of 
proteins such as calmodulin and troponin C (360). This method of peptide design is based on 
the idea that the shape of a protein, e.g. a receptor, is in part determined by the location of its 
hydrophobic and hydrophilic residues in the sequence rather than the actual amino acid 
identity, this can be referred to as the hydropathy pattern. By exactly inverting this 
hydropathy pattern a peptide should be generated with a complementary surface with which it 
can bind to the receptor or protein in question (361). This was the method use to generate the 
CALP peptide (360).  
In order to test the efficacy of CALP in activating calmodulin, a phosphodiesterase activation 
assay was employed, cAMP hydrolysis was measured in the presence of calmodulin and 
CALP. Application of CALP increased the percentage of cAMP hydrolysed by 
phosphodiesterase, but did not have an effect in the absence of calmodulin; indicating that 
CALP was not directly interacting with phosphodiesterase but rather mediating its effects via 
calmodulin. This effect was not lost upon chelating of cytosolic Ca2+ with EGTA. 
Furthermore, CALP increased resting and ACh-induced tension in bladder smooth muscle 
cells. As experiments were undertaken at a low Ca2+ concentration, it was unlikely that CALP 
facilitated Ca2+ binding to calmodulin but rather, the effect on smooth muscle cells tension 
was due to CALP mediated activation of calmodulin directly (360). The CALP peptide used 
was 8 amino acids in length, which was designated CALP1 in subsequent studies; in spite of 
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strong evidence for it binding to the EF hand of calmodulin and activating the protein, this 
had not been directly demonstrated at that point. CALP1 had been designed to be 
complementary to the ancestral Ca2+ binding site but not specifically for the EF hand of 
calmodulin, as such a further three complementary peptides were developed with a similar 
sequence and of varying lengths (361). CALP2 was designed as a more specific peptide for 
the EF hand of calmodulin, with an inverted hydropathic pattern and was twelve amino acids 
in length. The CALP peptides were shown to bind to calmodulin and induce conformational 
changes in a similar manner to conformational changes induced by Ca2+ (361). CALP3 is the 
same length as CALP1, 8 amino acids and is the first eight amino acid residues of CALP2. 
CALP2 had a higher affinity for the EF hand of calmodulin than CALP1 and a similar 
affinity to Ca2+. CALP3, the most similar in structure to CALP2, had a higher affinity for the 
calmodulin EF hand than CALP1, by two fold. Researchers observed nuclear magnetic 
resonance (NMR) spectra from calmodulin bound to Ca2+ and calmodulin bound to CALP1 
and found peaks in common, and additional peaks in the calmodulin/CALP1 spectrum, 
indicating that CALP1 has conformational changes in common with Ca2+ but also had some 
additional changes. These were largely similar to conformational changes induce by Ca2+ 
binding with the C-terminus of calmodulin, indicating the location of CALP binding was an 
EF hand on the C-terminus, with no evidence that CALP1 or CALP3 bound the N-terminus 
EF hands of calmodulin (361).  
As the CALP peptides only bound the C-terminus of calmodulin, whereas Ca2+ binds all four 
EF hands on both N- and C-terminal domains of calmodulin, it was necessary for the 
researchers to determine if the conformational changes elicited by CALP/Calmodulin 
complexes were functional or not. CALP2 did not elicit any changes in the cGMP hydrolysis, 
and was found to entirely inhibit cGMP hydrolysis under conditions where both Ca2+ and 
calmodulin were present; this was reversible when the concentration of Ca2+ present was 
increased (361). The opposite was true for CALP3.   
Calmodulin localises primarily in the cytosol in cells, in order to activate calmodulin the 
CALP peptides must have been cell permeable, but this had not been demonstrated at this 
point. A fluorescent form of CALP1 was generated - F-CALP; F-CALP1 was visualised, 
using confocal microscopy, being rapidly taken up into neocortical neurones and Jurkat T 
cells (362). Furthermore, it was observed that both CALP1 and CALP3 were able to block 
Ca2+ channels. The neurones were stimulated with glutamate, which elicited a sustained 
increase in cytosolic Ca2+ levels, this increase in cytosolic Ca2+ was inhibited by CALP1 and 
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CALP3 in a dose dependent manner. The NMDA receptor, to which glutamate binds and 
initiates intracellular signalling pathways, was inhibited with its specific antagonist – MK801 
to inhibit glutamate-induced cytosolic Ca2+ signals, acting as a positive control. Pre-treating 
cells with W-7, thus inhibiting calmodulin, before CALP3 was applied restored the elevation 
in cytosolic Ca2+ in response to glutamate. The data suggests the CALP3 was inhibiting the 
NMDA receptor activity, via calmodulin (362). In electrophysiological recordings CALP1 
reversibly inhibited glutamate-induced NMDA currents. The peptide was used to inhibit non-
selective cation channel currents in Jurkat T cells, this inhibition was due to a reduction in the 
open probability of the channel rather than an inhibition of the channel conductance, with 
evidence indicating that CALP1 was acting from the cytoplasmic side of the channel. 
Glutamate is an excitatory stimulus to neurones and at high concentrations it can cause 
cytotoxicity. CALP1 and CALP3 reduced the extent of cell death caused by glutamate, as 
measured by propipidium iodide, in a dose-dependent manner with IC50 of 52.48 and 50.97 
µM respectively. More specifically, apoptosis measurements were made and both CALP 
peptides were found to inhibit apoptosis in the neuronal culture. It was concluded that this 
amelioration in cell death and apoptosis were due to inhibition of Ca2+ influx pathways by 
CALP peptides (362). 
Excessive alcohol intake is a primary cause of acute pancreatitis, largely mediated by the 
non-oxidative alcohol metabolites fatty acid ethyl esters such as palmitoleic acid ethyl ester 
(POAEE) (237,252,363). Fatty acid ethyl esters, such as POAEE, act on pancreatic acinar 
cells and result in the release of Ca2+ from the intracellular stores, and subsequent activation 
of trypsinogen intracellularly (363). Ethanol itself can also have somewhat toxic effects on 
pancreatic acinar cells, however these are only at extremely high concentrations (237), it was 
found that 200 mM ethanol, when applied to intact pancreatic acinar cells, resulted in 
cytosolic Ca2+ elevations (359). However, in permeabilised cells 10 mM ethanol was 
sufficient to liberate Ca2+ from the intracellular stores (359). The addition of 2.5 µM full-
length calmodulin to the extracellular solution of permeabilised cells had free access to the 
intracellular compartment of the cell, this addition was observed to dramatically reduced the 
amplitude of cytosolic Ca2+ increase. The Ca2+ signals in intact cells exposed to 200 mM 
ethanol were somewhat varied in their dynamics, typically in response to such high 
concentrations of ethanol there was a remarkably small but sustained increase in cytosolic 
Ca2+. Further there were a subset of cells in which the cytosolic Ca2+ signal was oscillatory in 
nature. In the presence of CALP3, 200 mM ethanol application resulted in a sustained 
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increase in cytosolic Ca2+ in significantly fewer cells and significantly more cells that did not 
respond to ethanol. This result was amplified when higher concentrations of CALP were 
utilised (359). There was an increase in the number of cells that responded in an oscillatory 
manner when treated with ethanol in the presence of CALP compared with ethanol treatment 
alone, although in the presence of CALP-3 the amplitude of the oscillations was dramatically 
reduced. This data indicated that there was a shift in the dynamic of the Ca2+ signal from a 
sustained elevation in cytosolic Ca2+ concentration to a signal that was short lasting and local 
in nature, which was unlikely to result in the intracellular activation of digestive enzymes 
(359). 10 mM ethanol treatment in permeabilised cells was sufficient to activate intracellular 
trypsinogen and 100 mM ethanol further increased the levels of trypsinogen activation. 
Ethanol induced trypsinogen activation was calmodulin sensitive, incubating cells with 
calmodulin alone significantly inhibited enzyme activation and incubating cells with 
calmodulin and CALP3 further inhibited enzyme activation, achieving almost complete 
inhibition (363).  
The mechanism of this protective effect is hypothesised to be mediated by the calmodulin 
dependent inhibition of IP3R, due to the binding of calmodulin to the IP3R (269). It has 
previously been demonstrated that 10 µM calmodulin markedly reduced the open probability 
of the IP3R and 20 µM completely inhibited the IP3R channel opening, even at high 
cytoplasmic Ca2+ levels. In order to remove the calmodulin inhibition on IP3R channel 
currents, high micromolar concentrations of 400 µM or more of the calmodulin antagonist, 
W-7, were required to restore the current (269).   
Research in Jurkat T cells indicated that the inhibition of the non-selective cation channels by 
CALP1 was thought to be through its interaction with calmodulin, rather than blocking the 
pore of the channel (362). Further evidence indicated that CALP1 was able to block the 
CRAC channel in RBL-2H3 mast cells (364). With this data in mind, in addition to the 
proposed mechanism that CALP3 modulates Ca2+ release from the ER through IP3R in 
response to ethanol (359), the protective effects of CALP3 against ethanol induced Ca2+ 
elevations could be mediated through inhibition of store-operated Ca2+ pathways, which are 
largely mediated by STIM1/Orai1 CRAC channels in pancreatic acinar cells. Section 4.1.3 
details the role of calmodulin in store-operated Ca2+ entry further.  
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4.1.3 Calmodulin and CRAC channels 
In addition to being a cytoplasmic Ca2+ binding protein, calmodulin also associates with 
certain ion channels and pumps and aids their regulation. It has been known for some time 
that calmodulin binds to and regulates the PMCA and also voltage gated Ca2+ channels 
(161,358); of late is has been  determined that there is a Ca2+ binding domain present in the 
CRAC channel structure. It is thought that the association of calmodulin to the CRAC 
channel mediates the Ca2+-dependent negative feedback of the channel (159), similarly to the 
manner in which the Ca2+ dependent inactivation of voltage gated Ca2+ channels is mediated 
by calmodulin (161).  
Section 1.5 extensively details the constituent components of the CRAC channel, with Orai1 
as the pore-forming subunit that resides in the plasma membrane (152–154) and STIM1 as 
the ER Ca2+ sensor with an EF hand on the luminal side of the ER (150,151,155). Ca
2+ 
dependent inactivation of the CRAC channel comes in two forms, fast Ca2+-dependent 
inactivation and slow Ca2+-dependent inactivation. The fast Ca2+-dependent inactivation is 
thought to be mediated by calmodulin binding to a calmodulin binding domain on Orai1, and 
also a cytoplasmic domain of STIM1, adjacent to Orai1. Several years ago a putative 
calmodulin binding site was identified in the N-terminus of Orai1, amino acid residues 68-91 
(159). The researchers searched for hydrophobic amino acid residues within this region, as 
hydrophobic residues are known to be a target for calmodulin binding (365). Several residues 
were identified in the N-terminal calmodulin binding domain of Orai1 and a series of mutated 
constructs were generated. Five of the mutations resulted in a loss of calmodulin binding to 
Orai1 and subsequent loss of Ca2+-dependent inactivation; in two further mutations the 
calmodulin binding domain of Orai1 retained the ability to bind calmodulin and thereby Ca2+-
dependent inactivation was also retained (159). The activation of Orai1, however, appeared to 
be largely unaffected by the mutation of the calmodulin binding domain.  
The nature of the interaction between the Orai1 and calmodulin was still not entirely clear 
until a crystal structure confirmed that the C-terminal domain of calmodulin binds to the N-
terminal Orai1 calmodulin binding domain (160). The N-terminal domain of calmodulin also 
has the capacity to bind Orai1 but it has a much lower affinity for the calmodulin binding 
domain on Orai1; furthermore, the shape of the calmodulin N-terminal domain is less 
complementary to the calmodulin binding domain of Orai1 than that of the C-terminal 
domain surface. When bound to the calmodulin binding domain, calmodulin is in a Ca2+ 
bound state (160).  
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A group studying the selective activation of NFAT, a downstream event of local Ca2+ influx 
through Orai1 channels which can be used as a read out of Orai1 activity, found that whilst 
Ca2+ influx through Orai1 channels activated NFAT translocation to the nucleus, Ca2+ influx 
through Orai3 channels (pre-activated by 2-APB) failed to activate NFAT translocation to the 
nucleus (177). The N-terminal calmodulin binding domain of Orai3 was found to have 
several conserved residues in common with the N-terminal calmodulin binding domain of 
Orai1, but overall the N-terminal domain of Orai3 was much shorter. It was thought that if 
the calmodulin binding domain is functional it would be less effective in binding calmodulin, 
when compared with its Orai1 counterpart. Two chimeras of Orai1 and Orai3 were formed, 
the first in which Orai1 was combined with the N-terminal domain of Orai3 (N3-Orai1) and 
the second in which Orai3 was combined with the N-terminal domain of Orai1 (N1-Orai3). In 
cells expressing the N1-Orai3 protein NFAT was successfully activated, albeit to a lesser 
extent than in cells expressing STIM1/Orai1; indicating that the N-terminal domain of Orai1 
and the calmodulin binding domain were sufficient to allow for downstream NFAT activation 
following local Ca2+influx. Furthermore, utilising a Ca2+ insensitive calmodulin mutant 
(Calmodulinmut1,2,3,4), in which there was a point mutation of aspartate to alanine in all four 
EF hands that resulted in a mutant that could no longer bind Ca2+, the researchers observed a 
reduction in the fast inactivation of the CRAC current compared with control cells (177). 
This recapitulated the findings of a previous study that found that the fast Ca2+-dependent 
inactivation of the CRAC channel was reduced utilising a Ca2+ insensitive mutant form of 
calmodulin (366). The reduction in fast Ca2+-dependent inactivation observed with the Ca2+ 
insensitive mutant was not observed using calmidazolium (177), which was similar to the 
opposing effects of observed when using the calmodulin insensitive mutant (358) and 
calmidazolium (367) on cells expressing voltage operated Ca2+channels. Researchers did not 
observe any effect of calmidazolium on the Ca2+-dependent inactivation and facilitation of 
voltage gated Ca2+ channels (367), instead of ruling out a role for calmodulin in these 
processes they employed a mutant form of calmodulin in which three of the EF hands were 
mutated and so were no longer able to bind Ca2+. Using this mutant a strong inhibition of 
Ca2+ dependent inactivation and facilitation of the channel was observed, that was not 
observed when calmidazolium was used (358). A hypothesis has been developed that because 
the calmodulin is associated with the channel and not a free molecule it is somehow protected 
from the action of calmidazolium (358), this is used to explain why calmidazolium does not 
dramatically affect NFAT translocation to the nucleus, as calmodulin associated with Orai1 is 
shielded (177).  
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Conversely to the previous studies, calmidazolium and W-7 were found to potentiate SOCE 
in pulmonary artery smooth muscle cells when applied at 10 µM to the extracellular solution 
(368). The same potentiating effect of W-7 and calmidazolium on Ca2+ influx induced by 
thapsigargin was observed in MDCK cells (352,353). This concentration of calmidazolium 
also resulted in a dramatic increase in cytosolic Ca2+ levels when applied to cells in which 
Ca2+ stores were replete, in the presence of extracellular Ca2+; such an effect was not 
observed in the absence of extracellular Ca2+ (368). Further to these studies, calmidazolium 
also potentiated Ca2+ entry induced by thapsigargin in HEK293 cells (369). To contradict 
these studies, there is evidence from experiments in hepatocytes that pre-incubating cells in 
the presence of calmidazolium was sufficient to inhibit store-operated Ca2+ influx induced by 
thapsigargin store depletion (370).  
A calmodulin binding domain was also discovered in the polybasic region of STIM1, part of 
the cytoplasmic domain, which was found to have lots of hydrophobic residues, known 
calmodulin binding targets (176,365). A putative calmodulin binding site was identified 
(371). Further experiments provided biochemical analyses that demonstrated that both 
STIM1 and STIM2 bind calmodulin with high affinity, in a Ca2+-dependent manner (176). 
Residues 667 – 685 of STIM1 bind calmodulin and residues 730-746 of STIM2 bind 
calmodulin. These regions of STIM1 and STIM2 were subsequently found to overlap with 
the lysine rich domain which is known to interact with the phosphoinositides in the plasma 
membrane, mediating the interaction of the ER Ca2+ sensor with the plasma membrane and 
thereby CRAC channels (372). Deleting the lysine-rich domain dramatically reduced the 
calmodulin binding ability of STIM1 and STIM2 C-terminal domain peptides (372). 
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4.2 Results 
4.2.1 Inhibition of calmodulin 
Calmodulin is known as a cytosolic Ca2+ buffer and has been demonstrated to protect 
pancreatic acinar cells from ethanol induced trypsinogen activation in vitro (359). 
Furthermore, in intact cells the addition of CALP3 reduced the increase in cytosolic Ca2+ 
elicited by ethanol. However, it was unclear whether this reduction in cytosolic Ca2+ levels 
was solely due to a reduction in intracellular Ca2+ release or a reduction in Ca2+ influx across 
the plasma membrane. As both Orai1 (159,160), STIM1(176,371) and PMCA (341) have 
calmodulin binding domains, modulation of calmodulin has the potential to alter Ca2+ influx 
via store-operated Ca2+ entry mechanisms and also clearance of cytosolic Ca2+ by the PMCA 
both of which serve to reduce cytosolic Ca2+ levels. 
Calmidazolium is an inhibitor of calmodulin (344), it has been shown to elicit Ca2+ release 
when applied to cells, this release is similar in dynamics to Ca2+ release elicited by IP3 (373); 
further it has been shown to activate store independent Ca2+ influx (368,373,374). In order to 
determine the effect of calmodulin inhibition on SOCE in pancreatic acinar cells, CPA was 
used to deplete intracellular stores, which was applied to cells in nominally Ca2+ free 
extracellular solution; as such Ca2+ was unable to re-enter the cell until it was re-admitted to 
the extracellular solution. Figure 4.1 A demonstrates the effect of 10 µM calmidazolium 
application to cells after store depletion (according to the protocol in section 2.5.2). In the 
previous chapter when inhibitors were added to the extracellular solution it was during store 
depletion with either CPA or thapsigargin, however due to the potential for calmidazolium to 
increase cytosolic Ca2+ concentration it was was added once cytosolic Ca2+ levels had 
returned to baseline levels after store depletion. Cells pre-incubated with calmidazolium 
exhibited a significant reduction in the amplitude of Ca2+ influx, the amplitude was reduced 
by 22.4 ± 2.5 % compared with control cells (figure 4.1 B). Furthermore, the half time of 
Ca2+ influx was significantly increased (40.9 ± 6.0%) in the presence of calmidazolium 
compared to control cells. The half time of Ca2+ efflux was not significantly affected by pre-
incubation Calmidazolium (31.6 ± 6.8 % increase (figure 4.1 C). In this experiment Ca2+ 
influx was induced by the addition of 10 mM Ca2+ to the extracellular solution. 






Figure 4.1 calmidazolium, a calmodulin inhibitor, inhibited store-operated Ca2+ entry in pancreatic 
acinar cells  
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A - ER stores were depleted according to the protocol in section 2.5.2 and then cells were pre-incubated 
with 10 µM Calmidazolium for 400 seconds before 10 mM Ca2+ was subsequently re-introduced to the 
extracellular solution. Blue trace represents control cells (n = 10). Red trace represents 10 µM 
Calmidazolium (n = 29). B- Summary of the changes in ratio amplitude due to Ca2+ influx (from cells in 
figure A) control (blue bar) and calmidazolium treated (red bar) (p = 0.0186). C- Summary of the changes 
in the half time of Ca2+ influx (bottom bars p = 0.0085.) control - blue, calmidazolium treated - red. Half 
time of Ca2+ efflux (upper bars p = 0.3779) control – blue, calmidazolium treated - red. D- 10 µM 
Calmidazolium was applied to cells according to the protocol in section 2.5.2 and pre-incubated with cells 
for 400 seconds before the re-introduction of 5 mM Ca2+  to the extracellular solution, blue trace – control (n 
= 26 ) and red trace – 10 µM Calmidazolium (n = 17). E- Summary of changes in ratio amplitude due to 
Ca2+ influx in control (blue bar) and calmidazolium treated (red bar p = 0.0172). F- Summary of the 
changes in half time of Ca2+ influx (bottom bars p = 0.0190) control –blue. Calmidazolium treated – red. 
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In figure 4.1 D 10 µM calmidazolium was used to inhibit calmodulin in cells where Ca2+ 
influx was initiated by addition of 5 mM Ca2+ to the extracellular solution. The experiment 
was performed identically to that in figure 4.1 A, calmidazolium was introduced to the 
extracellular medium once cytosolic Ca2+ levels returned to baseline levels. Pre-incubation 
for 400 seconds was sufficient to significantly decrease the amplitude of Ca2+ influx (23.5 ± 
2.6%, figure 4.1 E). In addition to inhibiting the amplitude of Ca2+ influx, pre-incubation with 
calmidazolium was sufficient to increase the half time of Ca2+ influx compared to control 
cells (25.9 ± 6.8 %). Similarly to figure 4.1 C, 10 µM calmidazolium pre-incubation was 
insufficient to significantly affect the half time of Ca2+ efflux compared to control cells (54.6 
±2.9% decrease, figure 4.1 F). 
As in chapter 3, 2 mM Ca2+ was introduced to the extracellular solution to permit Ca2+ to re-
enter the cytosol, as it is closer to physiological concentrations of extracellular Ca2+. In figure 
4.2 A cells were pre-incubated with 10 µM calmidazolium, in an identical protocol to figure 
4.1 A and D, before the re-introduction of 2 mM Ca2+ to the extracellular solution. Ca2+ 
influx in control cells was reduced compared to Ca2+ influx in control cells where 5 mM Ca2+ 
was re-admitted to the extracellular solution (figure 4.1 D), as there is a reduced driving force 
for Ca2+ into the cytosol. Furthermore, Ca2+ influx was significantly reduced in cells pre-
incubated with calmidazolium, compared to control cells (61.6 ± 1.2 %, figure 4.2 B). In 
addition to reducing the amplitude of Ca2+ influx, calmidazolium also increased the time 
taken for Ca2+ influx to reach half maximal compared to control cells (18.1 ± 2.3 %). The 
time taken for Ca2+ efflux to reach half maximal was also prolonged compared to the time 
taken for control cells (115.2 ± 3.8 %, figure 4.2 C). 
Another inhibitor of calmodulin was also utilised to confirm that inhibition of calmodulin 
results in a reduction of Ca2+ influx, as this finding contradicts some studies (368,374). W-7 
is also a calmodulin antagonist that inhibits the Ca2+/calmodulin complex (375,376). In figure 
4.3 A 100 µM W-7 was pre-incubated with cells, in an identical protocol to calmidazolium in 
figure 4.1 A, C and figure 4.2 A, after cytosolic Ca2+ levels had returned to baseline levels 
after store depletion. 






Figure 4.2- Calmidazolium inhibited Ca2+ entry activated by 2 mM extracellular Ca2+ 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to protocol in section 2.5.2 and the cells were pre-incubated 
with 10 µM calmidazolium for 400 seconds before the re-introduction of 2 mM Ca2+ to the 
extracellular solution. Control - blue trace (n = 6) calmidazolium treated- red trace (n = 25). B- 
Summary of changes in ratio amplitude due to Ca2+ influx (from cells in figure A) in control (blue 
bar) and calmidazolium treated (red bar p = 0.0005). C- Summary of the changes in half time of 
Ca2+ influx (bottom bars p = 0.0102) control – blue, calmidazolium treated – red.  Half time of 
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After store-depletion and pre-incubation with W-7, 10 mM Ca2+ was introduced to the 
extracellular solution, cells pre-incubated with W-7 exhibited a qualitatively large reduction 
in the amplitude of Ca2+ influx compared to Ca2+ influx in control cells, however the change 
was not significant (43.4 ± 1.2 %, figure 4.3 B). The time taken for Ca2+ influx to reach half 
maximal was significantly prolonged by pre-incubation with 100 µM W-7 compared to 
control cells (57.0 ± 4.6 %). The time taken for Ca2+ efflux to reach half maximal however, 
was not significantly prolonged by pre-incubation with 100 µM W-7 (16.1 ± 3.3 %, figure 4.3 
C). The data generated from the two inhibitors, assuming their specificity for calmodulin, 
indicates that the rate of Ca2+ influx is regulated by calmodulin.  
The Ca2+ insensitive protein described in section 4.1.3, in which all four EF hands have been 
mutated so that it can no longer bind Ca2+ has been developed and used extensively 
(366,377,378). It was found the amplitude of Ca2+ influx in cells expressing the Ca2+ 
insensitive protein was not affected, but the fast Ca2+ dependent inactivation of CRAC 
channels was affected (177). The plan was to use Ca2+ insensitive protein in this chapter to 
determine the effects of inhibiting the Ca2+ binding ability of calmodulin on the dynamics of 
SOCE in pancreatic acinar cells. Initial pilot studies resulted in conflicting results as to what 
the effects of Calmodulinmut1,2,3,4 on Ca2+ handling in pancreatic acinar cells were, this was 
mostly due to the fact it was not possible to visualise cells expressing the mutant protein. As 
pancreatic acinar cells cannot be cultured, AR42J cells were used and transfected with the 
mCherry tagged version of both wild-type (mCherry-CalmodulinWT) or mutant (mCherry-
calmodulinmut1,2,3,4) for three days according to previous protocols (328). Cells were loaded 
with Fura-2 and imaged according to the protocols in section 2.4.3 and 2.4.4 respectively. 
The experiment shown in figure 4.4 A is one in which 10 µM ACh and 30µM CPA were 
used to release Ca2+ from the ER store, in the presence of 1 mM Ca2+ in the extracellular 
solution. Cells expressing the mutant calmodulin exhibited a reduction in the amplitude of the 
subsequent cytosolic Ca2+ transient observed compared with cells expressing WT calmodulin. 
The amplitude of Ca2+ transient observed in both Calmodulinmut1,2,3,4 and calmodulinWT are 
reduced compared to neighbouring cells on the coverslips that were not expressing the 
fluorescently tagged calmodulin plasmids. The differences were not statistically significant, 
likely due to insufficient statistical power. This can be overcome by repeating the experiment. 
Figure 4.4 B is a summary of the changes in amplitude of cytosolic Ca2+ transient in WT and 
mutant calmodulin expressing cells. 








 Figure 4.3 W-7, a calmodulin inhibitor, inhibited Ca2+ entry activated by 10 mM 
extracellular Ca2+ 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted using thapsigargin according to the protocol in section 2.5.2 and then 
cells were pre-incubated with 100 µM W-7 for 400 seconds before the re-introduction of 10 mM 
Ca2+ to the extracellular solution, blue trace – control (n = 10) and red trace – 100 µM W-7 treated 
(n = 4). B- Summary of changes in ratio amplitude due to Ca2+ influx (from cells in figure A) 
control – blue, W-7 treated – red (p = 0.1878). C- Summary of the changes in half time of Ca2+ 
influx (bottom bars p = 0.03) control – blue, W-7 treated – red. Half time of Ca2+efflux (upper bars 
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Figure 4.4 Expression of Ca2+ insensitive mutant calmodulin in AR42J cells 
resulted in a reduced amplitude of cytosolic Ca2+ signal   
Averages traces (± SEM) of Fura-2 loaded AR42J cells 
A- mCherry-CalmodulinWT and mCherry-Calmodulinmut1,2,3,4 were generated according 
to the protocol in section 2.7 andwere expressed in AR42J cells according to the protocol 
in section 2.4. 2. Cells were loaded with Fura-2 according to the protocol in section 
2.4.3. 10 µM ACh and 10µM CPA were applied to cells in the presence of 1 mM Ca2+ in 
the extracellular solution. B- summary of the overall changes in amplitude of cells 
expressing mCherry-Calmodulinmut1,2,3,4 (n =21) and untransfected cells (n = 20) and also 
the changes in amplitude of cytosolic Ca2+ in cells expressing mCherry-CalmodulinWT (n 
= 45) and untransfected cells (n = 28).  
A 
B 
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4.2.2 Activation of calmodulin 
CALP3, the calmodulin activator that inhibited ethanol induced elevation in cytosolic Ca2+ 
concentration, was utilised in figure 4.5 to determine if CALP3 had a dual effect of inhibiting 
Ca2+ release from intracellular stores and inhibiting Ca2+ entry. Based on data from a pilot 
experiment, in which 10 µM CALP3 was sufficient to significantly inhibit Ca2+ influx, in 
figure 4.5 A cells were exposed to a two-step store depletion (according to the protocol in 
section 2.5.4) and then were pre-incubated with 10 µM CALP3 for ten minutes before the re-
introduction of 10 mM Ca2+ to the extracellular solution. This pre-incubation did not reduce 
the amplitude of Ca2+ influx in cells pre-incubated with CALP3 compared to Ca2+ influx in 
control cells (figure 4.5 B). In addition to having no significant effect on the amplitude of 
Ca2+ influx, 10 minutes pre-incubation with 10 µM CALP3 was insufficient to prolong the 
time taken for Ca2+ influx to reach half maximal compared with Ca2+ influx in control cells. 
Neither was there an effect on the time taken for Ca2+ efflux to reach half maximal compared 
with control cells (figure 4.5 C).  
The pilot experimental data was obtained utilising 10 mM Ca2+ in the extracellular solution. 
this concentration of Ca2+ extracellularly would have provided a larger driving force for Ca2+ 
across the plasma membrane than 2 mM Ca2+ , thus resulting in a larger increase in cytosolic 
Ca2+ concentration. Higher concentrations of cytosolic Ca2+ are likely to be sufficient to 
completely activate calmodulin in the cytosol and associated with channels and pumps. 
Applying a calmodulin activating peptide is unlikely to have an additional effect. For the 
following experiments using CALP3, 2 mM Ca2+ was added to the extracellular solution 
instead of 10 mM Ca2+ in an attempt to avoid pre-activating calmodulin. Figure 4.5 D 
demonstrates the effect of increasing the CALP3 concentration to 100 µM, cells were pre-
incubated with this concentration for 10 minutes before the re-introduction of 2 mM Ca2+ to 
the extracellular solution. This pre-incubation did not significantly affect the amplitude of 
Ca2+ influx compared to control cells (figure 4.5 E).  The time taken for Ca2+ influx to reach 
half maximal was significantly shorter in cells pre-incubated with 100 µM compared to 
control cells (reduced by 22.0 ± 1.7 %). The time taken for Ca2+ efflux to reach half maximal 
however, was unaffected by the pre-incubation with 100 µM CALP3 compared with control 
cells (figure 4.5 F).  
When ER stores are depleted using 10 µM CPA, although an efficient concentration for 
depleting the intracellular store of Ca2+, the increase in cytosolic Ca2+ is rapid and substantial, 
sufficient to activate calmodulin in order to buffer increases in Ca2+, to prevent the cytotoxic 
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effects of sustained elevation in cytosolic Ca2+ levels, such as intracellular activation of 
digestive proenzymes (234). As CALP3 is an activator of calmodulin, it would be ineffective 
if applied after calmodulin activation by elevated Ca2+ levels. A two-step store depletion 
protocol was employed, the first step a low concentration of CPA (1 µM) was applied to cells 
which induced a slower and more gradual passive leak of Ca2+ from ER. This was followed 
by the second step, in which cells were briefly exposed to 10 µM CPA to ensure the stores 
were entirely depleted. In addition to the two-step store depletion protocol the concentration 
of CALP3 was increased to 200 µM; pre-incubating cells with this concentration for ten 
minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution, is shown in 
figure 4.6 A. This pre-incubation was sufficient to significantly inhibit Ca2+ influx compared 
to influx in control cells (figure 4.6 C). Figure 4.6 B depicts another experiment in which 
cells were pre-incubated with 200 µM CALP3 for 10 minutes before re-introduction of 2 mM 
Ca2+ to the extracellular solution, undertaken using the same experimental protocol as figure 
4.6 A; however the store depletion phase with 1 µM CPA was shorter, as such as the 
experiments were not time locked they could not be combined to make one average trace. 
Despite this minor change, this pre-incubation was sufficient to significantly inhibit the 
amplitude of Ca2+ influx compared to influx in control cells (figure 4.6 C). The inhibition of 
Ca2+ influx in CALP3 pre-incubated cells was significant in both experiments (77.8 ± 1.8%).




Figure 4.5 CALP3, a calmodulin activating peptide, had no effect on Ca2+ entry when pre-incubated 
with cells at 100 µM 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol 2.5.4 and then cells were pre-incubated with 10 µM 
CALP3 for 10 minutes before the re-introduction of 10 mM Ca2+ to the extracellular solution. Blue trace – 
control (n = 8) and red trace – 10 µM CALP3 (n = 7). B- Summary of changes in ratio amplitude due to 
Ca2+ influx (from cells in Figure A) in control (blue bar) and CALP3 treated (red bar p = 0.7608). C- 
Summary of the changes in half time of Ca2+ influx (bottom bars p = 0.1810) control - blue CALP3treated – 
red.) Half time of Ca2+ efflux (upper bars p = 0.4563) control – blue, CALP3 treated – red. D- ER stores 
were depleted according to the protocol in section 2.5.2 and then cells were pre-incubated with 100 µM 
CALP3 for 10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution, blue trace – 
control (n = 8 ) and red trace – 100 µM CALP3 (n = 15). E- Summary of changes in ratio amplitude due to 
Ca2+ influx (from cells in figure D) control (blue bar) and CALP3 treated (red bar p = 0.6779). F- Summary 
of the changes in half time of Ca2+ influx (bottom bars p = 0.0004) control – blue, CALP3 treated - red. Half 



















Figure 4.6 CALP3, a calmodulin activating peptide, inhibited Ca2+ influx when pre-incubated with 
cells at 200 µM  
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A – Cells were treated according to the protocol in section 2.5.4, cells were pre-incubated with 200 µM 
CALP3 for 10 minutes before 2 mM Ca was subsequently re-introduced to the extracellular solution. 
Control cells – blue trace (n= 11) and 200 µM CALP3 – red trace (n = 15). B – a similar experiment to part 
A, on different time scale. 2 mM Ca2+ was re-introduced to the extracellular solution after pre-treatment 
with CALP-3. Control cells – blue trace (n = 5) and 200 µM CALP3 – red trace (n = 7). C-  Summary of 
the changes in ratio amplitude due to Ca2+ influx, from A and B, in control cells (blue bar) and 200 µM 
CALP3 (red bar p < 0. 0001). D- Summary of the changes in the half time of Ca2+ influx, from A and B 
(bottom bars p < 0.0001) blue – control and red – 200 µM CALP3 and the half time of Ca2+ efflux (upper 
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In addition, the time taken for Ca2+ influx to reach half maximal was significantly increased 
in cells pre-incubated with CALP3, compared to control cells (146.8 ± 6.3 %). Lastly, the 
time taken for Ca2+ efflux to reach half maximal was significantly decreased in cells pre-
incubated with CALP3, compared to Ca2+ efflux in control cells (38.1 ± 6.8 %, figure 4.6 D).  
As CALP3 is a cell permeable peptide (362), it likely does not need a prolonged pre-
incubation period in order to access the cytosol and exert its action. When pre-incubated with 
cells for 100 seconds before the re-introduction of 2 mM Ca2+ to the extracellular solution, in 
figure 4.7 A 200 µM CALP3 was sufficient to significantly inhibit the ratio amplitude of Ca2+ 
influx in  pre-treated cells compared to control cells in (35.1 ± 3.3 %, figure 4.7 B). The time 
taken for Ca2+ influx to reach half maximal in cells pre-incubated with 200 µM CALP3 was 
significantly prolonged compared to the time to half maximal Ca2+ influx in control cells 
(141.3 ± 1.6 %). The time taken to reach half maximal Ca2+ efflux was unchanged in cells 
pre-incubated with 200 µM CALP3 compared to that in control cells (decreased by 1.8 ±14.2 
%, figure 4.7 C).  
As it is not possible to treat patients for an acute disease, such as acute pancreatitis, in 
advance it is necessary to find a treatment that is effective in ameliorating the pathological 
stimulus once it has been triggered and the disease has been set in motion, therefore any 
potential therapeutic needs to be effective when applied in an acute manner. Figure 4.7 E 
demonstrates the effect of applying 200 µM CALP3 in an acute protocol in the presence of a 
sustained increase in cytosolic Ca2+ due to the re-admittance of Ca2+ to the extracellular 
solution. In control cells, shown in figure 4.7 D, re-admittance of Ca2+ to the extracellular 
solution was followed by a rapid increase in cytosolic Ca2+, upon reaching a peak there was a 
slight decrease and then an elevated plateau was established. This plateau remained 
significantly elevated compared to baseline and remained remarkably constant in the 
sustained presence of Ca2+ in the extracellular solution. The addition of 200 µM CALP3 to 
the extracellular solution, in figure 4.7 E, in the maintained presence of Ca2+ extracellularly 
and a sustained elevation in cytosolic Ca2+ resulted in a decrease in cytosolic Ca2+ levels, 
contrasting with control cells. The effect of this acute application of 200 µM CALP3 was to 
significantly reduce cytosolic Ca2+ levels by 57.2 ± 3.9 % (p = 0.0357). 









Figure 4.7 200 µM CALP3 inhibited Ca2+ entry when only briefly pre-incubated with cells and 
when applied acutely 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and the cells were pre-incubated 
with 200 µM CALP3 for 100 seconds before the re-introduction of 2 mM Ca2+ to the extracellular 
solution. Blue trace – control (n = 25) and red trace – 200 µM CALP3 (n = 24). B- Summary of changes 
in ratio amplitude due to Ca2+ influx (from cells in figure A) control (blue bar) and CALP3 treated (red 
bar p = 0.0018). C- Summary of the changes in half time of Ca2+ influx (lower bars p = 0.0001) control 
– blue, CALP3 treated – red. Half time of Ca2+ efflux (upper bars p = 0.7928) control - blue, CALP3 
treated – red. D & E - cells were treated according to the protocol in section 2.5.3, D is a control for E, 
in which 200 µM CALP3 was introduced to the extracellular solution in the continued presence of 2 
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Although significant, the reduction in cytosolic Ca2+ levels was incomplete; however, 
cytosolic Ca2+ was steadily decreasing and had the experiment been left for longer the 
reduction may have been more significant. Removal of Ca2+ from the extracellular solution 
resulted in a further reduction of cytosolic Ca2+ levels to baseline levels. 
As AR42J cells are a model pancreatic acinar cell line, it was sought to determine if the effect 
of pre-incubating cells with 200 µM CALP3 was similar to that in primary pancreatic acinar 
cells, or if the differences that were observed with Pyr6 and Pyr10 treatment between AR42J 
cells and primary cells observed in chapter 3 were true for CALP3 treatment. AR42J cells 
were pre-incubated with 200 µM CALP3 for ten minutes before the re-introduction of 2 mM 
Ca2+ to the extracellular solution, figure 4.8 A. There was subsequent influx of Ca2+ in control 
cells and in cells pre-incubated with CALP3, the amplitudes of which were not significantly 
different from each other (figure 4.8 B). This was starkly in contrast with the results obtained 
in primary pancreatic acinar cells in which a ten minute pre-incubation resulted in a dramatic 
reduction in Ca2+ influx as observed in figure 4.6, a significant reduction in Ca2+ influx was 
observed with a short incubation with 200 µM CALP3 in figure 4.7, as well as the decrease in 
cytosolic Ca2+ observed after acute application with 200 µM CALP3. The half time of Ca2+ 
influx in AR42J cells pre-treated with CALP3 was significantly faster than in control and the 
time taken to reach half maximal Ca2+ efflux was also significantly slowed in AR42J cells 
pre-incubated with CALP3, compared with control (figure 4.8 C). The effect of CALP3 on 
the half-time of Ca2+ influx in AR42J cells was much more similar to pancreatic acinar cells 
than the effect of CALP3 on the amplitude of Ca2+influx. 
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Figure 4.8 CALP3 significantly slowed the rate of store-operated Ca2+ influx and 
Ca2+ efflux in AR42J cells 
Average traces (±SEM) from Fura-2 loaded AR42J cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and then cells 
were pre-incubated with 200 µM CALP3 for ten minutes before 2 mM Ca2+ was 
subsequently re-introduced to the extracellular solution. Blue trace represents control 
cells (n = 19). Red trace represents 200 µM CALP3 (n = 20). B- Summary of the 
changes in the ratio amplitude due to Ca2+ influx (from cells in figure A) control (blue 
bar) and CALP3 treated (red bar) (p = 0.8927). C- Summary of the changes in the half 
time of Ca2+ influx (bottom bars) control – blue, CALP3 treated – red (p = 0.0024). 
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4.2.3  Combined inhibition of Orai1 and Calmodulin 
Inhibition of CRAC channels using several different inhibitors resulted in a significant 
reduction in store-operated Ca2+ entry (see chapter 3); furthermore, inhibition of calmodulin, 
using two different inhibitors also resulted in a decrease in store-operated Ca2+ entry. The aim 
of the following experiments was to determine the extent to which Ca2+ influx could be 
reduced when both CRAC channel inhibition and calmodulin inhibition were employed. 
Figure 4.9 A demonstrates the effect of pre-incubating cells with 10 µM GSK7975-A and 10 
µM calmidazolium for 10 minutes before the re-introduction of 10 mM Ca2+ to the 
extracellular solution, to maximally activate SOCE across the membrane. This pre-incubation 
was sufficient to significantly reduce the amplitude of Ca2+ entry compared to the amplitude 
of Ca2+ entry in control cells ( 49.9 ± 2.3 %, figure 4.9 B). In cells pre-incubated with 10 µM 
Calmidazolium and 10 µM GSK7975-A the elevated plateau in cytosolic Ca2+ did not remain 
constant; upon Ca2+ re-addition to the extracellular solution cytosolic Ca2+ levels rapidly 
reached a peak but almost immediately started to decline. This decrease in cytosolic Ca2+ 
continued at a steady rate until Ca2+ was removed from the extracellular solution, at which 
point the rate at which in cytosolic Ca2+ levels decreased became steeper until baseline levels 
in Ca2+ were re-attained. This decrease in cytosolic Ca2+ levels after the re-introduction of 
Ca2+ to the extracellular solution was not observed in control cells. In addition to reducing the 
amplitude of Ca2+ influx the pre-incubation with the calmodulin inhibitor and the CRAC 
channel inhibitor also significantly prolonged the half time to maximal Ca2+ influx in cells, 
compared with control cells (22.2 ± 4.7 %, p = 0.0129). The time taken to reach half maximal 
Ca2+ efflux was also prolonged in cells pre-incubated with 10 µM GSK7975-A and 10 µM 
calmidazolium compared with control cells (86.9 ± 4.2 %, figure 4.9 C. 




Figure 4.9 Combined inhibition of Orai1 and calmodulin significantly inhibited Ca2+ influx 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.2 and then cells were pre-
incubated with 10 µM calmidazolium and 10 µM GSK7975-A for 10 minutes before the re-
introduction of 10 mM Ca2+ to the extracellular solution. Blue trace – control (n = 5) and red trace – 
10 µM Calmidazolium and 10 µM GSK7975-A (n = 28). B- Summary of the changes in ratio 
amplitude due to Ca2+ influx in control (blue bar) and calmidazolium +  GSK7975-A treated (red bar 
p = 0.0001). C- Summary of the changes in half time of Ca2+ influx (lower bars p = 0.0129) control – 
blue, calmidazolium + GSK7975-A – red. Half time of Ca2+ efflux (upper bars p = 0.0001) control – 
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Figure 4.10 Combined calmodulin and Orai1 inhibition reduced Ba2+ entry activated by 10 mM 
extracellular Ba2+ 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.2 and then cells were pre-incubated 
with 10 µM Calmidazolium and 10 µM GSK7975-A for 10 minutes before the introduction of 10 mM 
Ba2+ to the extracellular solution, blue trace – control (n = 19) and red trace – 10 µM Calmidazolium and 
10 µM GSK7975-A (n = 18). B- Summary of the changes in ratio amplitude due to Ca2+ influx in 
control (blue bar) and Calmidazolium + GSK7975-A treated (red bar p = 0.0001). C- Summary of the 
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As described in chapter 3, Ba2+ can be used to assess the unidirectional flux of divalent ions 
into the cell, as CRAC channels are permeable to Ba2+ but PMCA and SERCA are incapable 
of actively pumping Ba2+ from the cytosol in the way they would pump Ca2+. As in figure 
3.13, in figure 4.10 A the ER Ca2+ stores were depleted using CPA, during the store depletion 
phase 10 µM GSK-7975A and 10 µM Calmidazolium were introduced to the extracellular 
solution and pre-incubated with the cells for 10 minutes before the introduction of 10 mM 
Ba2+ to the extracellular solution. In control cells there was an increase in cytosolic Ba2+ 
levels. There was also an increase in Ba2+ influx in cells pre-treated with the calmodulin 
inhibitor and CRAC channel inhibitor.  The amplitude of Ba2+ influx in cells pre-treated with 
the calmodulin inhibitor and the CRAC channel inhibitor was significantly reduced compared 
with control cells (73.6 ±  4.0, figure 4.10 B). The time to half maximal Ba2+ influx was not 
significantly different in cells pre-incubated with calmidazolium and GSK-7975A compared 
to control cells (increase of 4.6 ± 5.0, figure 4.10 C). The gradients of the increase in Ca2+ 
influx from control cells and that from GSK-7975A and calmidazolium treated cells are 
clearly different. However, as a plateau in cytosolic Ba2+ concentration was not attained, the 
measurement of half time likely does not reflect this difference as accurately as measurement 
of the gradient might.  
4.2.3 Effect of calmodulin and calmodulin-derived peptides on Ca2+ entry 
CALP3, when applied to pancreatic acinar cells was able to inhibit SOCE in addition to its 
previously demonstrated capacity to reduce Ca2+ release in cells treated with ethanol (359). 
An additional finding of this paper was that the application of calmodulin to permeabilised 
cells resulted in decreased Ca2+ release from intracellular Ca2+ stores. 
In figure 4.11 A a calmodulin containing extracellular solution was used to perfuse intact 
pancreatic acinar cells after store depletion using a two-step store depletion protocol 
described in section 2.5.4. Cells were pre-incubated with 10 µM calmodulin, derived from 
bovine brain, for ten minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution. The amplitude of Ca2+ influx in cells pre-incubated with 10 µM calmodulin was 
significantly reduced compared to the amplitude of Ca2+ influx in control cells (18.0 ± 3.8 %, 
figure 4.11 B).




Figure 4.11 Pre-incubation with full length Calmodulin significantly inhibited Ca2+ entry 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and then cells were pre-
incubated with 10 µM calmodulin for 10 minutes before the re-introduction of 2 mM Ca2+ to 
the extracellular solution. Blue trace – control (n = 19) and red trace – 10 µM Calmodulin (n = 
14). B- Summary of the changes in ratio amplitude due to Ca2+ influx in control (blue bar) and 
calmodulin treated (red bar p = 0.0006). C- Summary of the changes in half time of Ca2+ influx 
(lower bars p = 0.0001) control – blue, calmodulin treated – red. Half time of Ca2+ efflux 
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Furthermore, the time taken to reach half maximal influx in cells pre-incubated with 10 µM 
calmodulin was significantly prolonged compared with the half time of Ca2+ influx in control 
cells (108.2 ± 17.3 %). The time taken to reach half maximal efflux in cells pre-incubated 
with 10 µM calmodulin was significantly shorter than in the half time of Ca2+ efflux in 
control cells (33.2 ± 4.1 %, figure 4.11 C.  
It is highly unlikely that calmodulin, a 148 amino acid long protein, would be able to pass 
through the plasma membrane. In addition, there are not any known extracellular calmodulin 
binding domains through which calmodulin can bind and activate intracellular signal 
transduction pathways that have the ability to initiate intracellular calcium signalling and 
regulation of CRAC channels. A suspension of freshly isolated pancreatic acinar cells that 
have been partially digested from the whole tissue using collagenase is likely to contain cells 
that have undergone necrosis, which have released their cellular contents to the extracellular 
medium. The primary physiological function of pancreatic acinar cells is the synthesis of 
digestive pro-enzymes, which are stored in zymogen granules; ordinarily the proenzymes are 
activated after they are released from the cell via exocytosis. However, under necrotic 
conditions these proenzymes are released and are activated establishing a positive feedback 
cycle of digestion and necrosis. In addition to the release of digestive proenzymes other 
intracellular proteins would also be released. Proteases, such as trypsin and chymotrypsin, are 
the major class of digestive enzymes synthesised and stored harmlessly in zymogen granules 
as trypsinogen and chymotrypsinogen in the apical pole of acinar cells. In acute pancreatitis, 
once the proteases are activated extracellularly, the intracellular proteins that are released are 
highly vulnerable to proteolytic cleavage. There are many protease cleavage site on 
calmodulin, including several trypsin and chymotrypsin cleavage sites (see appendix Figure 
1).  
It was hypothesised that following cellular necrosis, once the cellular components have been 
released to the extracellular solution, the various proteases including trypsin and 
chymotrypsin cleave proteins such as calmodulin, forming smaller peptide products that are 
able to inhibit Ca2+ entry via SOCE channels. The mechanisms of the inhibition are to be 
determined. Interestingly, when AR42J cells, the pancreatic acinar like cell line, are pre-
incubated with full length calmodulin at the same concentration for the same duration (figure 
4.12 A), the inhibitory effect on the amplitude of Ca2+ entry observed in figure 4.11 A was 
not observed. 
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Figure 4.12 Calmodulin did not affect the amplitude of store-operated Ca2+ influx but significantly 
slowed the rate of store-operated Ca2+ influx and Ca2+ efflux in AR42J cells 
Average traces (±SEM) from Fura-2 loaded AR42J cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and then cells were pre-incubated 
with 10 µM calmodulin for ten minutes before 2 mM Ca2+ was subsequently re-introduced to the 
extracellular solution. Blue trace represents control cells (n = 10). Red trace represents 10 µM calmodulin 
(n = 13). B- Summary of the changes in the ratio amplitude due to Ca2+ influx (from cells in figure A) 
control (blue bar) and calmodulin treated (red bar) (p = 0.7027). C- Summary of the changes in the half 
time of Ca2+ influx (bottom bars) control – blue, calmodulin treated – red (p = 0.0001). Half time of Ca2+ 
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The change in ratio amplitude due to Ca2+ influx, summarised in figure 4.12 B, was not 
statistically significant. The time taken to reach half maximal Ca2+ influx was significantly 
faster in calmodulin pre-treated cells as was the time taken to reach half maximal Ca2+ efflux 
(figure 4.12 C). This data is surprising, as unless differentiated AR42J cells have not been 
reported to be secretory, these AR42J cells are not differentiated. This data suggests that this 
effect of calmodulin, by whatever mechanism, is non-specific.   
Hypothetically, if the proteases released by acinar cells are inhibited, then calmodulin would 
not be cleaved and no smaller peptide fragments would be formed. Soybean trypsin inhibitor 
was used to inhibit trypsin in the extracellular solution and prevent its proteolytic action on 
calmodulin. Figure 4.13 A demonstrates the effect of pre-incubating cells with 0.01% trypsin 
inhibitor during the second step of store-depletion with 10 µM CPA (according to the 
protocol in section 2.5.5), both control cells and cells subsequently incubated with 
calmodulin were treated with trypsin inhibitor. After 400 seconds 10 µM calmodulin was 
introduced to the extracellular solution and pre-incubated with cells for ten minutes before 
the re-introduction of 2 mM Ca2+ to the extracellular solution. In control cells, in the presence 
of trypsin inhibitor but absence of calmodulin, after the re-introduction of Ca2+ to the 
extracellular solution there was an increase in cytosolic Ca2+ due to Ca2+ influx. This Ca
2+ 
influx event was qualitatively no different in dynamics to Ca2+ influx in the absence of 
trypsin inhibitor, as seen in preceding experiments. In cells pre-incubated with calmodulin 
Ca2+ influx was significantly inhibited compared to control cells (63.5 ± 4.8 %, figure 4.13 
B). Pre-incubation of cells with calmodulin in the presence of trypsin inhibitor significantly 
prolonged the time taken to reach half maximal Ca2+ influx (46.8 ± 7.6 %), whereas the time 
taken to reach half maximal Ca2+ efflux was not significantly affected by the calmodulin pre-
incubation (decreased by 1.3 ± 5 %, figure 4.13 C). Evidently, inhibition of trypsin did not 
prevent cleavage of calmodulin, however there are other minor proteases that remain 
uninhibited.  
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Figure 4.13 Pre-incubation with trypsin inhibitor and full length Calmodulin significantly 
inhibited Ca2+ entry 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, 0.01% trypsin inhibitor was 
added to the extracellular solution during the second step of store depletion in both conditions. After 
400 seconds 10 µM calmodulin was introduced to the extracellular solution and pre-incubated with 
cells for 10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution, blue trace – 
control (n = 37) and red trace – 10 µM calmodulin (n = 17). B- Summary of the changes in ratio 
amplitude due to Ca2+ influx (from cells in Figure A) in control (blue bar) and calmodulin treated (red 
bar p = 0.0001), both in the presence of 0.01% trypsin inhibitor. C- Summary of the changes in half 
time of Ca2+ influx (lower bars p = 0.0002) control – blue, calmodulin treated – red. Half time of Ca2+ 
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Chymotrypsin in another protease that is synthesised and stored by the pancreatic acinar cells, 
this is also likely to be released and activated after cellular necrosis. Chymostatin is a 
chymotrypsin inhibitor and was used in a similar protocol to figure 4.13 A to inhibit 
chymotrypsin in the extracellular medium, thus preventing its proteolytic action on 
calmodulin. In figure 4. 4 A control cells and cells incubated with calmodulin were all pre-
incubated in the presence of chymostatin, according to the protocol in section 2.5.5. After 400 
seconds 10 µM calmodulin was introduced to the extracellular solution and pre-incubated 
with cells for ten minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution. The amplitude of Ca2+ influx was not significantly different in cells pre-incubated 
with calmodulin compared with the amplitude of Ca2+influx in control cells (increased by 
17.5 ± 18.6 %, figure 4.14 B). However, the time taken to reach half maximal Ca2+ influx in 
cells pre-incubated with calmodulin was significantly less than the time taken to reach half 
maximal Ca2+ influx in control cells (30.2 ± 4.3 %) The time taken to reach half maximal 
Ca2+ efflux in cells pre-incubated with 10 µM calmodulin was significantly prolonged 
compared with the time taken to reach half-maximal Ca2+ efflux in control cells (41.9 ± 15.2 
%, figure 4.14 C). 
 Although trypsin and chymotrypsin are the major proteases synthesised and stored in the 
pancreatic acinar cells, to a lesser extent acinar cells also synthesise and secrete other types of 
proteases. In order to inhibit as many proteases as possible, a protease inhibitor cocktail 
solution was applied to cells in the extracellular solution in both control and calmodulin 
treatment, according to the protocol in section 2.5.5, in figure 4.15 A. After 400 seconds 10 
µM calmodulin was introduced to the extracellular solution and incubated with cells for 10 
minutes before the re-addition of 2 mM Ca2+ to the extracellular solution. Cells pre-incubated 
with 10 µM calmodulin in the presence of the protease inhibitor cocktail exhibited a 
significantly larger amplitude in Ca2+ influx compared to cells in the presence of the protease 
inhibitor cocktail alone (61.6 ± 6.2 %, figure 4.15 B). The time taken to reach half maximal 
Ca2+ influx was unaffected by pre-incubation with calmodulin compared with control cells 
(increased by 8.6 ± 7.6%). The time taken to reach half maximal Ca2+ efflux was significantly 
prolonged in cells pre-incubated with calmodulin, compared with control cells (45.1 ± 10.4 
%, figure 4.15 C).  
 





Figure 4.14 Pre-incubation with the chymotrypsin inhibitor, chymostatin and full length 
Calmodulin had no significant effect on Ca2+ entry 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, 10 µM chymostatin was 
added to the extracellular solution during the second step of store depletion in both conditions. 
After 400 seconds 10 µM Calmodulin was introduced to the extracellular solution and pre-
incubated with cells for 10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution, blue trace – control (n = 12) and red trace – 10 µM Calmodulin (n = 8). B- Summary of 
the changes in ratio amplitude due to Ca2+ influx (from cells in Figure A) in control (blue bar) and 
calmodulin treated  (red bar p = 0.3813), both in the presence of 10 µM chymostatin. C- Summary 
of the changes in half time of Ca2+ influx (bottom bars p = 0.0076) control – blue, calmodulin 








  148 
A B C 
D E F 
Figure 4.15 Pre-incubation with a protease inhibitor cocktail and full length Calmodulin 
significantly potentiated Ca2+ entry 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, protease cocktail inhibitor 
solution was added to the extracellular solution during the second step of store depletion in both 
conditions. After 400 seconds 10 µM calmodulin was introduced to the extracellular solution and 
pre-incubated with cells for 10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution, blue trace – control (n = 25) and red trace – 10 µM Calmodulin (n = 24). B- Summary of 
the changes in ratio amplitude due to Ca2+ influx (from cells in figure A) in control (blue bar) and 
calmodulin treated (red bar p = 0.0001), both in the presence of the protease inhibitor cocktail. C- 
Summary of the changes in half time of Ca2+ influx (bottom bars p = 0.3822), control – blue, 
calmodulin treated. Half time of Ca2+ efflux (upper bars p = 0.0004). D- in a similar experiment to 
figure A,  protease inhibitor cocktail solution was added to the extracellular solution during store 
depletion, after 400 seconds 10 µM calmodulin was introduced to the extracellular solution and 
incubated for a shorter time of 100 seconds before the re-introduction of 2 mM Ca2+ to the 
extracellular solution. E- Summary of the changes in ratio amplitude due to Ca2+influx (from cells in 
figure D) in control cells (blue) and cells pre-incubated with calmodulin (red p = 0.7507). F- 
Summary of changes in half time of Ca2+ influx (lower bars p = 0.0001) control – blue, calmodulin 
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Although it is unlikely that full length calmodulin was exerting an effect on intracellular Ca2+ 
signalling from the extracellular side of the plasma membrane, in an attempt to functionally 
determine if the action of calmodulin, in the presence of a protease inhibitor cocktail, on Ca2+ 
entry was due to an extracellular action or an intracellular action a short pre-incubation period 
with calmodulin was utilised in figure 4.15 D. Cells were pre-incubated with calmodulin for 
100 seconds before the re-introduction of 2 mM Ca2+ to the extracellular solution, this shorter 
duration of pre-incubation with calmodulin was insufficient to potentiate Ca2+ entry as it had 
in figure 4.15 A, there was no significant difference in the amplitude of Ca2+ entry in 
calmodulin pre-incubated cells compared with control cells (decreased by 9.4 ± 15.5 %, 
figure 4.15 E). However, in spite of the lack of effect of calmodulin pre-incubation on the 
amplitude of Ca2+ influx, the time taken to reach half maximal Ca2+ influx in cells pre-
incubated with calmodulin was significantly prolonged compared to Ca2+ influx in control 
cells (155.4 ± 14.3 %,). The time taken to reach half maximal Ca2+ efflux was not 
significantly affected by the pre-incubation with calmodulin (decreased by 32.0 ± 9.5 %, p = 
0.0557). Figure 4.15 F summarises the changes in Ca2+ influx and Ca2+ efflux. The 
differences in dynamics of Ca2+ influx in calmodulin treated cells from figure 4.15 A and 
4.15 D could be due to the difference in time cells were incubated with calmodulin for and in 
theory the cleavage peptides. It could have been due to the difference in the incubation time 
of the protein with proteases in the extracellular medium, 100 seconds may have been 
insufficient time for substantial protein cleavage.  
In addition to trypsin and chymotrypsin and other proteases, metalloproteases are also found 
in the pancreas, although it is not entirely clear if they are of acinar cell origin. Neutrophils 
also express matrix metalloproteases and have been implicated in activating trypsinogen in 
acute pancreatitis (379). Metalloproteases are not inhibited by the protease inhibitor cocktail 
used in figure 4.15. EDTA has been used extensively as a broad spectrum metalloprotease 
inhibitor. In figure 4.16 A EDTA was introduced to the extracellular solution during the 
second step of store depletion with 10 µM CPA, in both conditions. In cells pre-incubated 
with 10 µM calmodulin, EDTA and calmodulin were introduced to the extracellular solution 
simultaneously. In cells pre-incubated with calmodulin, calmodulin was applied to cells and 
incubated for ten minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution, significantly reducing the amplitude of Ca2+ influx compared to control cells (46.0 ± 
12.4 %, figure 4.16 B). The time taken to reach half maximal Ca2+ influx in cells pre-
incubated with calmodulin was not statistically different (+65.3 ± 30.2 %). The time taken to 
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reach half maximal Ca2+ efflux was significantly prolonged in cells pre-incubated with 
calmodulin compared with control cells (52.4 ± 20.0 %, figure 4.16 C).  
In figure 4.17 A combined protease inhibition approach was undertaken, both a protease 
inhibitor cocktail solution and 0.01% trypsin inhibitor were introduced to the extracellular 
solution during the second stage of store depletion with 10 µM CPA. After 400 seconds 10 
µM calmodulin was introduced to the extracellular solution and incubated with cells for ten 
minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution. The pre-
incubation with calmodulin in the presence of the protease inhibitor cocktail and trypsin 
inhibitor resulted in a significant reduction in the amplitude in Ca2+ entry compared with 
control cells (71.8 ± 56 %, figure 4.17 B). The time taken to reach half maximal Ca2+ influx 
was significantly shorter in cells pre-incubated with calmodulin than in control cells (43.3 ± 
10.8 %) and the time taken to reach half maximal Ca2+ efflux was also significantly shorter in 
cells pre-incubated with calmodulin compared with control cells (37.2 ± 4.0 %, figure 4.17 
C).  
  151 
C 
A B 
Figure 4.16 Pre-incubation with a metalloprotease inhibitor, EDTA, and full length 
Calmodulin significantly inhibited Ca2+ entry 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, EDTA was added to 
the extracellular solution during the second step of store depletion. In cells pre-incubated with 
10 µM calmodulin, EDTA was added to the extracellular solution simultaneously with 
calmodulin. Cells were pre-incubated with calmodulin for ten minutes before the re-
introduction of 2 mM Ca2+ to the extracellular solution, blue trace – control (n = 6) and red 
trace – 10 µM Calmodulin (n = 4). B- Summary of the changes in ratio amplitude due to Ca2+ 
influx(in cells from Figure A) in control (blue bar) and calmodulin treated (red bar p = 
0.0381), both in the presence of EDTA. C- Summary of the changes in half time of Ca2+ 
influx (bottom bars, 0.2571) control – blue, calmodulin treated – red. Half time of Ca2+ efflux 
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Figure 4.17 Contrasting effects of short and long pre-incubation with full-length calmodulin in 
the presence of with a protease inhibitor cocktail and trypsin inhibitor 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, a protease inhibitor cocktail and 0.01 
% trypsin inhibitor were added to the extracellular solution during the second step of store depletion. After 
400 seconds 10 µM calmodulin was introduced to the extracellular solution and pre-incubated with cells for 
10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution, blue trace – control (n = 
27) and red trace – 10 µM calmodulin (n = 15). B- Summary of the changes in ratio amplitude due to Ca2+ 
influx (from cells in Figure A) in control (blue bar) and calmodulin treated (red bar p = 0.0001), both in the 
presence of a protease inhibitor cocktail and trypsin inhibitor. C- Summary of the changes in half time of 
Ca2+ influx (lower bars, p = 0.0001) control – blue, calmodulin treated – red. Half time of Ca2+ efflux 
(upper bars p = 0.0001). D – Similar experiment to figure A, a protease inhibitor cocktail and 0.01% trypsin 
inhibitor were added to the extracellular solution, and after 400 seconds 10 µM calmodulin was introduced 
to the extracellular solution and incubated with cells for 100 seconds before the re-introduction of 2 mM 
Ca2+ to the extracellular solution, blue trace – control (12) and red trace – 10 µM calmodulin (n = 12). E-
Summary of the changes in ratio amplitude due to Ca2+ influx (from cells in Figure D) in control (blue) and 
calmodulin treated (red p = 0.1304). F- Summary of the changes in half time of Ca2+ influx (lower bars p = 
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In a similar experiment to figure 4.17 D, a short pre-incubation of calmodulin with cells in 
the presence of the protease inhibitor cocktail solution and trypsin inhibitor was undertaken 
in figure 4.17 D. The amplitude of Ca2+ influx in cells pre-incubated with calmodulin was not 
significantly different to the amplitude of Ca2+ influx in control cells (increased by 30.9 ± 
13.2 %, figure 4.17 E), which contrasted with the reduction in amplitude of Ca2+ influx in 
cells pre-incubated with calmodulin over a longer time course (figure 4.17 A). The time taken 
to reach half maximal Ca2+ influx was significantly prolonged in cells pre-incubated with 
calmodulin, compared with control cells (69.2 ± 14.8 %). However, there was no statistical 
difference in the time taken to reach half maximal Ca2+ efflux in cells pre-incubated with 
calmodulin compared with control cells (29.2 ± 7.2 %, figure 4.17 F). 
Figure 4.17 demonstrates the effect of inhibiting proteases and trypsin on calmodulin induced 
inhibition of Ca2+ entry, however in this protocol neither chymotrypsin nor metalloproteases 
were inhibited. Figure 4.18 A demonstrates the effect of pre-incubating cells with 100 µM 
EDTA, a protease inhibitor cocktail and 0.01 % trypsin inhibitor during the second stage of 
the store-depletion protocol. Cells were then incubated with 10 µM calmodulin, in the 
maintained presence of inhibitors for ten minutes before the re-introduction of 2 mM Ca2+ to 
the extracellular solution. The change in ratio amplitude due to Ca2+ influx in cells pre-
incubated with calmodulin was not significantly different to the amplitude of Ca2+ influx in 
control cells (increased by 25.6 ± 32.9 %, figure 4.18 B). The time taken to reach half 
maximal Ca2+ influx was significantly prolonged in cells pre-incubated with calmodulin 
compared with control cells (74.3 ± 16.7 %) and the time taken to reach half maximal Ca2+ 
efflux was significantly shortened in cells pre-incubated with calmodulin compared with 
control cells (40.0 ± 4.1 %, figure 4.18 C). From figure 4.11 A to figure 4.18 A calmodulin 
was introduced to the imaging chamber by hand addition rather than continuous perfusion of 
the solution over cells in the imaging chamber, which how experiments are typically 
performed. 
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Figure 4.18 Combined inhibition of trypsin, metalloproteases and generic proteases and the 
effect on calmodulin mediated inhibition on Ca2+ entry. 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.55, a protease inhibitor cocktail, 0.01 
% trypsin inhibitor and 100 µM EDTA were added to the extracellular solution during the second step 
of store depletion. After 400 seconds 10 µM Calmodulin was introduced to the extracellular solution 
and pre-incubated with cells for 10 minutes before the re-introduction of 2 mM Ca2+ to the extracellular 
solution, blue trace – control (n = 9) and red trace – 10 µM Calmodulin (n = 7). B- Summary of the 
changes the in ratio amplitude due to Ca2+ influx (from cells in Figure A) in control (blue bar) and 
calmodulin treated (red bar p= 0.8217), both in the presence of a protease inhibitor cocktail, trypsin 
inhibitor and EDTA. C- Summary of the changes in half time of Ca2+ influx (lower bars p = 0.0007) 
control – blue, calmodulin treated- red. Half time of Ca2+ efflux (upper bars p = 0.0005). D-Identical to 
experiment in A except that Calmodulin was introduced to the extracellular solution, by perfusion rather 
than hand addition, and then pre-incubated with cells for 10 minutes before the re-introduction of 2 mM 
Ca2+ to the extracellular solution, blue trace – control (n = 5) and red trace – 10 µM Calmodulin (n = 4). 
E- Summary of the  changes in ratio amplitude due to Ca2+ influx (from cells in Figure D) in control 
(blue bar) and calmodulin treated (red bar 0.0635), both in the presence of a protease inhibitor cocktail, 
trypsin inhibitor and EDTA. F- Summary of the changes in half time of Ca2+ influx (lower bars p = 
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Figure 4.18 D utilised the same combination of inhibitors as figure 4.18 A, EDTA, a protease 
inhibitor cocktail solution and trypsin inhibitor and the incubation with these inhibitors was 
for the same duration. 10 µM calmodulin was introduced to the extracellular solution by 
perfusion rather than hand addition, cells were again incubated for ten minutes before the re-
introduction of 2 mM Ca2+ to the extracellular solution. There was not a statistically 
significant difference in the amplitude of Ca2+ entry in cells pre-incubated with calmodulin 
compared with control cells (decreased by 36.9 ± 14.6 %, figure 4.18 E). The time taken to 
reach half maximal Ca2+ influx was not significantly different in cells pre-incubated with 
calmodulin compared with control cells (increased by 1.4 ± 11.9 %, p = 0.999) and the time 
taken to reach half maximal Ca2+ efflux was not significantly different in cells pre-incubated 
with calmodulin compared with control cells (decreased by 19.3 ± 4.3 %, figure 4.18 F). 
In the experiments in figure 4.18 A and D chymotrypsin was not inhibited and therefore was 
able to cleave calmodulin and potentially give rise to peptide fragments that could modulate 
Ca2+ influx. In figure 4.19 A the protease inhibitor cocktail was removed in attempt to 
determine the minimum inhibitor requirements to prevent the calmodulin-mediated inhibition 
of Ca2+ entry, and was replaced with chymostatin. Chymostatin, trypsin inhibitor and EDTA 
were all introduced to the extracellular solution and incubated with cells before the 
introduction of calmodulin to the extracellular solution, by perfusion. Cells were incubated 
with calmodulin and the inhibitors for ten minutes before the re-introduction of 2 mM Ca2 to 
the extracellular solution. The amplitude of Ca2+ entry in cells pre-incubated with calmodulin 
was not significantly different to control cells (increased by 34.0 ± 9.7 %, figure 4.19 B). The 
time taken to reach half maximal Ca2+ influx in cells pre-incubated with calmodulin was 
significantly prolonged compared with control cells (20.2 ± 2.4 %) and the time taken to 
reach half maximal Ca2+ efflux was not statistically significant (14.0 ± 1.4 %, figure 4.19 C). 
 




Figure 4.19 Combined inhibition of trypsin, metalloproteases and chymotrypsin prevents 
the calmodulin-mediated inhibition on Ca2+ entry. 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, 10 µM Chymostatin, 0.01 
% trypsin inhibitor and 100 µM EDTA were added to the extracellular solution during the 
second step of store depletion. After 400 seconds 10 µM calmodulin was introduced to the 
extracellular solution, by perfusion rather than hand addition, and pre-incubated with cells for 10 
minutes before the re-introduction of 2 mM Ca2+ to the extracellular solution, blue trace – 
control (n = 8) and red trace – 10 µM Calmodulin (n = 4). B- Summary of  the changes in ratio 
amplitude due to Ca2+ influx (from cells in Figure A) in control (blue bar) and calmodulin 
treated (red bar p = 0.3677), both in the presence of  chymostatin, trypsin inhibitor and EDTA. 
C- Summary of the changes in half time of Ca2+ influx (lower bars p = 0.0485) control – blue, 
calmodulin treated – red. Half time of Ca2+ efflux (upper bars p = 0.2646) control - blue, 
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In figure 4.20 A the trypsin inhibitor was removed from the inhibitor solution, chymostatin 
and EDTA were utilised to inhibit chymotrypsin and metalloproteases. 10 µM chymostatin 
and 100 µM EDTA were introduced to the extracellular solution during the second stage of 
store depletion and were incubated with cells before calmodulin was introduced to the 
extracellular solution by perfusion. Cells were incubated with calmodulin in the continuous 
presence of the inhibitors for ten minutes before the re-introduction of 2 mM Ca2+ to the 
extracellular solution. The amplitude of Ca2+ influx in cells pre-incubated with calmodulin 
was not significantly different to the amplitude of Ca2+ influx in control cells (increased by 
15.3 ± 21.7 %, figure 4.20 B). The time taken to reach half maximal Ca2+ influx was 
significantly prolonged in cells pre-incubated with calmodulin compared with control cells 
(26.3 ± 4.9 %, p = 0.0122) and the time taken to reach half maximal efflux in cells pre-
incubated with calmodulin was significantly shorter compared with control cells (35.9 ± 
6.5%, figure 4.20 C).  
Some initial pilot experiments with small peptide fragments are shown in figure 2 and 3, in 
the appendix of the thesis. They demonstrate some preliminary data utilising fragments of 
calmodulin predicted by the protease cleavage computer models detailed in section 4.3.2. 
One peptide, designated CaM-A, resulted in a significant reduction in the amplitude of Ca2+ 
influx (p = 0.0054) but did not affect the rate of Ca2+ influx or efflux. The second peptide, 
designated CaM-B, did not significantly alter the amplitude or the half time of Ca2+ influx or 
efflux.






Figure 4.20 Combined inhibition of chymotrypsin and metalloproteases relieved the 
calmodulin-mediated inhibition on Ca2+ entry. 
Average traces (±SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.5, 10 µM Chymostatin and 100 
µM EDTA were added to the extracellular solution during the second step of store. After 400 
seconds 10 µM calmodulin was introduced to the extracellular solution, by perfusion rather than 
hand addition, and pre-incubated with cells for 10 minutes before the re-introduction of 2 mM Ca2+ 
to the extracellular solution, blue trace – control (n = 6) and red trace – 10 µM calmodulin (n = 7). B- 
Summary of the changes in ratio amplitude due to Ca2+ influx (from cells in Figure A) in control 
(blue bar) and cells pre-incubated with 10 µM calmodulin (red bar p = 0.3566), both in the presence 
of a  chymostatin and EDTA. C- Summary of the changes in half time of Ca2+ influx (lower bars p = 
0.0122) control – blue, calmodulin treated – red. Half time of Ca2+ efflux (upper bars p = 0.0006) 
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4.3 Discussion.  
Since the undertaking of the experiments in this chapter a paper has been published detailing 
recent evidence that indicates, in an overexpression model of Orai1/STIM-1 and calmodulin, 
the Ca2+-dependent inactivation of the CRAC channel is calmodulin independent (380). 
Utilising the Ca2+ insensitive mutant form of calmodulin, researchers could find no difference 
in the fast Ca2+-dependent inactivation of the CRAC channel current compared with cells 
expressing WT calmodulin. This contradicts previous evidence, not only from this research 
group utilising Orai1 mutants that were no longer able to bind calmodulin (159), but also 
evidence from other research groups, utilising the Ca2+ insensitive form of calmodulin, that 
demonstrated a small but significant reduction in the fast inactivation in cells expressing the 
mutant protein (177,366). A possible explanation for this apparent discrepancy is that the 
recent study was undertaken in overexpression systems of Orai1, STIM1 and Ca2+ insensitive 
calmodulin (380), whereas the other two studies were undertaken utilising RBL-1 cells and 
an immortalised liver cell line both of which express endogenous CRAC channels as opposed 
to overexpressed channels (177,366) and then overexpressing the Ca2+ insensitive mutant 
calmodulin. It could be that the overexpressed Orai1/STIM1 CRAC channel is gated 
somewhat differently and does not interact with overexpressed calmodulin in quite the same 
manner as the endogenous form of the channel does.  
Although the CaM binding domain may (159,160,177) or may not (380) be necessary for 
Ca2+-dependent inactivation of the CRAC channel; the inactivation domain of STIM1 is 
necessary(381). It is interesting to note that calmodulin has also been found to bind to the 
cytoplasmic domain of STIM2 (372). In the first instance a putative calmodulin binding 
domain was identified on the C-terminal domain of STIM1 (371) which was further 
supported by biochemical evidence of calmodulin binding to both STIM1 and STIM2 (176). 
There is evidence that cytosolic Ca2+ as well as ER luminal Ca2+ concentrations have a role in 
store operated Ca2+ entry via CRAC channels. A study found that Ca2+ bound-calmodulin had 
an inhibitory role in SOCE when it bound STIM1, but apo-calmodulin lacked such an effect. 
This was repeatable for STIM2 expressing cells (176,382). 
4.3.1 CALP3 
It was shown that the CALP peptides CALP1, designed to have inverse hydropathy for an 
ancestral Ca2+ binding site, CALP2 and CALP3, designed to have inverse hydropathy to the 
EF hand 4 of calmodulin, have a complementary surface to Ca2+ binding sites and can bind 
the calmodulin EF hand. CALP1 induced conformational changes and activated calmodulin 
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resulting in subsequent phosphodiesterase activation and cGMP hydrolysis (361), although it 
cannot be assumed that due to structural similarity that CALP3 will induce the same changes. 
Based on the hypothesis that Ca2+ bound-calmodulin can bind to STIM1 and act as the 
molecular switch for STIM1/Orai1 disassembly thus resulting in a cessation of Ca2+ influx, 
then it is plausible that CALP3 bound-calmodulin could also bind to STIM1 in the same way 
(176). This hypothesis would then provide an explanation for why the incubation of cells 
with CALP3 results in a decrease in cytosolic Ca2+ due to a reduction in SOCE, which is true 
for ten minute pre-incubation with CALP3 (figure 4.6 A & B ), a much shorter pre-incubation 
with CALP3 (figure 4.7 A ) and acute application of CALP3 (figure 4.7 E). 
CALP3/Calmodulin can bind to STIM1 and provide the molecular switch for disassemble of 
STIM1/Orai1. This hypothesis is yet to be tested. 
In the paper where CALP3 was shown to be a protective agent for pancreatic acinar cells it 
was effective at 100 µM (359). However, whether due to experimental difficulty or not, 100 
µM was ineffective at inhibiting Ca2+ influx only 200 µM demonstrated a significant 
inhibitory effect. It is highly possible that this is a non-specific effect of a supramaximal 
concentration of CALP3. 
4.3.2 Calmodulin inhibitors and mutant calmodulin 
Both calmidazolium and W-7 were found to potentiate SOCE, initiated by thapsigargin in 
pulmonary artery smooth muscle cells (368) and furthermore in HEK293 cells (369) and 
MDCK cells (352,353). Extracellular application of 10 µM calmidazolium, in smooth muscle 
cells with replete intracellular Ca2+ stores, elicited a significant elevation in cytosolic Ca2+ 
levels in the presence of extracellular Ca2+. In the absence of extracellular Ca2+ 
calmidazolium did not elicit a significant increase in cytosolic Ca2+, suggesting the elevated 
Ca2+ was due to an influx pathway that was store independent and not due to Ca2+ release 
from intracellular stores (368,374). In a somewhat conflicting report it has been demonstrated 
that calmidazolium has no effect on the development or the amplitude of the store-operated 
Ca2+ current (Isoc) compared with control cells in liver cells in the presence of 10 mM Ca
2+ in 
the extracellular solution (366), potentially indicating no role for calmodulin in the activation 
of the store-operated Ca2+ current. These findings were not true for the effect of 
calmidazolium on SOCE in pancreatic acinar cells when 10 mM Ca2+ was also added to the 
extracellular solution (figure 4.1 A & B). At least when measured using fluorescent calcium 
imaging the application of 10 µM calmidazolium significantly inhibited the amplitude of 
Ca2+ entry. Furthermore the rate of Ca2+ influx, which more accurately represents the number 
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of CRAC channels open than the amplitude, was significantly slower compared with control 
cells. The difference in amplitude of Ca2+ influx between treated and untreated cells was not 
as remarkable as when a CRAC channel inhibitor was used (see chapter 3) but the difference 
indicates that calmodulin inhibition is effective in reducing Ca2+ influx. This difference 
between calmidazolium treated cells and control cells was more remarkable when the driving 
force for Ca2+ was decreased towards more representative physiological concentrations of 
extracellular Ca2+ such as 2 mM (figure 4.2 A & B), then pre-incubation with 10 µM 
calmidazolium resulted in a further reduction in amplitude of Ca2+ entry in pancreatic acinar 
cells compared with control cells and compared with figure 4.1 A. An older study found that 
in hepatocytes calmidazolium treatment inhibited store operated Ca2+ influx (370), although 
this was not repeatable in a later study in a liver cell line (383). This could be due to the 
difference between primary hepatocytes and hepatocyte cell line, data from primary 
hepatocytes (370) is in line with data generated in this chapter in primary pancreatic acinar 
cells (figure 4.1 A, D and figure 4.2 A). Inhibition of Ca2+ influx by calmidazolium has also 
been demonstrated in cardiac myocytes (356) although this is likely by affecting calmodulin 
associated with voltage gated Ca2+ channels.  
The plateau in elevated cytosolic Ca2+ levels that is attained during Ca2+ influx in this type of 
protocol is an equilibrium between Ca2+ influx mechanisms into the cytosol and Ca2+ 
extrusion mechanisms from the cytosol. At all points during the SOCE protocol either 
thapsigargin or CPA the SERCA pump inhibitors are present, removing active Ca2+ uptake 
into the ER as an extrusion mechanism; Ca2+ extrusion is almost entirely mediated by the 
PMCA. A plateau in cytosolic Ca2+ is attained at the point that Ca2+ influx through CRAC 
channels is equal to Ca2+ extrusion by PMCA, resulting in no net change in cytosolic Ca2+ 
levels (234). It is well established that the PMCA pump is regulated by calmodulin (341), 
thereby inhibiting calmodulin ought to have a dual effect on the plateau in cytosolic Ca2+ 
levels attained. So rather than a direct action of calmidazolium on the CRAC channel, from 
which position it is hypothesised to be protected from pharmacological target, it is possible 
that the effect of calmidazolium is mediated through the interaction of calmodulin with 
PMCA. Although, inhibition of calmodulin has been demonstrated to slow the rate of Ca2+ 
removal from the cytosol via PMCA previously (177).  
W-7 was also observed to potentiate store-operated Ca2+ entry in pulmonary artery smooth 
muscle cells (368) and MDCK cells (353); although the concentration used in MDCK cells 
was five times higher than used in this study which is a possible explanation for the 
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contrasting effects observed in pancreatic acinar cells. The amplitude of Ca2+ influx was 
qualitatively inhibited in pancreatic acinar cells, compared with control cells (figure 4.3). 
However, as previously mentioned the rate of Ca2+ influx is a more accurate measure of the 
number of CRAC channels that are open than the steady-state amplitude measurement, as it is 
less of a dynamic equilibrium between Ca2+ influx and Ca2+ efflux pathways and largely 
driven by Ca2+ influx into the cytosol. The rate of Ca2+ influx in cells pre-incubated with W-7 
is significantly inhibited compared with control cells, in a similar manner to cells pre-
incubated with calmidazolium. There are known instances where pharmacological agents are 
known to have biphasic effects on CRAC channels, 2-APB is well established to potentiate 
CRAC channel activity at low concentrations whilst acting in an inhibitory manner when 
applied at higher concentrations (192,295), this could provide one explanation. Another is 
that, like calmidazolium, W-7 too activates a store-independent Ca2+ influx pathway. When 
applied to RBL-1 cells W-7 was found to inhibit CRAC channel currents, in whole cell patch 
clamp experiments. The current was activated by depleting ER stores using EGTA. This 
finding is similar to data in figure 4.3. Furthermore, W-7 was found to inhibit store-operated 
Ca2+ influx induced by thapsigargin in primary liver cells (370) and also in a liver cell line 
(383), which are more similar to primary pancreatic acinar cells than MDCK cells. 
The Ca2+ insensitive mutant form of calmodulin has been employed to more accurately 
determine the role of calmodulin in CRAC channel activation and inactivation in previous 
studies as the data from pharmacological interventions, such as calmidazolium, were difficult 
to interpret at times (384). RBL-1 cells expressing the mutant form of calmodulin exhibited a 
reduced amplitude and rate of store-operated Ca2+ entry compared with cells that were not 
transfected with the mutant protein, however the rate of Ca2+ efflux remained unaffected 
(384). For the most part, this is in line with data in this chapter (figure 4.4) in which there is a 
reduction in amplitude of a Ca2+ transient in cells expressing the Ca2+ insensitive mutant form 
of calmodulin, compared with cells expressing the WT form of calmodulin. The data from the 
overexpression of mutant calmodulin is similar to data obtained with calmidazolium and W-
7, that is by inhibiting calmodulin there was a resultant reduction in cytosolic Ca2+ (figure 
4.2, 4.3 and 4.4). Findings surrounding the effect of calmodulin inhibition on rate of efflux is 
somewhat different in this chapter compared with previous studies, in that rate of Ca2+ 
extrusion from the cytosol was prolonged in cells treated with calmidazolium (figure 4.1 C 
and figure 4.2 C), which is similar to findings in RBL-1 cells treated with calmidazolium 
(177), whereas it was unaffected in RBL1 cells expressing the mutant calmodulin. One 
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possibility for this is that the duration of expression of the mutant calmodulin was insufficient 
to turn-over all calmodulin in the cell (384).  
The calmodulin pharmacological data in pancreatic acinar cells was very similar to RBL-1 
cells, in which the rate of Ca2+ efflux is slowed in cells treated with calmidazolium (177). The 
effect of calmidazolium on the rate of Ca2+ efflux in RBL-1 cells was not as dramatic as the 
effect on efflux in pancreatic acinar cells (figure 4.1 and figure 4.2); this was due to the fact 
that researchers were reluctant to pre-incubate cells with calmidazolium due to its ability to 
cause Ca2+ influx independent of store depletion in smooth muscle cells (368,374). Either 
thapsigargin or CPA are used to induce store-depletion and activate CRAC channels in the 
experiments in this chapter, pre-incubating pancreatic acinar cells with calmidazolium did not 
activate any further Ca2+ influx, as it was applied in nominally Ca2+ free extracellular 
solution, even if calmidazolium activates a non-store operated Ca2+ influx pathway there was 
minimal extracellular Ca2+ and therefore no chemical gradient for Ca2+ influx (figure 4.1 and 
figure 4.2).  
It is likely that a combination of therapeutic targets will be necessary to rapidly resolve 
severe cases of acute pancreatitis. Thus far it is evident that inhibiting CRAC channels 
directly utilising a CRAC channel blocker is efficient in dramatically reducing cytosolic Ca2+ 
overload driven by Ca2+ influx; furthermore evidence in this chapter indicates that indirectly 
targeting CRAC channels by interfering with the gating mechanisms i.e. targeting calmodulin 
is also a mechanism by which cytosolic Ca2+ overload can be dramatically reduced. SOCE 
experiments based on the hypothesis of targeting both the CRAC channel directly, with an 
inhibitor, and targeting calmodulin regulation of the channel are demonstrated in figure 4.9 A 
and figure 4.10 A. Pre-incubating cells with both calmidazolium and GSK-7975A resulted in 
a dramatic reduction in Ca2+ influx, compared with calmidazolium treatment alone (figure 
4.1A) and also a dramatic reduction of unidirectional Ba2+ influx, which reflects only Ca2+ 
influx not efflux.  
Previous experiments in pancreatic acinar cells demonstrated that in permeabilised cells the 
effect of ethanol on Ca2+ release from intracellular stores was dramatically greater than the 
effect of ethanol on intact cells. This exacerbation of the Ca2+ signal was attributed to the loss 
of calmodulin from cells upon permeabilisation (359). This effect was also seen in another 
study where calmodulin was lost from the cell to the patch pipette (382). Application of 
calmodulin in both instances resulted in the return of its protective effect and an inhibition in 
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the cytosolic Ca2+ signalling. This is an intriguing premise in pancreatic acinar cells, which 
are by their very nature highly proteolytic. In a freshly isolated pancreatic acinar cell 
preparation there is an unavoidable percentage of cellular necrosis, due to the use of 
collagenase to disperse cells from the tissue, to enable them to be studied using microscopy. 
This cellular necrosis will result in the release of the digestive pro-enzymes, much like during 
an acute pancreatitis attack. Subsequent activation of digestive enzymes results in the 
destruction of pancreatic tissue in vivo, in addition to the large scale proteolytic attack there is 
likely a smaller scale digestion of intracellular proteins that are also released during cellular 
necrosis; calmodulin would be one such protein.  
Chymotrypsinogen and trypsinogen are the two major digestive proenzymes synthesised by 
pancreatic acinar cells, calmodulin possesses several trypsin and chymotrypsin cleavage sites 
in its amino acid sequence (figure 1, in appendix). These cleavage sites were utilised to 
determine the primary sequence of bovine brain calmodulin (385). In addition to 
chymotrypsin and trypsin cleavage sites. Figure 4.11 A depicts the inhibition of Ca2+ influx 
elicited by pre-incubation of pancreatic acinar cells with calmodulin, as calmodulin is 148 
amino acids in length it is unlikely to permeate the cell and presently there is no known 
extracellular CRAC channel calmodulin binding domain, making these ideas unlikely 
mechanisms by which Ca2+ influx is inhibited by calmodulin. Data generated using CALP 
peptides led to the hypothesis that inhibition in store-operated Ca2+ entry could be mediated 
by smaller peptide fragments of calmodulin. Predictions about which peptide products could 
be made from protease cleavage of calmodulin were generated using protease cleavage 
predicting computer tools such as the peptide cutter  (http://web.expasy.org/peptide_cutter/) 
and another free tool called PROSPER (https://prosper.erc.monash.edu.au/webserver.html) 
(386). The cleavage data from computer models and functional data in which chymotrypsin 
inhibitor, trypsin inhibitor, protease inhibitor cocktail and metalloprotease inhibitor were used 
demonstrated that when the majority of pancreatic proteases are inhibited the reduction in 
store operated Ca2+ influx induced by calmodulin pre-treatment was no longer observed. 
However, this functional data does not provide any insight into what peptide sequence was 
mediating the inhibitory effect or how long the peptide is, and furthermore, there is no 
mechanistic information as to how the peptide is inhibiting store-operated Ca2+ influx. It is 
possible that inhibition of Ca2+ influx is mediated by blocking of the Ca2+ influx channel pore, 
either CRAC channels or non-specific cation channels such as TRPC channels, which are 
also expressed by pancreatic acinar cells. Appendix figures 2 and 3 depict two small peptide 
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fragments derived from predictions made of protease cleavage of calmodulin. The peptides 
were designated CaM A and CaM B.  
4.4 Further experiments 
As there is evidence to indicate that Ca2+ bound calmodulin binds with STIM1, it should be 
determined if this is sufficient to trigger the disassembly of STIM1/Orai1 to prevent further 
Ca2+ influx (176,382). It should also be determined if CALP3 bound calmodulin is able to 
bind STIM1 to mediate this process. It is possible that rather than calmodulin binding to 
STIM1 it is the complex of CALP3 bound calmodulin binding to Orai1 (159,160) that 
mediates Ca2+ dependent inactivation of Orai1, as has long been thought the process 
(159,177,366).  
There is evidence supporting the hypothesis that a cleavage product of calmodulin, due to 
action of activated digestive enzymes, could be used to inhibit SOCE in pancreatic acinar 
cells. However, in order to determine the peptides that are mediating the inhibitory effects on 
the channel in an efficient manner it may be necessary to attempt to mimic conditions in 
vitro. The first step would be to incubate a solution of chymotrypsin and trypsin with 
calmodulin to allow proteolytic cleavage of calmodulin. After the incubation, in order to 
determine the sequence of the peptides a high-pressure liquid chromatography (HPLC) linked 
to a mass spectrometer can be used. HPLC ionises the peptide and electrosprays peptide ions 
into the mass spectrometer which can determine the sequence of the amino acids in the 
peptide (387). Armed with peptide sequences, derived from the mass spectrometry one can 
compare these with computer model predictions, and select peptides to be synthesised and 
tested functionally for inhibitory properties for CRAC channels. A small molecule microarray 
can be used with the minimal functional domains of CRAC channels to determine where 
peptides bind to in order to modulate channel activity, as in (209).  
Experiments in which calmidazolium and GSK7975-A were combined demonstrated 
significant inhibition of Ca2+ influx. CALP3, also demonstrated remarkable inhibition of 
store-operated Ca2+ entry alone, it would be interesting to see if when combined with 
GSK7975-A whether there would be a further inhibitory effect on Ca2+ influx compared to 
treatment of cells with either drug alone. 
Pharmacological interventions are always problematic due to limited specificity of inhibitors 
for their targets. CRISPR/Cas9 mediated deletion of calmodulin in cells would be a more 
efficient way to determine the effects of calmodulin on cells. It may be possible to determine 
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the exact role calmodulin plays in CRAC channel activation and inactivation. However, this 
approach is limited by the ubiquitous nature of calmodulin and its plethora of intracellular 
functions. This makes it a somewhat complicated therapeutic target, as modulation of 
calmodulin activity is unlikely to result in just the therapeutically desired action but also a 
multitude of off-target effects. For further information about therapeutic targets in treating 
acute pancreatitis see chapter 5.
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5 General discussion 
 Implications of modulating Ca2+ influx 
The aim of this thesis was to find a means of reducing cytosolic Ca2+ overload, the primary 
trigger in a series of events that results in acute pancreatitis. Figure 5.1 demonstrates this 
chain of events, between the stages the figure details general interventions that can be 
undertaken in an attempt to prevent disease progression. The vast majority of drugs that have 
made their way to clinical trials to treat acute pancreatitis have been agents that were directed 
at preventing the latter stages of the disease; interventions such as administration of protease 
inhibitors, anti-secretory or anti-inflammatory agents (267,276). However, despite numerous 
clinical trials using a variety of different classes of agents there has been a distinct lack of 
success in finding a treatment for acute pancreatitis. It is thought that the lack of success is 
because the intervention strategies have not been targeting the trigger for the chain of events 
but rather are attempting to prevent the disease from progressing any further, in its latter 
stages (276), once there is already significant amount of pancreatic necrosis and 
inflammation.  
Utilising inhibitors of the Ca2+ release channels, or even inhibitors of accessory proteins that 
regulate the Ca2+ release channels would serve to prevent the initial Ca2+ signal that leads to 
all future steps, including the activation of store-operated Ca2+ entry which drives the 
sustained phase  of Ca2+ elevation leading to cytosolic Ca2+ overload and intracellular 
proenzyme activation. Further to inhibition of Ca2+ release from intracellular stores, 
inhibition of CRAC channel mediated Ca2+ influx can also be undertaken to prevent cytosolic 
Ca2+ overload. A clinical study sought to use an intracellular Ca2+ chelator, DP-b99, in the 
treatment of acute pancreatitis, in an attempt to inhibit the elevation of cytosolic Ca2+ 
associated with intracellular proenzyme activation;  however, the study was terminated due to 
slow recruitment (276,388). Therefore, the field is no further forward in terms of clinical 
evidence that modulation of Ca2 signalling, with a view to reduce cytosolic Ca2+ overload, is 
clinically beneficial and a viable therapeutic option for treating acute pancreatitis; However, 
the evidence generated using CRAC channel inhibitors to reduce cytosolic Ca2+ overload in 
vitro and in mouse models is highly promising (130,253,268). CRAC channel inhibitors are 
likely to be the most promising means of achieving this goal, with the attention of multiple 
different fields of enquiry converging on this one target (389,390), a clinically approved drug 
is highly likely to come to fruition. CM_128 is due to start phase I trials in the near future. 
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Figure 5.1 Flow diagram depicting the chain of events involved in the onset of acute pancreatitis 
The major events in the onset of acute pancreatitis are detailed in the flow diagram, from the cytosolic 
Ca2+ overload to the digestion of pancreatic tissue and subsequent inflammatory response this mediates. 
At each step interventions (listed in red) are highlighted that might prevent the progression of the 
disease to the next stage.   
1. Using inhibitors to prevent Ca2+ release from intracellular stores and inhibitors of Ca2+ entry channels 
to prevent cytosolic Ca2+ overload. Agents that prevent mitochondrial dysfunction 2. Using inhibitors of 
Ca2+ signalling and protease inhibitors to inactivate trypsin/chymotrypsin to prevent digestion. 3. Using 
protease inhibitors. 4. Using protease inhibitors and anti-inflammatory agents to prevent the 
inflammatory response. 5. Using anti-inflammatory agents to prevent both the local inflammatory 
response and potential systemic inflammatory response  
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Modulation of calmodulin as a potential therapy for acute pancreatitis is a possibility as both 
agonists (CALP1 and CALP3) and antagonists (trifluoperazine, calmidazolium and W-7) of 
calmodulin exist for use in vitro and trifluoperazine is used clinically already to treat 
schizophrenia (391). Calmodulin antagonists, such as trifluoperazine, have been 
demonstrated to sensitise pancreatic cancer cells to chemotherapy agent induced cell death 
(392) and inhibit cancer cell migration in lung cancer (393). Furthermore, a patent has been 
filed to use calmodulin inhibitors to treat ribosomal-related diseases known as 
ribosomapathies (394). In addition to direct inhibition of calmodulin, there are instances in 
which modulation of calmodulin dependent kinases has been used as therapies for heart 
disease such as calmodulin kinase II inhibitors and calmodulin dependent kinase IV inhibitors 
have been shown to have promise in the treatment of autoimmune diseases (395). This 
demonstrates that inhibitors of calmodulin are a viable treatment option for diseases. 
However, calmodulin is the primary cytosolic Ca2+ sensing protein and is found in almost all 
cell types where it is implicated in several different signal transduction pathways, calmodulin 
dependent kinase pathways, calcineurin/NFAT pathway (35,343). Calmodulin in particular 
has an important role in the regulation of cellular components involved in Ca2+ handling in 
cells, such as regulation of voltage gated Ca2 channels in cardiac myocytes,  RyR in both 
skeletal and cardiac muscle and SERCA via its regulation of phospholamban (396). Due to its 
vital role in the intracellular Ca2+ signal transduction using calmodulin modulators in order to 
treat acute pancreatitis is likely to affect lots of other cell types, including vital cells such as 
cardiac myocytes and skeletal muscle.  Using calmodulin as a target to treat acute pancreatitis 
could be achieved if a pharmacological agent is used at submaximal concentration in 
combination with another inhibitor, such as a CRAC channel inhibitor at submaximal 
concentration, this strategy has proved effective as a potential therapy for nasal polyps (326).  
Extensive tests would be required on isolated pancreatic acinar cells before determining if the 
strategy is effective to translate initially to a mouse model of the disease.  
CRAC channels are also ubiquitous cellular components (127,183). In the same way that 
targeting calmodulin as a therapeutic for acute pancreatitis is likely to be complex due to its 
ubiquitous expression, targeting of CRAC channels is also likely to not only affect the 
pancreatic acinar cells but also other cell types. Primarily, it is non-excitable cells that are 
dependent on the activity of CRAC channels to provide Ca2+ influx in response to store 
depletion. Immune cell functionality is largely dependent on cytosolic Ca2+ signals (314), 
patients suffering with SCID were found to have inactive Ca2+ influx due to a mutation in 
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Orai1 (152). One potential issue with inhibiting CRAC channels is the potential 
immunosuppression of patients. However, it has been demonstrated that excitable cells such 
as cardiac myocytes, including pacemaker cells (397), neurones (398) and skeletal myocytes 
(399,400) also possess functional CRAC channels that contribute to Ca2+ influx. CRAC 
channels are not the primary Ca2+ influx pathway in these cells. Excitable cells have a myriad 
of voltage gated Ca2+ channels (401) and also the NCX which in reverse mode and permit 
Ca2+ to enter the cells (20). It would seem that CRAC channel mediated Ca
2+ influx plays 
more of a role in pathological remodelling in cardiac myocytes (402). As such, even though 
these channels are ubiquitous, targeting of CRAC channels as a therapeutic for acute 
pancreatitis should not have a significant impact on the functioning of excitable cells. Non-
excitable cells, such as hepatocytes that are dependent on Ca2+ influx through CRAC 
channels to drive cellular processes such as exocytosis are likely to be affected by CRAC 
channel inhibition. However, it has been demonstrated, at least in vitro that hepatocytes are 
minimally affected by the CRAC channel inhibitor GSK-7975A (130). Another notable 
finding of the study was that GSK-7975A pre-treatment had only minor effects on the 
physiological Ca2+ signals induced by both ACh and CCK in pancreatic acinar cells. As the 
treatment of acute pancreatitis by its very nature will be an acute treatment, any undesired 
side effects of treatment, provided they do not impact on an individual’s brain, heart or 
skeletal muscle (breathing) can more easily be tolerated as the treatment is not prolonged.   
 Limitations 
Measuring intracellular Ca2+ in real time allows for monitoring of Ca2+ fluxes with a 
relatively good temporal resolution. As a fluorescent Ca2+ indicator Fura-2 allows for 
measurement of changes in intracellular Ca2+ signals in real time. Fura-2 is a dual excitation 
wavelength dye and as such is an ideal dye for quantitative Ca2+ measurements. When 
measuring smaller amplitude Ca2+ signals, such as Ca2+ oscillations that are restricted to the 
apical pole induced by physiological concentrations of either ACh or CCK, can be difficult 
when using Fura-2; because Fura-2 has a higher buffering capacity for free Ca2+ than other 
fluorescent Ca2+ indicators such as Fluo-4 (kd of Fura-2 = 145 nM kd of Fluo-4 = 345 nM). It 
has also been noted that Fura-2 is more resistant to photo-bleaching making it ideal for 
experiments in which Ca2+ signals are measured over extended periods of time (403). As this 
thesis was not particularly focused on the spatial aspects of Ca2+ signalling Fura-2 was 
suitable for measuring changes in cytosolic Ca2+ due to store-operated Ca2+ entry and was of 
particular use as experiments were often in excess of 30 minutes.  
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The modulation of calmodulin was the primary aim of chapter 4, as a role for calmodulin has 
been implicated in the regulation of CRAC channel function, due to its binding to both Orai1 
(159,177) and STIM1 (176). The most notable aspect of store-operated Ca2+ hypothesised to 
be affected by calmodulin modulation is the Ca2+-dependent inactivation of the CRAC 
channel. However, it is difficult to measure the inactivation of the CRAC channel using 
fluorescent microscopy, most investigators have measured inactivation of CRAC channels 
using electrophysiology (148,366,404). It is possible, using this technique, to observe the 
change in channel conductance, due to channel inactivation, in the sustained presence of 
extracellular Ca2+ in isolation from other factors that contribute to Ca2+ homeostasis in the 
cell.  
In addition, using electrophysiological techniques, such as whole cell patch clamp, it is 
possible to monitor the current through the ion channel of interest, without interference from 
other ion channel fluxes. When measuring the effect of inhibitors of Ca2+ influx, using 
fluorescent Ca2+ indicators, increased cytosolic Ca2+ would be observed due to Ca2+influx 
through non-selective cation channels, such as TRPC3, as well as through CRAC channels. 
TRPC3 is also speculated to be a STIM1 gated, store-regulated ion channel (222) and 
therefore would be activated by thapsigargin or CPA mediated store depletion. Using 
fluorescent Ca2+ indicators identification of Ca
2+
 influx through each channel is only possible 
by using inhibitors of the channels and therefore is limited by the specificity of said 
inhibitors, whereas CRAC channel currents and TRPC3 channel currents have distinct 
biophysical properties and so can be differentiated through electrophysiological experiments 
(127,405). It is possible to simultaneously measure channel conductance using whole cell 
patch clamp whilst monitoring intracellular Ca2+ flux using fluorescent indicators such as 
Fura-2 or Fluo-4 using microscopy. This method has been used effectively in the past to give 
a real time read out of channel currents and spatiotemporal aspects of Ca2+ signals, in 
pancreatic acinar cells (123).  
Intracellular Ca2+ homeostasis is a dynamic equilibrium between Ca2+ influx mechanisms into 
the cytosol, across the plasma membrane and across the ER membrane; and Ca2+ efflux 
pathways from the cytosol, across the plasma membrane, across the ER membrane and into 
the mitochondria (as depicted in figure 1.1). In measuring global Ca2+ influx, using 
fluorescent microscopy, there is interference in the Ca2+ signal by the activation of Ca2+ 
efflux mechanisms, mostly due to activation of PMCA. It is possible to measure only Ca2+ 
influx activity using fluorescence microscopy, used in this thesis, Ca2+ ions in the 
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extracellular solution are substituted for Ba2+ ions. CRAC channels are more permeable to 
Ba2+ than Ca2+, furthermore Ba2+ can bind to Fura-2 resulting in fluorescent changes 
associated with influx of Ba2+ into the cytosol of Fura-2 loaded cells. The dynamic 
equilibrium of Ca2+ homeostasis employed by cells is subverted as although Ba2+ can 
permeate the ion channels in the plasma membrane, the Ca2+ ATPases cannot pump Ba2+ 
either into the ER or across the plasma membrane (310–312). Such measurements allow for 
effects of pharmacological agents on CRAC channel activity to be observed without 
interference of their potential effects on Ca2+ extrusion mechanism; which would largely be 
PMCA as CRAC channel activity is measured in the presence of SERCA pump inhibitors, 
either CPA or thapsigargin. Measurement of the half time of Ca2+ influx can be problematic, 
as in some experiments a plateau in cytosolic Ca2+ levels after re-introduction of Ca2= to the 
extracellular solution was not attained. This was to ensure that all experiments were time-
locked, but proved problematic for analysis. An alternative method of analysis would be to 
measure the initial rate of rate of influx.  
Experiments in chapter 4 which assessed the effect of CALP3 on store-operated Ca2+ influx 
were undertaken in Fura-2 loaded cells in the presence of extracellular Ca2=. If Ca2+ ions were 
substituted for Ba2+ ions the effect of CALP3 on Ca2+ influx could have been measured in 
isolation from Ca2+ efflux mechanisms. As CALP3 and other agents used in chapter 4 are 
modulators of calmodulin and it is known that calmodulin regulates PMCA as well as Orai1 
and STIM1 measuring the effect of each agent on Ca2+ influx in isolation from Ca2+ efflux by 
using Ba2+ substitution would give a more accurate results on the effect of calmodulin 
modulation of Ca2+ influx. Using electrophysiology would provide more insight on the effect 
of calmodulin modulation on the Ca2+ dependent inactivation of the CRAC channel. 
 Future considerations 
One of the biggest problems of clinical trials testing drugs with the potential to treat acute 
pancreatitis is primarily the time frame in which patients are required to receive treatment 
after onset of symptoms. In order to be successful most treatments need to be administered to 
patients as quickly as possible from the onset of the disease, to prevent extensive pancreatic 
necrosis and injury. It is difficult to determine the time of onset of the disease, it has been 
demonstrated that the onset of pancreatic necrosis in human pancreatitis can take up to four 
days to be detected (406), rather than approximately 6 hours in a mouse model (253). Any 
therapeutic intervention that is made, will be made after the onset of symptoms, but the 
earlier it is made the more likely it is to prevent the onset of necrosis and subsequent 
  173 
inflammation. It is evident from all studies to date that the pre-treatment with any therapeutic 
agent offers maximal protection against Ca2+ overload and subsequent pancreatic necrosis 
(chapter 3 and 4), (130,359); as such steps are being taken by the field to determine 
biomarkers that precede the onset of acute pancreatitis. Detection of biomarkers in patients 
allows for early identification of the disease, allowing for earlier intervention and improved 
chances of survival. There are also indications that the earlier someone is treated the fewer 
days they spend in hospital, improving the burden placed on global healthcare systems. There 
are clinical trials underway in China, that are seeking to test for the presence of micro RNAs 
and long non-coding RNA in the blood, to see if it could be correlated with a diagnosis of 
acute pancreatitis that is likely to develop persistent organ failure (407,408) 
 Concluding remarks 
Targeting the initial trigger of acute pancreatitis seems likely to be the most efficient means 
of treating this multi-faceted disease. Targeting individual cellular components that are 
responsible for contributing to cytosolic Ca2+ overload in isolation or by targeting multiple 
components simultaneously would remove the trigger for the premature activation of 
digestive enzymes. One such mechanism to achieve this is to utilise CRAC channel 
inhibition, using CRAC channel inhibitors and thereby preventing Ca2+ influx triggered by 
the emptying of intracellular Ca2+ stores. Stopping the disease in its earliest stages has been 
demonstrated in animal models of the disease, it is now to be determined if this is the case in 
the human disease. 
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Appendices 
M A D Q L T E E Q I  A E F K E A F S L F 
D K D G D G T I T T  K E L G T V M R S L 
G Q N P T E A E L Q  D M I N E V D A D G 
N G T I D F P E F L  T M M A R K M K D T  
D S E E E I R E A F  R V F D K G N G Y I  
S A A E L R H V M T  N L G E K L T D E E 
V D E M I R E A D I  D G D G Q V N Y E E 
F V Q M M T A K 
Figure 1 Amino acid sequence of calmodulin with predicted protease cleavage sites 
Light blue amino acids mark the site of chymotrypsin cleavage and bold/red amino acids mark trypsin 
cleavage sites. Red amino acids are multiple other serine protease cleavage sites 
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F K E A F S L F D 
Figure  2 Pre-incubation with a peptide fragment predicted to be derived from 
proteolytic cleavage of calmodulin inhibited amplitude of Ca2+ influx but not rate 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and then cells were 
pre-incubated with 10 µM CaM A for 10 minutes before the re-introduction of 2 mM Ca2+ 
to the extracellular solution. Blue trace – control (n = 12) and red trace – 10 µM CaM A (n 
= 8). B- Identical experiment to figure A with different time scale of Ca2+ addition to the 
extracellular solution, Blue trace – control (n = 4) and red trace – 10 µM CaM A (n = 6).  
C- Summary of the changes in ratio amplitude due to Ca2+ influx (from cells in Figure A 
and B) in control (blue bar) and CaM A treated (red bar). D – Summary of the changes in 
half time of Ca2+ influx (lower bars) control – blue, CAM A treated – red. Half time of 
Ca2+ efflux (upper bars) control – blue, calmodulin treated – red.  
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N Y E E F V Q M M 
Figure  3 Pre-incubation with a second peptide fragment predicted to be derived 
from proteolytic cleavage of calmodulin did not affect the amplitude of Ca2+ influx 
nor the rate of Ca2+influx 
Average traces (± SEM) from Fura-2 loaded pancreatic acinar cells 
A- ER stores were depleted according to the protocol in section 2.5.4 and then cells were 
pre-incubated with 10 µM CaM B for 10 minutes before the re-introduction of 2 mM Ca2+ 
to the extracellular solution. Blue trace – control (n = 2) and red trace – 10 µM CaM A (n 
= 5). B- Summary of the changes in ratio amplitude due to Ca2+ influx (from cells in 
Figure A) in control (blue bar) and CaM A treated (red bar). C – Summary of the changes 
in half time of Ca2+ influx (lower bars) control – blue, CAM A treated – red. Half time of 
Ca2+ efflux (upper bars) control – blue, calmodulin treated – red.  
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